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Abstract
Pyroglutamyl Peptidase I  (PAP1, EC 3 4 19 3) hydrolytically cleaves pyroglutamic acid 
(pGlu) from the N-terminal o f most pGlu-peptides In higher organisms Thyrothropin 
Releasing Hormone is a notable biologically active substrate o f  PAP1 The sequence o f  
bovine PAP1 (Accession No XM 866409) was obtained from GenBank at NCBI 
(www ncbi nlm mh gov) Using suitable primers cDNA was synthesised using RNA 
extracted from bovine brain tissue Following expression o f recombinant bovine PAP1 
in Escherichia cob, the protein was purified using immobilised nickel affinity 
chromatography resulting in a yield o f 2 6 mg o f PAP1 per litre culture The Michaehs- 
Menten constant (K J fo r  the fluorometnc substrate pGlu-7-amino-4-methyl coumarin 
was determined as 59 fiM and the turnover constant (Kcat) was determined as 3 5 s 1 
Optimal enzyme activity was observed at pH  range 9 0-9 5 and temperature range 30- 
37 °C A comparative study carried out with the human and bovine recombinant forms 
o f the enzyme has highlighted interesting differences at ammo acid, expression and 
enzymatic activity levels Site-directed mutagenesis o f human PAP1 has revealed that 
an acidic residue is required for catalytic activity A series o f active mutants were 
generated fo r  human PAP1 using a random mutagenesis approach Biochemical and 
kinetic analysis o f  the mutant PAP1 enzymes has shown that methionine residues could 
potentially have an important role in PAP1 protein expression An attempt to crystallise 
human PAP1 was carried out However, this proved to be unsuccessful although it is 
believed that the C-terminal His-tag is causing interference and thus preventing proper 
crystallisation o f human PAP1
XVI
C H A P T E R  O N E
Introduction
11 Pyroglutamyl Peptidase
Pyroglutamyl peptidase (PAP) hydrolytically removes pyroglutamic acid (pGlu residue) 
from the N-terminus o f pGlu containing peptides To date, two classes of PAP have 
been characterised which include Type I (PAP1) and Type II (PAP2) PAP1 is a widely 
distributed cytosolic peptidase with a broad substrate specificity for pGlu-peptides and 
is found in a wide range of prokaryotic and eukaryotic organisms, including Homo 
sapiens and Bos taurus PAP1 is the subject of this study and is reviewed in detail in 
Section 1 3 PAP2 (see Section 14) is a membrane bound zinc-dependent 
metallopeptidase of high molecular mass with a narrow substrate specificity cleaving 
the pGlu-His bond of Thyrotropin-Releasing Hormone (TRH) or very closely related 
tnpeptides A serum form of PAP2 also exists and has been termed Thyrohbermase 
(Bauer e ta l,  1981)
12 pGlu-Peptides
pGlu is a cyclised derivative of glutamic acid (see Figure 1 1) which was first described 
by Haitinger (1882) who reported that when glutamic acid was heated to 190°C it 
transformed into a different compound having lost a molecule of water There are 
numerous reports of the enzymatic synthesis of pGlu from glutamic acid and glutaminyl 
peptides (Orlowski and Meister, 1971) The enzymatic formation of pGlu suggests that 
this residue may possess important biological and physiological functions This theory 
is supported by the observation that many bio active peptides (eg neuropeptides) 
exhibit an N-terminal pGlu residue (see Table 11)
Table 1 1 Peptides With an N-terminal pGlu Residue
Peptide3 Sequence
Thyrotropin-Releasing Hormone pGlu-His-Pro-NH2
Luteinizing Hormone-Releasing Hormone pGlu-His-T rp-Ser-Tyr-
Bombesin pGlu-Gln-Arg-Leu-Gly-
Neurotensin pGlu-Leu-T yr-Glu-Asn-
Gastrin pGlu-Gly-Pro-Trp-Leu-
Eledoisin pGlu-Pro-Ser-Lys-
Human Gastrin pGlu-Gly-Pro-trp-Leu-
Anorexigemc Peptide pGlu-His-Gly
a Further examples are given by Awade e t a l (1994)
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Neuropeptides released into the autocrine, paracrine and endocrine systems allow 
intercellular communications to occur which are required to integrate and regulate the 
basic processes of life such as metabolic activity, cell differentiation and growth. 
Structurally, neuropeptides are usually short polypeptide chains with specific 
modifications to individual residues, such as an N-terminal pGlu residue. Such 
modifications can govern the distinctive biological activity o f  each individual 
neuropeptide. An N-terminal pGlu residue can determine highly specific biological 
properties o f neuropeptides, such as their ability to recognize and bind to cell surfaces 
and their susceptibility to inactivation by neuropeptidases. For example, TRH binds to 
its receptor via specific interactions between the pGlu ring and certain residues of the 
trans-membrane TRH receptor (Perlman et a l., 1994a; 1994b). Slight structural 
substitution in the pGlu ring results in an almost complete loss o f receptor binding 
ability. TRH is one o f  the most widely documented biologically active pGlu-peptides. It 
was initially defined as a hormone for its ability to stimulate the release o f Thyrotropin 
Stimulating Hormone (TSH) from the anterior pituitary gland and prolactin from the 
pituitary gland (Jackson, 1982). It has features that also qualify it as a neurotransmitter 
and/or neuromodulator. These include its extrahypothalamic distribution in the brain , 
its localisation and release at the synaptic level as well as its attachment to high affinity 
receptors, which show remarkable degree o f anatomical localisation. It exhibits specific 
effects on neuronal activity and stimulates a wide range o f  centrally mediated 
behavioural effects.
Figure 1.1 PAP Cleavage o f TRH
The cleavage o f  TRH by PAP liberates pGlu. The remaining Ilis-Pro-Nlfo undergoes non-cnzymatic 
cyclisation to cyclo(His-Pro). Illustrated using ChemSketch (see Section 2 .11).
cydo< llis-P ro) o
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The cleavage of TRH by PAP yields free pGlu and His-Pro-NH2 (see Figure 1.1). The 
subsequent non-enzymatic cyclisation of His-Pro-NFh generates cyclo(His-Pro) which 
has been shown to posses pharmacological, endocrine, electrophysiological and 
cardiovascular activity of its own (Prasad, 1995). Functions o f pGlu as a free acid are 
less clear. It has been observed in the tissues of patients with Hawkinsinuria disease, 
whilst elevated levels of free pGlu have been demonstrated in the plasma of patients 
suffering from Huntington’s disease (Cummins and O’Connor, 1998). Russo et al., 
2002 reported that amyloid-/3-peptides commencing with pGlu residues have a higher 
tendancy to form insoluble aggregates than other amyloid-/S-peptides and as a result are 
likely to worsen the progression of Alzheimers Disease
1.3 PAP1
1.3.1 Discovery and Occurrence of PAP1
PAP1 activity was initially discovered in prokaryotic cells by Doolittle and Armentrout 
in 1968. The original aim o f their work was to isolate an enzyme which would open 
pyrrolidonc rings to aid amino acid sequencing work. A mircoorganism which was 
capable of utilizing free pGlu as a sole carbon and nitrogen source was isolated and 
identified as a strain o f Pseudomonas fluorescens. A crude extract of P. fluorescens was 
tested and resulted in free pGlu and alanine being liberated from pGlu-alanine. This 
hydrolysis was due to novel enzyme PAP1 (P/wPAPl).
PAP1 was subsequently documented in a wide range of prokaryotes including Bacillus 
suhtilis (Bsu?A?\, Szewcz.uk and Mulczyk, 1969), Klebsiella cloacae (Ax/PAP 1, 
Kwiatkowska et al., 1974), Streptococcus cremoris (ScrPAPl, Exterkate, 1977), 
Streptococcus faecium (SfaPAP1, Sullivan et alM 1977), Bacillus amyloliquefaciens 
(Bam ?A?\, Tsuru et al., 1978), Streptococcus pyogenes (5/?yPAPl, Cleuziat et al., 
1992), Staphylococcus aureus (SauP API, Patti et a I., 1995), Enterococcus faecalis 
(£/i/PAPl, Mineyama and Saito 1998), Pyrococcus horikoshii (Pho?A? \ , 
Kawarabayasi et a l 1998), Pyrococcus furiosus (P/i/PAPl, Tsunasawa et al., 1998), 
Thermococcus litoralis (77/PAP 1, Singleton et al., 1999a) and Mycobacterium bovis 
(A/60PAPI, Kim et al., 2001).
In 1970 Szcwczuk and Kwiatkowska reported the prcscncc o f PAP1 activity in various 
vertebrates and plants. Vertebrate sources included human (Homo sapiens: HsaPAP1), 
bovine (Bos taurus: BtaPAP1), porcine (Sus scrofa: SscPAPl), rabbit (Oryctolagus
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c u m c u lu s  0cm  P API), mouse (M u s  m u sc u lu s  M m u ? A ? \ ) ,  Rat (R a ttu s  n o r v e g ic u s  
ÆnoPAPl), guinea-pig (C a v ia  p o r c e l lu s  C p o ? A ? \ \  pigeon (C o lu m b a  Co/PAPl), 
chicken (G a llu s  g a llu s  GgaPAPl) and fish (C y p r in u s  c a rp io  CcaPAPl) PAP1 activity 
was detected in all tissues examined including pancreas, spleen, lung, intestines, brain, 
heart muscle, skeletal muscle and uterus with highest activity found in both liver and 
kidney Various plants which were tested included bean, oats, wheat, parsley, carrot, 
cabbage, potato and cauliflower Non-mammalian animal sources such as avian, fish 
and amphibian tissues have also been reported to display PAP1 activity (Albert and 
Szewczuk, 1972, Tsuru e t  a l , 1982, Prasad e t a l , 1982, Szewczuk and Kwiatkowska, 
1970) Morty e t  a l ,  (2006) report a protozoan form of PAP 1 activity from African 
trypanosome which has been detected m the plasma of infected rats
13 2 Classification of PAP1
PAP1 is classified as a cysteine omega peptidase (EC 3 4 19 3) which hydrolytically 
removes the ammo terminal L-pyroglutamic acid (pGlu) residue from pGlu-peptides and 
pGlu-proteins PAP1 was initially classified as EC 3 4 11 8 and has also been referred to 
as pyrrohdonyl peptidase, pyrrolidone carboxyl peptidase, 5-oxoprolyl-peptidase, 
pyrase and pyroglutamyl aminopeptidase (Awade e t  a l , 1994)
Omega peptidases (EC 3 4 19) are exopeptidases that remove terminal residues which 
are substituted, cyclized or linked by isopeptide bonds
In cysteine peptidases the catalytic mechanism (see Figure 1 2) requires a nucleophile 
and a proton donor The nucleophile is the thiol group of a Cys residue The proton 
donor is usually the îmidazolmm ring of a Histidine residue In some cases a third 
residue is required to orientate the îmidazolium ring of the His, there are a number of 
families m which only a catalytic dyad is necessary (Barret e t  a l , 1998)
In the Merops database PAP1 has been assigned as family C l5, clan CF To date, no 
other peptidases have been assigned to this family or clan (Barret and Rawings, 2001)
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Figure 1.2 Catalytic Mechanism of Cysteine Peptidases
The catalytic mechanism o f cysteine proteases is represented via a generic dipeptide (blue-red). The 
thiolate ion o f  the Cys residue is the catalytic nucleophile and is stabilized through the formation o f  an ion 
pair with neighbouring imidazolium ring o f  a His residue (1). Catalysis proceeds through the formation of 
a covalent intermediate (2). The dipeptide is cleaved (3) and both fragments are liberated (4). For amino 
acid information see Appendix D. Illustrated using ChemSketch (see Section 2.11).
1.3.3 Purification of PAP1
PAP1 has been purified from various prokaryotic cell cultures including P. fluorescens 
(Armentrout and Doolittle, 1969), B. subtilis (Swewczuk and Kwiatkowska, 1970), 
Kiebsiella cloacae (Kwiatkowska el al.. 1974), S. faecium (Sullivan el al.. 1977) and B. 
amyloliquefaciens (Tsuru el al., 1978) to name but a few. This enzyme has also been 
purified from a wide range of eukaryotic tissues including rat (Armentrout, 1969), 
chicken (Tsuru el al., 1982), bovine (Cummins and O’Connor, 1996) and human 
(Mantle el al.. 1989, 1990, 1991). Recently, trypanosome PAP1 (77>rPAPl) was 
purified from the plasma of rats infected with Trypanosoma brucei bmcei (Morty el al., 
2006). Conventional chromatography methods were employed to purify PAP1 including 
ammonium sulphate fractionation, gel filtration, anion exchange chromatography, 
hydrophobic interaction chromatography and thiol affinity chromatography.
The substrate analogue/inhibitor 2-pyrrolidone was often used as a PAP1 stabilizing 
agent during purification (Armentrout and Doolittle, 1969).
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The cloning of various PAP1 genes (see Section 13 9) facilitated the over-expression of 
several recombinant prokaryotic and eukaryotic active PAP1 enzymes in E coh 
(Cleuziat et a l , 1992, Gonzales and Awade, 1992, Awade et a l , 1992, Yoshimoto et 
a l , 1993, Gonzales and Robert-Baudouy, 1994, Tsunasawa et a l , 1998, Singleton et 
a l , 2000, Sokabe et a l , 2002) Dando et a l , (2003) overexpressed both the human and 
mouse PAP1 enzymes utilizing Spodoptera frugiperda insect cells In some cases a 
fusion with six histidine codons allowed expression of PAP 1 enzymes having a 6xHis 
tag on their N-terminal (Patti et a l , 1995, Kim et a l , 2001), facilitating a one-step 
purification by nickel chelate affinity chromatography
13 4 Detection of PAP1 Activity
In 1970, Mulczyk and Szewczuk developed a simple colorimetric assay using synthetic 
PAP1 substrate L-pynrohdonal-jft-naphthylamide (pGlu-0-NA) The release of /3-NA by 
PAP1 was determined colonmetrically using coupling with azotised-o-diamsidine 
Various commercial kits using pGlu-/3-NA to detect PAP1 activity were developed 
using paper strips which contained dried chromogemc substrates for PAP1 They 
proved very useful for the rapid differentiation of entrococci and streptococci in clinical 
material (Mitchell et a l , 1987, Dealler et a l , 1989, Kaufhold et a l , 1989)
Assays using both synthetic chromogemc substrate pGlu-p-nitroaniline and fluorogemc 
substrate pGlu-7-amino-4-methylcourmarin (pGlu-AMC) were developed for detection 
of PAP 1 activity by Fujiwara and Tsuru (1978) Hydrolysis by PAP1 could be followed 
by conventional colorimetric and fluorimetnc procedures Liberation of /?-nitroaniline 
by PAP1 caused an increase in the absorbance at 410 nm while cleavage of pGlu 
yielded free AMC which can be detected fluorometncally at emission and excitation 
wavelengths of 440 and 370 nm, respectively (see Figure 1 3) The fluorogemc assay 
which was used throughout this work was reported to be one thousand fold more 
sensitive than the chromogemc assay
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Figure 1.3 PAP1 Cleavage of pGlu-AMC
pGlu-AMC is cleaved by PAP1 to yield free AMC. which fluoresces at 440 nm when exited at 370 nm. 
Illustrated using ChemSkctch (see Section 2 .11).
1.3.5 Physiological Significance of PAP1
Identification o f the exact physiological role o f PAP1 currently remains 
unaccomplished although numerous suggestions have been put forward. Albert and 
Szewczuk (1972) suggested that PAP1 may participate in the absorption o f peptides and 
proteins from the mammalian alimentary tract due to the presence o f this enzyme in the 
small intestine, intestinal mucous membrane and duodenum.
An extensive distribution in differing tissues including skeletal muscle, brain, kidney, 
heart, liver, spleen and intestine has led some researchers to believe that PAP1 may be 
involved in the intracellular catabolism o f  peptides to free amino acids and consequently 
play a role in regulating the cellular pool o f free pGlu (Szewcuk and Kwiatkowska 
1970; Lauffart et al.. 1989; Mantle et al.. 1990; 1991).
The physiological implications o f this were demonstrated by Falkous et al., (1995) who 
reported a significant increase in levels of PAP1 activity in spinal cords o f patients 
suffering from motor neuron disease.
The inability o f PAP1 to obtain an extracellular location has raised doubt with regards 
to a physiologically significant role for this enzyme in neuropeptide metabolism (Charli 
et al.. 1987). As a result, researchers have hypothesized that PAP1, together with other 
cytosolic enzymes may be involved in a mechanism o f returning pGlu terminating 
neuropeptides released from damaged or aging vesicles back to the cellular amino acid 
pool (O’Cuinn et al.. 1990).
An interesting series o f  studies carried out by De Gandarias et al.. (1992; 1994; 1998; 
2000) has indicated that there is a correlation between PAP1 activity and TRH levels in 
the developing mammalian brain. Their results have indicated that a decrease in PAP1 
activity coincides with an increase in TRH levels as the brain develops and as a result 
has suggested that PAP1 could play a role in normal development o f mammalian brain. 
During early stages o f brain development, increased PAP1 activity was found to reflect
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an increase in cyclo (His-Pro) levels This research group also suggest that during the 
ontogency of the brain, PAP1 has different functions in brain development depending 
on the subcellular structure
Sanchez et a l , (1996) have demonstrated that environmental light conditions influences 
PAP1 activity resulting in increased levels in the hypothalamus and retina of rat 
Analysis carried out on various human semen fractions has indicated presence of PAP 1 
activity (Valdivia et a l , 2004) PAP1 activity was predominantly found in membrane- 
associated (particulate sperm and prostasome) fractions Activity was higher in semen 
fractions which were obtained from necrozoospermic fractions This research has 
indicated that PAP1 may participate in regulating the levels of seminal TRH analogues 
and in mediating sperm death associated with necrozoospermia
Abe et a l , (2004) found that PAP1 was distributed intracellularly in the pituitary, the 
target tissue of TRH, indicating that PAP1 might not be dominantly involved in the 
degradation of TRH in rats, although further depth into this study is required 
It has been demonstrated by Morty et a l , (2006) that PAP1 released from African 
trypanosomes could modulate plasma neuropeptide levels of infected hosts both in vitro 
and in vivo The abnormal degradation of TRH and gonadotropin-releasing hormone 
(GnRH) by trypanosome PAP1, may contribute to some of the endocrine lesions 
observed in African trypanosomiasis
Recently, a comprehensive study was conducted by Monsuur et a l , (2006) on the 
involvement of PAP 1 in coeliac disease They found that the PAP1 gene is located in a 
coeliac disease susceptibility locus and also determined PAP1 activity in duodenal 
biopsies However, following DNA sequencing, genetic association testing and 
quantifying RNA expression they reported that PAP1 is not involved in the aetiology 
and pathology of coeliac disease
Prokaryotic PAP Is are generally thought to be involved in protein maturation, protein 
degradation and in the utilization of peptides nutrients (Awade et a l , 1994, Gonzales 
and Robert-Baudouy, 1996) Since accumulation of peptides with an N-terminal pGlu 
may abnormally acidify prokaryotic cell cytoplasm, PAP1 may be involved in the 
detoxification of pGlu-peptides (Awade et a l , 1994)
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1.3.6 Inhibitors of PAP1
A series of active site-directed inhibitors were synthesised by Fujiwara et al., (1981a, 
1981b, 1982) for B. amyloliquefaciens PAP1 (see Figure 1.4). These inhibitors pGlu- 
chloromethyl ketone (pGluCK), Z-pGlu-chloromethyl ketone (Z-pGluCK) and Z-pGlu- 
diazomethyl ketone (Z-pGluDK.) were found to be highly specific, potent and 
irreversible inhibitors of PAP. Later in 1985, Wilk et al., synthesised another inhibitor 
pGlu-diazomethyl ketone (pGluDK) which proved to be significantly more inhibitory 
than its Z-derivative mentioned above. Activity could be completely restored by dialysis 
with a dithiothrcitol (DTT) or 2-/S-mercaptoethanol (2-ME) based buffer.
Z p G lu C K pCIuCK
2
Z p G lu D K
n n
H 0
pGluDK
Figure 1.4 Active Site-Directed Inhibitors of PAP1
Synthetic active site-directed inhibitors o f  PAP1: |-pG lu chloromethyl ketone (pGluCK), N°- 
carbobenzoxy-L-pGlu chloromethyl ketone (ZpGluCK). i.-pGlu diazom ethyl ketone (pGluDK) and Nft- 
carbobenzoxy-i.-pGlu diazomethyl ketone (ZpGluDK). Illustrated using ChemSketch (see Section 2.11).
The substrate analogue 2-pyrrolidone (see Figure 1.5) was initially used by Armentrout 
and Doolittle (1969) as a stabilizing agent for PAP1 activity following instability 
problems which were encountered by this enzyme in solution. 2-pyrrolidone acts as a 
reversible non-competitive inhibitor o f PAP 1 (Armentrout, 1969; Mudge and Fellows, 
1973; Sullivan et al., 1977; Cummins and O’Connor, 1996). Up to 50 % inhibition was 
observed with 0.1 M 2-pyrrolidone and complete inhibition was not achieved by 
increased concentrations. 100% activity was recovered following the removal o f 2- 
pyrrolidone by dialysis.
Benarthin, a competitive inhibitor o f PAP1 was found in the fermentation broth of 
Strcptomvccs xathophaeus MJ244-SF1. It was isolated as a colourless powder. An IC™ 
value o f  2.0 /xg.ml1 was determined for this inhibitor against PAP1. Benarthin has a low 
toxicity as no deaths occurred following its intravenous injection of 100 mg/kg to micc
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(Aoyagi et a l ,  1992a). The same group discovered another PAP1 inhibitor, 
pyrizinostatin, from culture filtrate o f the microbial strain SA2289 which had been 
isolated from a marine soil and was confirmed to belong to the genes Strepomyces. 
Pyrizinostatin was found to act as a non-competitive inhibitor towards PAP1 with an 
IC5 0  value o f 1. 8  fxg.ml 1 (Aoyagi et al., 1992b).
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Figure 1.5 Inhibitors 2-Pyrrolidone, Pyrizinostatin and Bcnarthin
Chemical structures o f reversible non-competitive inhibitor 2-Pyrrol idone, non-competitive inhibitor 
Pyrizinostatin and competitive inhibitor Benarthin. Illustrated usingChemSketch (see Section 2 .11).
Many cations such as Hg* , Zn~\ Cu~\ Co" , Ca‘\  Mn‘ \  Mg‘\  Ni*\ Ba2+, Sr2 and 
Cd2‘ have been reported to have an inhibitory effect on PAP1 activity. Activity could be 
partially restored by addition of EDTA to enzyme assay or by subjecting the enzyme to 
dialysis to remove the metal ion (Szewczuk and Mulczyk, 1969, Dando e t  a l.. 2003).
1.3.7 Substrate Specificity
Following the initial discovery o f  PAP 1 in P . f lu o r e s c e n s  (Doolittle and Armentrout, 
1969), numerous researchers have undertaken various studies to investigate the 
substrate specificity o f PAP1 (Uliana and Doolittle, 1969; Szewczuk and Mulczyk, 
1969; Armentrout, 1969; Mudge and Fellows, 1973; Kwiatkowska e t  a l . ,  1974; Sullivan 
e t  a l ., 1977; Podell and Abraham, 1978; Fujiwara e t  a l ., 1979; Tsuru e t  a l ., 1982; 
Browne and O’Cuinn, 1983; Lauffart e t  a l ., 1989; Mantle e t  a l 1990; Mantle e t  a l ., 
1991; Cummins and O’Connor, 1996; Mineyama and Saito, 1998; Tsunasawa e t  a l  
1998; Dando e t  a l.. 2003; Morty e t  a l., 2006). A distinctive feature o f PAP1 is its broad 
substrate specificity. It hydrolytically removes the pyroglutamic acid residue (pGlu) 
from the amino terminus o f  pGlu-pcptides and proteins with an apparent specificity for
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L-pGlu-L-amino acid optical isomers Results highlighted that the size of the peptide 
does not affect specificity and that the amino acid directly adjacent to pGlu affects the 
rate of hydrolysis The order of preference is Thr > Glu > Met > Ala > Lys > Gly > Ser 
> Tyr > Arg > Phe > His > Trp > Asp > Leu > Ile »  Val as determined for B a m ? A P I ,  
which is generally in agreement with the other PAP Is tested pGlu-Pro was not 
hydrolysed by PAPI, with one notable exception being K c l ? A ? \  However, the 
hydrolysis of pGlu-Pro by K c lP A P l  was significantly slower than pGlu-Ala or even 
pGlu-Val (Fujiwara et a l , 1979)
Cleavage of pGlu from several bioactive peptides including TRH, LHRH, GnRH, 
Liliberin, Neurotensin, Bombesin, Eledoisin and Leukopyrokinin has been widely 
demonstrated Synthetic substrates such as pGlu-AMC and pGlu-jSNA are readily 
hydrolysed by PAPI Substrate specificity of PAPI towards several organic nitrates and 
L-pGlu-L-Ala analogues was recently investigated by Abe et a l ,  2004b They 
demonstrated that PAPI allowed the replacements of the carbon atom at the 4-position 
of the L-pGlu moiety with a sulphur atom (l-OTCA), an oxygen atom (L-OOCA) or an 
NH group (l-OICA) (see Figure 1 6) The carbon atom at the 4-position of the L-pGlu 
moiety was located in the hydrophobic pocket of PAPI, suggesting that these 
compounds could insert into the hydrophobic pocket of PAPI The affinities of these 
substrates were much lower than substrates having the L-pGlu moiety indicating that the 
relatively large molecular size of the sulphur atom or the hydrophilic nature of the 
oxygen and nitrogen atoms compared to the carbon atom at the 4-position of the i,-pGlu 
moiety may interfere with the insertion of the moieties into the hydrophobic pocket of 
PAPI
H
H H H H
L -p G lu  L -O T C A  L -O O C A  L -O IC A
Figure 1 6 Substitution Analogues of L-pGlu
Synthetic analogues o f L-pGlu (L-5-oxopyrrolidine-2-carboxylic acid) having the carbon atom at position 
4 replaced by sulphur (L-5-oxothiazolidme-2-carboxylic acid, L-OTCA), oxygen (L-5-oxooxazolidme-2- 
carboxylic acid, L-OOCA) and nitrogen (L-5-oxoimidazolidine-2-carboxyhc acid, L-OICA) Illustrated 
using ChemSketch (see Section 2 11)
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13  8 Biochemical Characterisation of PAP1
Over the last few decades extensive research has been carried out on the biochemical 
characterisation of both eukaryotic and prokaryotic PAP1 (Szewczuk and 
Kwiatkowska, 1970, Kwiatkowska et a l , 1974, Sullivan et a l , 1977, Tsuru et a\, 
1978, Busby et a l , 1982, Tsuru et a l , 1982, Browne and O’Cuinn, 1983, Tsuru et a l , 
1984, Lauffart and Mantle, 1988, Lauffart et a l , 1989, Mantle et a l , 1991, Gonzales 
and Awade, 1992, Awade et a l , 1992, Yoshimoto et a l , 1993, Gonzales and Robert- 
Baudouy, 1994, Patti et a l , 1995, Cummins and O’Connor, 1996, Mineyama and Saito, 
1998, Tsunasawa et a l , 1998, Singleton et a l , 2000, Kim et a l , 2001, Dando et al 
2003, Morty et a l , 2006) Studies have shown that mammalian PAP1 exists as a soluble 
cytosolic monomeric enzyme with a low molecular mass of approximately 24 kDa 
under denaturing and non-denatunng conditions Molecular mass determinations for the 
prokaryotic enzyme under denaturing conditions indicate an average subunit mass of 25 
kDa, while an increase in molecular mass is obtained under native conditions The 
quaternary 3-D structure of BamPAPl, 77* PAP 1, PfuPAPX and PhoPAPl have been 
reported to be tetrameric (see Section 13 113)
Physiological temperature of 37°C has been used as the standard temperature for 
experimental analysis of eukaryotic PAP1 An optimum temperature of 50°C was 
determined for human PAP1 by Dando et a l , 2003 A range of temperatures have been 
reported for prokaryotic PAP1 Mesophilic prokaryotic PAP1 have been reported to be 
optimally active in the temperature range of 30 to 45°C while thermophilic enzymes 
ThPAPl and PfuPAPl displayed optimum activity at 70 and 90°C, respectively 
An optimum pH in the range of 6 0 and 9 5 has been determined for PAP1 in general, 
with a mean pH of 7 5
Classified as a cysteine peptidase (see Section 13 2) PAP1 displayed a strict 
requirement for a thiol-reducing agent, such as DTT or ¡3-ME In support of this, several 
studies have reported the inhibitory nature of sulfliydry 1-blocking reagents such as N- 
ethylmaleimide, PCMB, lodoacetamide and lodacetic acid
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Table 1 2 Characteristics of Various PAPI Enzymes
P A Pl D enatured  Native O ptim um  PI O ptim um  K m
size (Da) size (Da) pH  Tem p (°C) (mM )
CÖ /
HsaPAPl 
BlàPAP  1 r17 
C p o P A P lr7 
OcuPAPl rl 
C o /P A P lrl 
ÄwoPAPl 15 
GgaPAPl rf’ 
77)rPAP 1
y /yZPAPl r15 
ÆswPAP 1 
^ P A P l  r13 
M P A P 1  12
& rIO rl I m
i23
rl2
£ /aP A P l 
S/aPAPl r; 
BamPAPl
rl 8
r4 r8 rl4
CO
8a,
77*PAP1
P fu?A ? \
Sau? AP 1
r20
rl 9
rl6
6H
M>oPAPl r216H
n d
24.000 
n d
n d 
n d 
n d 
n d
25.000
23.500 
25,200
23.500 
n d
40.500
42.000
24.000
24.000 
22,937
30.000
29.000
24.000 
23,700
24.000
33.000
33.000
60.000 
86,000 
n d
41.000
91.000
85.000
74.000
82.000 
n d
72.000 
or 51,000
96.000 
96,300 
or 45,643
46.000
46.000
7 0 - 9 5 n d 50 0 05 b
8 5 n d n d 0 015b , 0 021
n d n d n d 0 15 b
7 5 n d n d n d
7 5 n d n d 0 13 a
8 0 - 8 4 n d n d n d
7 0 - 8 0 5 5 n d 0 73 a, 0 04 b
7 5 - 8 5 n d n d 0 28 b
6 5 - 8 5 4 9 30 0 2 1 a
6 8 - 7 5 n d n d 1 04 a
7 0 n d n d 1 79 a
6 0 - 7 5 n d n d n d
7 2 - 7 5 4 2 3 5 - 4 5 0 55 a
7 6 n d n d 0 86 a
7 0 - 8 0 5 4 45 0 13 a
7 0 - 8 0 n d 70 n d
6 0 - 9 0 n d 90 n d
7 8 n d n d n d
n d n d n d n d
[n d - not determined, a - determined for pGlu-/3-NA, b - determined for pGlu-AMC, r l ,  Szewczuk and 
Kwiatkowska, 1970, r2, Kwiatkowska e t a l 1974, r3, Sullivan et al 1977, r4, Tsuru e t a l, 1978, r5, 
Busby et a l 1982, r6, Tsuru e t a l, 1982, r7, Browne and O ’Cuinn, 1983, r8, Tsuru e t a l 1984, r9, 
Lauffart and Mantle, 1988, rIO Laufifart et a l 1989, r l  1, Mantle e t a l, 1991, r 12, Gonzales and Awade, 
1992, r l3 , Awade e t al 1992, rl4 , Yoshimoto et a l, 1993, rl5 , Gonzales and Robert-Baudouy, 1994, 
r 16, Patti e t al 1995, rl7 , Cummins and O ’Connor, 1996, r 18, Mineyama and Saito, 1998, rl9 , 
Tsunasawa et a l, 1998, r20, Singleton e t a l, 2000, r21, Kim e t a l, 2001, r22, Dando e t a l 2003, r23, 
Morty et al 2006]
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1.3.9 Sequence Data and Analysis of PAP1
The first PAP1 genes to be cloned and sequenced were BsuPAP\ (Awade et al., 1992a) 
and 5/?yPAPl (Cleuziat et al., 1992) respectively. These genes were isolated from B. 
subtil is and S. pyogenes by the construction o f gcnomic libraries which were followed 
by the subsequent transformation into E. coli. A plate colony assay using pGlu-/3-NA as 
described by Mulczyk and Szewczuk (1970) was utilised to screen the prokaryotic gene 
libraries for PAP1 activity in E. coli. Potential clones were subjected to restriction 
analysis followed by DNA sequencing and as a result the open reading frames (ORFs) 
o f Z?smPAP1 and SpyPAPl were identified. At that time, these sequences did not display 
homology with any other data available on Genbank (Benson et al., 1996), suggesting 
that these prokaryotic PAPs belonged to a new and unique class o f  peptidases. Several 
other prokaryotic PAP1 genes were later sequenced and ORFs for all prokaryotic 
PAPl’s were approximately 600-700 base pairs in length (see Table 1.3).
Table 1.3 Prokaryotic PAPI Sequences
Organism
PAPI
Gene
G enBank
Accession
ORF
(bp)
PAP1
Enzyme
Amino
Acids Reference
R. subiilis Bsu-papl X66034 645 ÄvuPAPl 215 Awade et ul., 1992
S. pyogenes Spy-papi X65717 645 Spy? AP  1 215 Cleuziat et al., 1992
B. amyloliquefaciens Bam-papl D11035 645 BamPAP\ 215 Yoshimoto eta l., 1993
P. fluorescens Pfl-pupl X75919 639 PfJPAP\ 213 Gonzales and Robert- 
Baudouy, 1994
S. aureus Sau-p a p i U 19770 636 SauPAPl 212 Patti e ta l. , 1995
P. furiosus Pfu-papl AB015291 624 PfuPAP I 208 Tsunasawa et al., 1998
T. litoralis Tli-papl Y 13966 660 77/PAP 1 220 Singleton et al., 2000
M. hovis Mho-pap! U91845 666 MboPAP\ 222 Kim et al., 2001
P. horikoshii Pho-papi AP000002 618 PhoPAP 1 206 Sokabc et al., 2002
An alignment of all confirmed prokaryotic PAP1 amino acid sequences is shown in 
Figure 1.7. Sequence homology is represented in grey scale shading, with black being 
the highest homology. The highly conserved areas have been labelled domains 1 to 4. 
Homology scores corresponding to this alignment arc shown in Table 1.4. BsuPAP  1 and 
tfii//iPAPl display the highest degree o f scqucncc homology showing 72% identity and 
85% similarity, while least homology exists between M boPAP\ and SawPAPl (27% 
identity, 48% similarity).
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Figure 1 7 Amino Acid Sequence Alignment of Prokaryotic PAPl
Alignment was created using MultAlin with Blosum62-12-2 parameters and edited using GenDoc 
(Section 2 11) Sequence homology is represented by grey scale shadmg, with black being the highest 
homology The most highly conserved domams have been labelled 1 to 4 For ammo acid in formation see 
Appendix D
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Table 1 4 Homology Scores for Prokaryotic PAPI Sequences
flswPAPl S /y P A P l SauP A P l P j7PAP1 P fuP A P l 77/PAP1 PhoPAPÌ M boPAPi
BamPAPX  72 (85) 48 (68) 41 (62) 43 (63) 38 (57) 32 (57) 41 (59) 32 (52)
B suP A P l 47 (65) 43 (62) 46 (65) 39 (57) 36 (59) 37 (56) 33 (50)
S/jyPAPl 49 (66) 41 (61) 36 (57) 34 (59) 39 (60) 31 (49)
SawPAPl 43 (60) 35 (50) 34 (54) 36(51) 27 (48)
PJIPAP1 38 (56) 37 (55) 40 (57) 36(51)
P fuP A P l 53 (71) 51 (73) 33 (54)
ra P A P i 53 (69) 32 (53)
[Identity scores are given, with similarity in parenthesis] P hoP A P l 34 (47)
Dando et a l , (2003) were the first group to clone and sequence two eukaryotic forms of 
PAP1 from vertebrates Both human PAP1 (Hsa?API) and mouse PAP1 (MmwPAPl) 
genes were expressed in insect cells The deduced ammo acid sequences each consisted 
of 209 amino acid residues that display 95% identity with each other Following this 
other eukaryotes including rat PAP1 (KnoPAPl) and trypanosome PAP1 (7ftrPAPl) 
were later cloned and sequenced using similar approached (Abe et a l , 2003, Morty et 
a l , 2006)
A BLAST search (see Section 2 11) of known PAP1 sequences against the current 
GenBank data reveals a number of confirmed and putative eukaryotic PAP1 gene 
sequences (see Table 1 5) many of which have not yet been documented in publications
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Table 1 5 Eukaryotic PAPI Sequences
O rganism Com m on Name
PA PI
Gene
G enB ank
Accession
O R F
(bp)
PAP1 gene 
p roduct
Amino
Acids
H  sapiens Human Hsa-papl AJ2788283 627 HsaVAV 1 209
M  musculus Mouse M mu-papl AJ2788293 627 MmuP AP 1 209
R norvegicus Rat Rno-papl AB098134b 624 ÆnoPAPl 208
Trypanosoma
Bruci
African
Trypanosome
Tbr-papl AJ2788290 669 7M>AP1 222
Strongylocentrot 
us purpurtus
Purple Urchm Spu-papl * XM_781811 594 SpuPAPl* 197
Takifugu
rubnpes
Japanese Pufferfish Tru-papl * AJ301641 633 TruPAP 1 * 211
Xenopus
tropicalis
Frog Xtr-papl * BC075524 624 A W AP1* 208
Brachydanio
rerio
Zebra Bre-papl * XM_681991 624 ÆrePAPl* 208
Anopheles
gambiae
Mosquito Aga-papl * XM_308793 627 AgaP AP 1 * 209
Drosophila
melanogaster
Fruit Fly Dme-papl * NM_168616 672 Dme PAP1* 224
Arabidopsis
thahana
Cress Ath-papl* N M _104547 657 ¿M PA Pl* 219
Caenorhabditis
elegans
Nematode
. ,  b A 1_____
Cel-papl *
f  C *  n .
NM 060090
_j__. _ l  ^ A A / '  4»
822 C el? API* 274
[a Dando et a l , 2 0 0 3 ,b Abe et a l , 2 0 0 3 ,c M orty  et a l , 2006, * Putative sequences]
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Figure 1 8 Alignment of Confirmed Ammo Acid Sequences of Eukaryotic PAP1
Alignment was created usmg MultAlin with Dayhoff-8-0 parameters and edited using GenDoc (Section 
2 11) Sequence homology is represented by grey scale shading, with black being the highest homology 
The most highly conserved domains have been labelled A to E For amino acid information see Appendix 
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Figure 1.9 Amino Acid Sequence Alignment of All Eukaryotic PAP1
A lignm en t w as c rea ted  using  M ultA lin  w ith  DayhofT-8-0 p a ram ete rs  an d  ed ited  u sing  G enD oc (S ection  
2 .11 ). S equence  hom ology  is  rep resen ted  by  g rey  sca le  shad ing , w ith  b lack  b e in g  the h ig h es t hom ology . 
T he m ost h igh ly  co n serv ed  d o m ain s  have  been labelled  A  to  E . F o r am m o  ac id  m fo rm an o n  see A ppendix  
D.
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20
Figure 1 8 shows an alignment of four eukaryotic PAP1 amino acid sequences, namely 
HsaPAPI, MwuPAPl, /faoPAPl and JfcrPAPl, which have been confirmed (Dando et 
a l , 2003, Abe et al 2003, Morty et a l , 2006) On this alignment the regions of highest 
homology have been designated domains 1 to 5 Catalytic residues cysteine and 
histidine are conserved in domains 3 and 4, respectively
An alignment of all eukaryotic PAP1 sequences, both confirmed and putative is shown 
in Figure 1 9, highlighting conserved domains 1, 2 and 3 The Ce/PAPl sequence has 
approximately 50-60 additional amino acid residues when compared to other 
eurkaryotic PAP1 sequences This as a result has led to a decrease in homologous 
domains within this alignment Table 1 6 gives a summary of the homology scores for 
this alignment The greatest degree of homology exists between the rodent sequences 
Mmu?AP\ and RnoPAPl (98% identity, 99% similarity) These also show closest 
homology to HsaP API (94% identity, 96% similarity) The trypanosome sequence 
TbrPkP\, plant sequence AlhPAPl and nematode sequence Cel?API exhibit the 
greatest divergence from all other eukaryotic sequences
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Table 1 6 Homology Scores for Eukaryotic PAPI Sequences
M m u P A P I R n o P A P l S p u P A P l T r u P A P l X tr P A P l B reP A P X A g a P A P l D m e  P A P I T b r P A P l A th P A P l C e lP A P l
H s a P A P l  94  (96) 94  (96) 42 (58) 68  (84) 73 (84) 41 (65) 29  (49) 28  (44) 12 (27) 1 5 (3 1 ) 2 0  (34 )
M m u P  A P I 98  (99) 41 (57) 68  (84) 71 (82) 41 (65) 29  (47) 29  (45) 12 (27) 1 5 (3 1 ) 2 0  (33)
R n o P A P l  41 (57) 67 (83) 70  (82) 4 1 (6 5 ) 29  (47) 29  (45) 12 (27) 1 5 (3 1 ) 2 0  (33)
S p u P A P l 44  (59) 41 (60) 29  (46) 29  (46) 25  (43) 14 (29) 1 5 (3 1 ) 19 (31)
TVk P A P I 63 (80) 41 (62) 28  (46) 28  (44) 12 (26) 17 (30) 21 (33)
X tr P A P l 3 9 (6 0 ) 28  (48) 25  (44) 1 1 (2 5 ) 15 (30) 1 8 (3 2 )
B r e  P A P I 22 (41) 21 (40) 10 (29) 1 5 (2 9 ) 18 (29)
A g a P A P l 35  (56) 1 0 (3 0 ) 14 (29) 23 (39)
D m e P A P l 1 0 (2 0 ) 14 (29) 28  (35)
T b r P A P l 23 (44) 10 (24)
[id e n ti ty  sco res  a re  g iven , w ith sim ila rity  in  p a ren th e s is] A th P A P l 12 (24)
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The prokaryotic sequence that HsaPA?\ exhibits most homology with is Bam?A?\. 
Figure 1.10 shows an alignment o f  these two sequences. They exhibit an identity o f  
25% and a similarity o f  45%, which is a higher score than seen among some o f  the 
eukaryotic sequences (see Table 1.6).
B a m P A P l : T g  G A A E |p A S  i l s  BQV P t M k M a V  : 53
H s a P A P l  : B j P R g A B ^ B - ^ B E H B A B l B c E B E K L G L g D S V D g H X ^ E Ip g g g c g jR  : 56
Domain 1
H s a P A P l : g l  PgSW E lfli-G M B B O n B ^  3 ^  AT 7g | L ® _  o  HjjKGY K G g -® C R F C f lG S g C C ^ D  : 111
Domain 2
B a m P A P l : ^  A Y H f c l * R § ^ | K K E f f l p A A | - - | r ' T 0 | E  • a fc - L M D B lg H H H E il : 162
H s a P A P l : H E S I C i l | D 5 D A | C K R lT T L ® . V 3 iT lB Q I ® R ^ B P T H  T B LY Q s | g  : 162
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Figure 1.10 Amino Acid Sequence Alignment of HsaPAPl and fiamPAPl
A lignm en t w as crea ied  u sing  M ultA lin  w ith  B lo su m 6 2 -l2 -2  param ete rs  and  ed ited  using  G enD oc 
(S ection  2 .11). S equence  hom ology  is rep resen ted  by  g rey  sca le  shad ing , w ith  b lack  b e in g  th e  h ighest 
hom ology . For am in o  ac id  in fo rm ation  see A ppendix  D.
1.3.10 Catalytic Residues of PAP1
The catalytic importance o f  a cystcinc thiol group in PAP1 activity has been well 
demonstrated by its absolute requirement for a thiol-reducing agent such as DTT o r 2- 
ME (Armentrout, 1969; Szewczuk and Mulczyk, 1969; Szewczuk and Kwiatkowska, 
1970; Kwiatkowska et a t 1974; Tsuru et al., 1978; Tsuru et al., 1982; Tsuru et al., 
1984; Prasad, 1987; Mantle et al., 1991; Cummins and O ’Connor, 1996; Tsunasawa et 
al., 1998; Singleton and Littlechild, 2001; Dando et al., 2003; Morty et al..2006).
Further demonstrating this are the findings that PAP1 activity is highly sensitive to nM 
concentrations o f  thiol-blocking compounds such as iodoacetate, iodoacetamide, p- 
chloromercuryhcnzoatc (/>-CMB), p-mcrcuriphcnylsulphonatc, N-cthylmalcimidc and 
sodium tctrathionate (Doolittle and Armentrout, 1968; Szewczuk and Mulczyk, 1969; 
Szewczuk and Kwiatkowska, 1970; Mudge and Fellows, 1973; Kwiatkowska et al.,
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1974; Prasad and Pcterkofsky, 1976; Tsuru e t  a l 1978; Bauer and Klcinkhauf, 1980; 
Tsuru e t  a l . ,  1982; Browne and O'Cuinn, 1983; Awade e t  a l ., 1992; Gonzales and 
Robert-Baudouy, 1994; Patti e t  a l . ,  1995; Cummins and O ’Connor, 1996; Tsunasawa e t  
a l . ,  1998; Mineyama and Saito, 1998; Singleton e t  a l . ,  2000; Singleton and Littlechild, 
2001; Dando e t  a l . ,  2003).
The selective serine peptidase inhibitor phenylmethylsulphonyl fluoride (PMSF) was 
found to exert no effect on the activity o f  PAP1 (Tsuru e t  a l . ,  1982; Lauffart e t  a l . ,  
1989; Mantle e t  al., 1990; Gonzales and Robert-Baudouy, 1994; Singleton e t  a l . ,  2000). 
Site-specific mutagenesis studies were conducted by various research groups to identify 
the catalytic residues o f  PAP1. The two cysteine residues o f  B a m ? A ? \ ,  Cys68 and 
C ysl44, were mutated to Ser by Yoshimoto e t  a l .  (1993). The mutant 
B a m P A P \  C68mS had wild type activity while B a r n P A P ]  C144mS was completely 
inactive, implicating C ysl44  as providing the essential active site thiol group. Le Saux 
e t  a l .  (1996) investigated several residues as possible contributors to the active site o f  
P f l P A P \ ,  based on homology alignments with known PAP1 sequences. Substitutions o f  
C ysl44  and H isl66 by Ala and Ser, respectively, were found to completely abolish 
activity o f  /y7PAPl without affecting protein conformation as shown by gel 
electrophoresis. Similarly, one o f  Glu81, Asp89 or Asp94 were shown to be a likely 
third member o f  an active triad o f  P f l P A P \  (Le Saux e t  a l . ,  1996). Tsunasawa e t  a l .  
(1998) substituted the Cys 142 residue o f  P fu P  API with Ser, resulting in loss o f  activity. 
In light o f  published data and by sequence analysis, these authors proposed the catalytic 
triad o f  P / u P A P \  to consist o fC y s l4 2 , H isl66 and Glu79, which correspond to Cysl44, 
His 168 and Glu81 oftfiw iPA Pl respectively. This catalytic triad was later confirmed by 
studies o f  the tertiary structure o f  B a m P A P l  and P f u P A P l  as outlined in Section 
1.3.11.3.
Recently, Morty e t  a l . .  (2006) substituted C ysl67  o f  trypanosome PAP1 with Ala, 
which resulted in complete loss o f  PAP1 enzyme activity. Residues G lu l04 , C ysl67  
and Hisl91 were fully conserved within the 77>rPAPl amino acid sequence when 
compared to a number o f  PAP 1 sequences including H s a P A P \  and B a m P A P l .
1.3.11 Stucturc of PAP1
Rcccntly the three-dimensional structures o f  four prokaryotic PAP1 enzymes were 
solved using X-ray crystallography. These four structures; the mesophilic Zta/wPAPl 
(Odagaki e t  a l . ,  1999), the thermophillic 7Y/PAP1 (Singleton e t  a l . ,  1999a; 1999b),
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Ffu?AP\ (Tanaka et al., 2001) and PhoPAPl (Sokabe et al., 2002) have been deposited 
in the Protein Data Bank (sec Section 2.11) as structural coordinate files [1AUG], 
[1A2Z], [HOF] and [1IU8] respectively.
1.3.11.1 Crystallisation of PAP1
Crystallisation studies were carried out using the hanging drop vapour-diffusion method 
as described in Section 2.19. Initial screening was carried out with the sparse matrix 
conditions using a crystal screen kit.
Initial crystals for B a m P A P X  were obtained using an ammonium sulphate solution. 
Needle-shaped crystals were produced and proved to cause problems at the diffraction 
stage. These crystals did not diffract to high resolution and as a result crystallisation 
conditions were screened again. Protein crystals obtained from the following attempt 
were pentagonal in shape with average dimensions o f 0.3 x 0.3 x 0.4 mm’ and were 
suitable for diffraction studies. A B a m P A P \  protein concentration o f 7 mg was used for 
this study. Crystallisation was performed using 0.05 M sodium cacodylate/IOhPO4 
buffer with 0.1 M magnesium acetate, pH 6.5. 10% w/v PEG 4000 was used as 
precipitant. All o f the aforementioned prokaryotic PAP1 enzymes were crystallised 
using methods similar to the above and crystals diffracted to a resolution o f 2.0, 1.73,
2.2 and 1.6 A  for B a m P  A P \ ,  T l iP API, P f u P A P \  and P h o P API respectively.
1.3.11.2 Monomeric Structure of PA PI
The subunit monomers o f B u m P A P \ ,  77/PAP 1, P f u P API and P h o P A P \  (see Figures
1.11 - 1.14) are folded into single a/(3 globular domains with approximate dimensions of 
75 A  x 55 A  x 45 A . The central core is an a/ft twisted open-sheet with a  helices on both 
sides o f  the 0  sheet. The active site is located within each monomer and faces toward 
the central channel o f  the tetramcric structure (sec Figure 1.15).
A hydrophobic pocket comprising o f PhelO, Phel3, Thr45, Gln71, lle92, Phcl42 and 
Vail 43 is found near the catalytic triad o f B a m PAP1. The feasibility o f  this substrate- 
binding pocket in B a m P A P \  was investigated by manually placing a pGlu-His model 
into the pocket through the use o f molecular dynamics simulation software. Two 
methylene carbon atoms from the pGlu pyrrolidonc ring point to the bottom of the 
hydrophobic pocket. The pyrrolidone ring is held between the aromatic ring of I'hcl3 
and the methylene chain o f Gln71. The pGlu main chain carbonyl forms a hydrogen 
bond with the guanidino group of Arg91, while the imidazole nitrogen o f  the histidine
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sidc-chain hydrogen bonds with the main-ehain of amide proton o f  Thrl41, indicating 
that PAP1 is not selective for residues in the second position. The mechanism of 
substrate recognition was observed (Ito et al.. 2001) by X-ray crystallography o f the 
substrate-inhibitor complex of Bam?AP\ and aldehyde pGlu analog 5-oxoprolinal. 
Results have indicated that the enzymatic recognition o f the pyrrolidone ring o f  
pyroglutamic acid is achieved by two hydrogen bonds between the inhibitor and the 
main chain located at the side o f the cavity. These hydrogen bonds help to orientate the 
pGlu residue for nucleophilic attack by Cysl44. Van der Waals interactions between the 
pyrrolidone ring and the hydrophobic pocket are also essential. The benzene rings o f  the 
3 phenylalanine residues of the hydrophobic pocket of PAP 1 and the pyrrolidone ring of 
the inhibitor are almost parallel. These three residues also fix the substrate pyrrolidone 
ring into the pocket. Phel3 along with Gln71 serve as an induced fit mechanism, while 
Phel42 provides hydrophobic properties. PhelO was conserved in most enzymes, 
however, Phel3 and Phel47 have been replaced with Tyr in some cases.
Cln l75
Figure 1.11 Subunit Monomer of /tamPAPl With Detail of Active Site Region
R ibbon d iag ram  o f  th e  su b u n it m onom er o f  B a m P A ? \.  T h e  en tire  m o n o m er is  show n on  th e  left. O n  the 
righ t is a  de ta il o f  th e  active site  reg ion . R esidues P helO . P he  13. T hr45, G ln71 , Ile92 . P h e l4 2  and  
V a ll4 3  con trib u tin g  to  the hydrophob ic pocket a re  co lou red  b lue. T h e  side-chain  o fG ln 7 1  is o rien ted  by  
hydrogen  bond ing  lo  G in  175. T h e  catHlytic tr iad  is co lou red  by  C P K  co lou r nehem e (C  w hite . O  -  red , 
N  b lue a n d  S = yellow ). F o r am ino  ac id  in fo rm ation  see A ppend ix  D. G enera ted  u sing  D eepV iew  (see 
Section  2.11).
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Figure 1.12 Subunit Monomer of 77/PAP 1 Highlighting Active Site
R ibbon d iag ram  o f  th e  subun it m o n o m er o f  77/PAP 1. R esidues co n trib u tin g  to  the h y d rophob ic  pocke t 
a re  co loured  b lue w h ile  th e  ca ta ly tic  tr iad  is  co loured  b y  C P K  co lo u r schem e (C  = w hite , O  = red . N  *  
b lue an d  S =  yellow ). F o r am in o  ac id  in fo rm ation  see  A ppendix  D. G enera ted  u sing  D eepV iew  (see  
Section  2.11).
Figure 1.13 Subunit Monomer of P/m PAP 1 Highlighting Active Site
R ibbon d iag ram  o f  th e  subun it m onom er o f  jy û P A P l. R esidues co n trib u tin g  to  th e  h y d rophob ic  pocke t 
a re  co lou red  b lue w h ile  the cata ly tic tr iad  is  co lou red  by  C P K  co lo u r schem e (C  w h ite , O  =  red . N  = 
b lue  an d  S yellow ). F or am in o  ac id  in fo rm ation  see A ppendix  D. G enera ted  u sing  D eepV iew  (see  
Section  2.11).
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Figure 1.14 Subunit Monomer of PhoPAP1 Highlighting Active Site
R ibbon d iag ram  o f  th e  subunit m o n o m er o f  P h o ? A P I .  R esidues co n trib u tin g  to  th e  hyd rophob ic  pocket 
a re  co lou red  b lue w h ile  res id u es involved in  ca ta lysis  a re  co lou red  by  C P K  co lo u r schem e (C  -  w h ite , O  
= red , N  *  b lue an d  S yellow ). F o r am in o  ac id  in fo rm ation  see  A ppend ix  D. G enera ted  u sing  D eepV iew  
(see S ec tion  2.11 ).
1.3.11.3 Quaternary Structure of PAP1
The quaternary structure for ZtamPAPl, 77/PAP 1, Pfu?A?\ and Pho?API is tetrameric 
and is composed o f four identical monomeric subunits designated A to D (see Figure 
1.15). Each monomer forms extensive contacts with two other monomers in the 
tetramer, one running along the longest axis o f the tetramer and the other across the 
short axis.
The A-D interaction o f  Bam?AP\ (see Figure 1.16) buries 1427 Â2 o f primarily 
hydrophobic surface, although apparent salt bridges arc also found (Odagaki et al., 
1999). Hydrophobic contacts dominate the A-D interaction. Ile85, Asn86, Leu87, 
Alai 11, Alai 12, Trpl 14, Tyrl37, Thrl38 and Thrl41 are all involved in hydrophobic 
interactions and have close contacts with the nearest atoms o f the adjacent monomer. 
The A-C interaction (see Figure 1.17) buries less hydrophobic surface (1355 Â:) than 
A-D interaction and forms no salt bridges. The following residues are involved in 
hydrophobic interactions; Met76, Ilel31, Prol32, Prol73, Thrl76, Leul77, Alai81, 
Pro 182 and His 188. The A-C interaction also features a thin well-ordered water layer 
between the monomers. This layer covers almost one third o f the A-C interface, and 
some of the hydrogen bonding between A and C is mediated by water molecules.
28
The tetrameric core of 77/PAP 1 is approximately 6000 A3 comprised of loops of each 
monomer of the enzyme (Singleton et a l , 1999) The core structure is maintained by 
hydrophobic interactions involving Phel79, Phel80, Leul81 and Leul82 of each 
subunit The A-B interface has hydrophobic interactions and salt bridges involving 
Arg81, Asp88, AsplOl and Argll9 also exist (see Figure 1 18) The A-C interface is 
formed by an external loop which folds towards the core structure Disulfide bridges 
exist between Cysl90 of each monomer (see Figure 1 19)
The A-C and A-D interfaces of PfuPAPX consist mostly of hydrophobic interactions 
(Tanaka et a l , 2001) There are no ionic interactions present at the A-C interface while, 
ten ionic bonds are present at the A-D interface (see Figure 1 20)
The A-B surface of Pho?A?l is rich in hydrophobic residues Val78, Val80, Asn81, 
Met82, Alal06, Alal07, Phel09, Vall29 and Leul30 which create an intersubunit 
hydrophobic core between A and B (Sokabe at a l , 2002) Residues Asp84, Asp97, 
A rg il, A rg il5 and Tyrl32 are also involved in ionic interactions at the A-B interface 
(see Figure 1 21) Two salt bridges (Glul73-Lysl22) and four hydrogen bonds (His72- 
Vall71, His72-Lysl74) exist between subunits A and C Most of the interactions 
between A and C are hydrogen bonds mediated by water, due to presence of a thin layer 
of water
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P/i/PAPI
77/PAP 1
Pho PA PI
Bam PAP I
Figure 1.15 Tetrameric Arrangement of PAP1.
R ibbon  d iag ram s o f  th e  te tram eric  crysta l s truc tu res  o f  /to /n P A P l, 77/PAP 1, P fu PAP1 and  P hoPA P X . T he  
m onom eric  subun its  a re  labelled  A  to  D  and  ind iv idually  co loured . T o  g ive  an idea o f  size , th e  d is tance  o f  
8 0  A h as  been ind ica ted  for fio m P A P l. G enera ted  using  D eepV iew  (sec  Section  2.11).
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Figure 1.16 The A-D Interface of BamPAP1.
R ibbon d iag ram  o f  th e  A -D  in terface o f  Æ am PA Pl. T h e  sam e subun it co lou r co d in g  as in F igure  1.11 
app lies. (1): R esidues Ile85 , A sn86 , L eu87 , A la i 11, A la i  12. T rp l 14. T y r l3 7 . T h r l3 8  and  T h rl4 1  o f  each  
m o n o m er co n tribu ting  to  h y d rophob ic  in te rac tions a re  show n. O n ly  th e  res id u es from  subun it A  have 
been labelled . (2): R esidues A rg82 , G lu89  and  l .y s l2 0  o f  each  m onom er involved in  ion ic  in te rac tio n s  are  
show n . For am ino  ac id  in fo rm ation  see A ppend ix  D. G enerated  u s in g  D eep  V iew  (see S ec tion  2.11).
Figure 1.17 The A-C Interface of Bam?A?l
R ibbon d iag ram  o f  th e  A -C  in terface o f  B am P A P  1. T h e  sam e subunit co lou r co d in g  a s  in F igu re  1 .1 1 
app lies. R esidues M ct76 , lie  1 3 1, P ro  132 . P ro  173. T h r l7 6 , L eu  177, A la  181, P ro  182  a n d  H is 188 
co n trib u tin g  to  h y d rophob ic  in te rac tions are  show n. O n ly  th e  res id u es from  su b u n it A  have been  labelled . 
For am m o  acid  in fo rm ation  see A ppend ix  D. G enerated  using  D eepV iew  (see  Section  2.11).
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Figure 1.18 The A-B Interface of 77/PAP1
R ibbon d iag ram  o f  th e  A -B  in terface  o f  77/PAP 1. T he sam e subun it co lou r co d in g  a s  in F igure  1.11 
app lies. R esidues invo lved  in ion ic  in te rac tions a re  show n. F or am in o  ac id  in fo rm ation  see A ppend ix  D. 
G enera ted  u sing  D eepV iew  (see Section  2 .1 1).
Figure 1.19 The A-C Interface of 77/PAP1
R ibbon d iag ram  o f  th e  A -C  in terface  o f  77/PAP 1. Ih e  sam e sub u n it co lou r co d in g  a s  m  F igure  1 .1 1 
app lies. T h e  d isu lph ide  b ridge is  show n an d  co loured  b y  CPK. co lo u r schem e (C  =  w hite . O  =  red . N  = 
b lue  a n d  S yellow ). F o r am in o  ac id  in fo rm ation  see A ppend ix  D. G enera ted  u sing  D eepV iew  (see  
Section  2.11).
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R ibbon d iag ram  o f  th e  A -D  in terface o f  P fuP /K P \. T he  sam e subunit co lou r co d in g  a s  in F igure  1.11 
app lies. (1): R esidues co n trib u tin g  to  hydrophob ic  in te rac tio n s a re  show n . O n ly  th e  re s id u es  from  sub u n it 
A have been labelled . (2): R esidues A rg80 . A sp87 , G lu99 . A sp  100 and  Lys 118 involved in  ionic 
in te rac tio n s  are  show n. F or am ino  ac id  in fo rm ation  see A ppend ix  D. G enera ted  u sing  D eepV iew  (see 
Section  2 .11).
Figure 1.20 The A-D Interface of P fuPAP1
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Figure 1.21 T he A-B In terface o f PhoPAP1
R ibbon d iagram  o f  th e  A -B  in terface  o f  P h o ? A P I .  The sam e su b u n it co lou r co d in g  a s  in F igu re  1.11 
app lies. (1): R esidues V al78 . V al80 . M et82, A la 106. A la 107. P h e l0 9 .  V a ll2 9  and  Leu 130 co n trib u tin g  to  
hyd rophob ic  in te rac tio n s a re  show n . O nly  th e  residues from  su b u n it A  have been labelled . (2): R esidues 
A rg77 . A sp84, A sp97 . A rg 115 and  T y r l3 2  involved in ion ic  in te rac tio n s  a re  show n. F or am ino  ac id  
in fo rm ation  see  A ppendix  D. G enera ted  using  D eep V iew  (see S ec tion  2.11).
BàinPAPl
T liP A P l
PfuPAPl
PhoPAPl
domain Z
BaaPAPl
T liP A P l
PfuPAPl
PhoPAPl
>ET SRHHPHIR
[fEkieTOTlI
H ATK T k
VTSaVHEDDIITGGGELH : 215 
S^LDYgEKDRDDIKIPL : 220
EeJ l -------------- : 208
SA2HSSQLR : 206
(lonm in 4
Figure 1.22 A m ino Acid A lignm ent of Æ am PA Pl, 77/PA P I, P/m PA P 1 and 
PhoPAPl
A lig n m en t w as crca tcd  using  M ultA lin  w ith  B losum 62-l2*2  p a ram e te rs  anil ed ited  u s in g  G en  D oc (see 
Section  2 .1 1). Sequence  hom ology  is rep resen ted  by  g re y  sca le  sh ad ing , w ith  b lack being  th e  h ighes t 
h om ology . C ata ly tic  re s id u es  have  been m arked  in red  (n u m b erin g  ap p lies  to  B a m P A P  1 ). F o r am in o  ac id  
in fo rm ation  see A ppend ix  D.
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1 .3 .1 2  M u t a t i o n a l  A n a l y s i s  o f  P A  P I
A scries of studies have been earned out using site-directed mutagenesis to probe a 
relationship between structure and function of PAP 1. This approach has also been used 
to determine the essential residues of the catalytic triad (see Section 1.3.10).
The three BamPAPX residues of the hydrophobic pocket PhelO, Phel3 and Phcl42 (see 
Section 1.3.11.2) were mutated to Tyr and Ala by Ito et al.. 2001. The catalytic 
efficiency of both /to/nPAPl F13mA and BamPAPI F 142mA decreased more than 
1000-fold while BamPAP 1 FI0mA which was severely destabilised and suffered a 
major structural change could not be purified. The Km value and ICcat obtained for 
BamPAP 1 FI OmY were 3.6-fold higher and 5.8-fold lower, respectively than wild type 
values.
The increased thermostability of 77/PAP1 (see Section 1.3.8) has been attributed to the 
inter subunit disulphidc bond formed by Cysl90 (see Figure 1.19). This residue 
corresponds to Seri85 in BamPAPX, Cysl88 in PfuPAPX and Seri81 in PhoPAPX by 
sequence alignment (see Figure 1.22). Although Cysl88 o f PfuPAPX is located in a 
similar position to Cysl90 in 77/PAP 1, PfuPAPX does not exhibit a disulphide bridge in 
the crystal structure (see Section 1.3.11.3).
To investigate the possibility o f intersubunit disulfide bonds effecting thermal stability 
in oligomeric enzymes Kabashima et al., (2001) substituted Seri 85 with a cysteine 
residue to yield /to/wPAPl S185mC. The enzyme was analysed by SDS-PAGE both 
with and without 2-ME. A molecular mass of 30 kDa and 60 kDa were obtained for the 
mutant, with and without 2-ME, respectively. These results suggest that the disulphide 
bridge between the mutated Cysl85 bonded two subunits. Introduction of the disulphide 
bond did not affect the catalytic efficiency of the enzyme, while thermal stability was 
increased by 30°C. However, under reducing conditions using 1 mM DTT, no 
difference in thermal stability was observed, indicating that the enhanced 
thermostability was due to the introduction of the intersubunit disulphide bond.
1 .4  P A P 2
In 1981, Browne et al.. were the first to report the presence of two distinct pyroglutamyl 
peptidase activities in guinea pig brain. They reported the presence o f a membrane- 
associatcd enzyme (classified PAP2) that possessed a high molccular weight and was 
rendered inactive in the presence of DTT and EDTA, while the soluble form of PAP (sec 
Section 1.3) required these substances to remain active.
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The Enzyme Commission List classifies PAP2 as an omega peptidase (EC 3 4 19 6) In 
the alternative Merops database PAP2 has been assigned under metallopeptidase clan 
MA, family Ml Zinc has been identified as the catalytically active metal ion for the 
majority of metalloproteases Researchers observed that after the enzyme was inactivated 
by EDTA treatment that it could be restored by the addition of Zn2+ (Czekay and Bauer,
1993, Gallagher and O’Connor, 1998)
PAP2 is primarily located m the mammalian central nervous system with significantly 
smaller levels observed in other tissues It appears to be associated exclusively with 
neurons, primarily on the synaptosomal membrane, and has been identified in a number 
of sources which include rat (Taylor and Dixon, 1979, Bauer, 1994), porcine ( Bauer,
1994, Schmeitmeier, et a l , 2002, bovine (O’Leary and O’Connor, 1995, Gallagher and 
O’Connor, 1998, guinea pig (O’Connor and O’Cuinn, 1985), rabbit (Wilk and Wilk, 
1989), mouse ( Cruz et a l , 1991), human (Schomburg et al f 1999)
PAP2 is of relatively large molecular size with estimates of 230,000-240,000 Da (O 
Connor and O’Cuinn, 1984, Wilk and Wilk, 1989, Bauer, 1994, O’Leary and O’Connor,
1995) The enzyme was found to be inhibited by the metal chelators EDTA, EGTA, 8- 
hydroxyquinoline, 1-10-phenanthrolme and showed no sensitivity towards sulphydryl 
reagents (O’Connor and O’Cuinn, 1984, Wilk and Wilk, 1989, Bauer, 1994, O’Leary 
and O’Connor, 1995, Gallagher and O’Connor, 1998) Inhibitors of cysteine, serine and 
aspartyl proteases did not affect PAP2 activity Active site directed inhibitors of PAP 1 
were also ineffective towards PAP2
In recent times a specific inhibitor of PAP2 has been identified It was identified by 
screening extracts from marine species of the Cuban coastline and was isolated from the 
marme annelida Hermodice carunculata, (HcPL) HcPL inhibited PAP2 with an apparent 
K, of 51 nM It was found to reduce both mouse pituitary and brain PAP2 activities It 
was the first Ml family zinc metallopeptidase inhibitor to be isolated from marme 
invertebrates (Pascual et a l , 2004)
The predominant feature of PAP2 is its unique substrate specificity PAP2 has been 
reported to remove the N-terminal pGlu residue from only TRH or closely related 
tnpeptides or tripeptide amides (O’Connor and O’Cuinn, 1984, , Elmore et a l , 1990) 
Enzyme activity was abolished when the pGlu residue of the TRH sequence was replaced 
with a Glu residue or when the His was replaced with either a Phe or Nval residue While 
PAP2 was capable of limited hydrolysis of pGlu-His-Pro-Gly, the lengthened substrates 
pGlu-His-Pro-Gly-NH2 and pGlu-His-Pro-Gly-Lys were not hydrolysed Only tripeptides
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containing histidine in the central position were hydrolysed Pyroglutamate-containing
dipeptides including pyroglutamyl histidine were not hydrolysed nor were pyroglutamyl-
containing peptides with more than three amino acids ( O’Connor and O’Cuinn, 1984)
The genes for rat and human PAP2 were cloned (Schauder et al 1994, Schomburg et
a l , 1999) The deduced highly homologous amino acid sequences are consistent with a
glycosylated, membrane anchored peptidase The extracellular domain of PAP2
%
contains the HEXXH + E motif which is consistent with zinc-dependent 
metallopeptidases where the three zinc ligands are the two His residues and the Glu 
residue C-terminal to the HEXXH motif
Human and rat PAP2 sequences were found to exhibit a high degree of conservation with 
96% of residues being identical Northern blot analysis demonstrated a restricted tissue 
distribution with highest transcript levels in the brain Southern analysis suggested that 
the gene is present as a single copy in human, monkey, rat, mouse, dog, bovine, rabbit 
and chicken DNA
A serum form of PAP2 of liver origin has been reported, which has the same degree of 
specificity for TRH and identical biochemical characteristics as the membrane-bound 
form (Cummins and O’Connor, 1998) A recent study (Schmitmeier et a l , 2002) has 
supported the hypothesis that both forms of PAP2 are derived from the same gene, 
whereby the serum enzyme is generated by proteolytic cleavage of the membrane- 
bound form in the liver
1 5 P ro je c t  A im s a n d  O b je c tiv e s
The main objective of this research project was to clone the gene for bovine PAP1 
followed by expression of this protein utilizing a method which had been previously 
developed for the expression of human PAP1 Following expression bovine PAP1 could 
be then purified using one-step affinity-tag chromatography This would allow for the 
molecular, biochemical and kinetic characterisation of bovine PAP1 Due to the 
availability of recombinant human PAP1 (Vaas, 2005), a comparative study of these 
two enzymes could be employed This study will allow us to further characterise this 
family of cysteine peptidases There are multiple homologues of this family and it is 
important to compare them to determine functionality and identify essential amino acid 
residues
A series of site-directed and random mutants would be generated for human PAP1, 
giving valuable insight into the catalytic and structural properties of human PAP1
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An attempt to crystallise human PAP1 would be made using a sparse matnx screening 
approach A visit to a laboratory specialising in protein crystallography in Toronto, 
Canada would also be made during this work Using X-ray crystallography and site- 
directed mutagenesis a structure/function relationship could be mvestigated Such 
studies would present an improved understanding of molecular structures and 
mteractions of proteins could open way to inhibitor design
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CHAPTER TWO 
M a te r ia ls  &  M e th o d s
2.1 Bacterial Strains, Primers and Plasmids
The bacterial strains, primers and plasmids used in this work are listed in Tables 2.1, 2.2 
and 2.3 respectively.
Table 2.1 Bacterial Strains
Strain Genotype Features/Uses Source
E sc h e r ic h ia  co li
X L -10 G o ld  A(/wc/ A )183 A (/w c/C B -/jsdSM R -m rr)173 H igh transfo rm ation  e ffic icn cy S tra tag en e
e n d  A. 1 re c A  1 re lA  1 gyrA .96  su p E 4 4  th i -1 la c  H te A n tib io tic  res istance
I P p r o A B  /flclqZAM  15 ::Tn lO f/rf" ) A m y  (cam *)J E xpression  host
Table 2.2 Primers (obtained from MWG-Biotech AG)
Name Sequence Tm
(5’ - 3 ’) C O
H u m a n  P A P I
A n a ly s is /M u ta g e n e s is
P A PH sA A A C A G A A G C A G G T C C G A G G 58.8
P A P H sB C A G G A T G A G G T C T T A G G A G A 57.3
P A PH sE m K -F A C A G T C A C A C T G A A G A A A T G T G G A C A C A A C 65.4
P A P H sE m K -R G T T G T G T C C A C A T T T C T T C A G T G T G A C T G T 65 .4
PA PH sF.m Q -F A C A G T C A C A C T G C A G A A A T G T G G A C A C A A C 66.8
P A P H sE m Q -R G T T G T G T C C A C  A  T IT C T G C A G T G T G A C T G T 66 .8
PA PH .sEm D -F A C A G T C A C A C T G G A T A A A T G T G G A C A C A A C 66.3
P A P R sE m D -R G T T G T G T C C A C A T T T A T C C A G T G T G A C T G T 66.3
B o v in e  P A P I
C lo n in g /M u ta g e n e s is
PA PB tA G A A C C C G C C A T G G A G C A G C C C A G G A A G G C G G 75.0
P A P B lB C A G C A A G G A T C C G T G rrC A T G G C A A C A G T T G 69.5
PA P B tE m Q -F A A C C G C A G T C A C A C T G G A C A A G F G T G G A C A 69.5
PA PBtF.m Q -R T G T C C  A C  A C T T G T  C C  A G T  G T G  A C T  G C G G T T 69 .5
PA P B tC m F -F G C A G G C A G G T A C C T C IT C G A C T T C A C C T A C 70.9
P A P B tC m F -R G T A G G T G A A G T C G A A G A G G T A C C T G C C T G C 70.9
P A P B tH m D -F C G C T C A G C C T T T G T T G A C G T G C C C C C T C T G 73.6
P A P B tH m D -R C A G A G G G G G C A C G T C A  A C  A  A A G G C T G A G C G 7 3 .6
P A P B tA m T -F T C A G G C A T G G C A A C C A C A G T C A C A C T G G A G 70.9
P A P B tA m T -R C rC C A G T G T G A C rG T G G T T G C C A T G C C T G A 70.9
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PA PB tC m Y -F
P A P B tC m Y -R
PA P B tE m K -F
P A P B tE m K -R
A m p-fo r
A m p-rev
C A G T C A G A A G G C A A A A IC A A C T A T T G C C A T  
A T G G C A A T A G T T G A  T T T T G C C T T C T G A C T G  
G G C A A A A T C A A C T G T T G C C A T A A A C A C G G A  
T C C G T G n T A T G G C A A C A G lT G A T T T T C C G  
G A G T A T T C A A C A T T T C C G T G  T C G C  
C C A A  T G C r r  A A T C A G T G A G G C 'A C
64 .0
64 .0
65.4
65 .4
61 .0  
60 .7
T m tak es into accoun t on ly  those  bases tha t b ind. 
T .  -  (69 .3  + 0.41(% G C )1 -  650/length
Sequencing
M 1 3rev (-29 )
M 1 3 un i(-21 )
PQ E for
P Q E rev
P T rcH isrev
M 13rev(-49)
C  A G G  A A A C A G C T  A T G  A C C  
T G T A A A A C G A C G G C C A G T  
G T A T C A C G A G G C C C T T T C G T C T  
C A T IA C T  G G A T C T A T C A  A C A G G  A G  
C rT C T G C G T T C T G A T T T  A A T C T G  
G A G C G G A T A A C A A T T T C A C A C A G G
(pC R 2.1  fo rw ard  p rim er. M W G -B io tech  
(pC R 2.1  reverse  p rim er, M W G -B io tech ) 
(pQ E -60  fo rw ard  prim er. M W G -B io tech  
(p Q E -6 0  reverse  p rim er. M W G -B io tech ) 
(pPC '225 forw ard  prim er, M W G -B io tech  
(pP C 225  reverse  p rim er, M W G -B io tech )
Tabic 2.3 Plasmids
Plasmid Description Source
V e c to rs
T A  c lon ing  vector: P lac, a m p K, kan*, lacZ a , C o lE l orig in . 
F igure  2.1
E xpression  vector: T 5  p ro m o ter//ac  o p eron , am p*, 6xH is 
sequence a t 3 ’ end  o f  M C S, C o lE l o rig in . F igure  2.2 
M odified  d e riva tive  o f  pK K 223-3  expression  vecto r from  
A m crsham  Pharm acia: P tac, am p*. C o lE l o rig in . E lim ination  o f  
/tom H I site ex ternal to  M CS
M odified  d e riva tive  o fp P C 2 2 3 . Insertion  o f  1800 bp fragm ent in 
B a m H l o f  M C S for ease o f  c lon ing . F igu re  2.3 
C lon ing  vector: P lac , am p*, la cZ a , tet*.
pC R 2.1
p Q E -6 0
P PC 223
pPC'225
p B R 322
Invi trogen  
Q iagen  
C la rk e  (2000 )
C la rk e  (2000)
A m ersham
P harm acia
Constructs
p Z K l
pZ K 2
p /.K 3
pC R 2.1  con ta in in g  bov ine  PAP1 O R F  T h is  W ork
p Q E -6 0  con ta in in g  bovine PAP1 O R F w ith  3 ’ 6xH is sequence  T h is  W ork 
fusion.
p P C 225  eo n tam m g  bovine PAP1 O R F w ith  3 '  6 x II is  seq u en ce  T h is  W ork 
fusion, sub-cloned  from pZ K 2, for expression  and  su b seq u en tly
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pRV5
purifica tion
pP C 225  con ta in ing  hum an  PAP1 O R F  w ith  3 ’ 6xH is sequence  V aas, 2005 
fusion for expression  and su b seq u en tly  pu rifica tio n
p Z K 3  m u ta n t d e r iv a tiv e s
p7.K 3_F.85m O M utation : F.85 to  0  (G A A  to  C A A ) T h is  W ork
PZ K 3_C 149m F M utation : C 149  to  F (T G C  to  T T C ) T h is  W ork
pZ K 3_H 168m D M utation : H I68  to  D  (C A C  to  G A C ) T h is  W ork
pZ K 3 _ A 8 1 m T M utation : A81 to  T  (G C A  to  A C A ) T h is  W ork
pZ K 3_C 205m Y M utation : C 205  to  Y (T G T  to  T A T ) T h is  W ork
pZ K 3_E 208m K M utation : E208 to  K  (G A A  to  A A A  ) T h is  W ork
p R V 5  m u ta n t d e r iv a tiv e s
S ite -D irec ted  M u ta g e n e s is
p Z K _ E 8 5 m D M utation : E85 to  D  (G A G  to  G A T ) T h is  W ork
pZ K _E 85m K M utation : E85 to  K  (G A G  to  A A G ) T h is  W ork
pZ K _E 85m Q M utation: E 85  to  Q  (G A G  to  C A G ) T h is  W ork
R a n d o m  M u ta g en esis
pZ K _G 35m D M utation : G 33 to  T  (G G C  to  G A C ) T h is  W ork
p Z K _ N 9 0 m D M utation : N 90  to  D  (A A C  to  G A C ) T h is  W ork
p Z K _M 192m T M utation : M 192 to  T  (A T G  to  A C G  ) T h is  W ork
p Z K _K 94m R M utation : K 94  to  R (A A G  to  A G G  ) T h is  W ork
p Z K A  165m  V M utation: A 165 to  V  (G C C  to  G T C  ) T h is  W ork
p Z K _P 48m R M utation : P48 to  R (C C G  to  C G G  ) T h is  W ork
p Z K _A 184m P M utation: A 184 to  P ( G C C  to  C C C  ) T h is  W ork
p Z K _P 48m Q .D 143m H M utation: P48 to  0  (C C G  to  C A G  ), D 143 to  H (G A T  to  C A T  ) T h is  W ork
p Z K _P 67m R M utation : P67 to  R (C A C  to  C G C  ) T h is  W ork
pZ K _M 122m V M utation: M 122 to  V  (A T G  to  G T G  ) This W ork
pZ K _G 77m D M utation: G 77 to  D  (G G C  to  G A C  ) T h is  W ork
pZ K _N 22m H M utation: N 22 to  H (A A C  to  C A C ) T h is  W ork
pZ K _A 27m T M utation : A 27 to  T  (G C A  to  A C A  ) T h is  W ork
p Z K _P 4m S ,S  164m P M utation: P4 to  C  (C C G  to  T C G ), S I 64  to  P (T C A  to  C C A ) T h is  W ork
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AndD-1 - A'AGCT T
Figure 2.1 pCR2.1 Vector
T h e  3 9 0 6  bp  T A  c lo n in g  vecto r pC R 2.1  (see T ab le  2 .3 ). T h e  m u ltip le  c lo n in g  s ite  (M C S ) en zy m e s are  
ind ica ted . T h e  T A  c lon ing  s ite  is  situa ted  w ith in  the L a c Z a  O RF (g reen), w hich is under th e  con tro l o f  the 
P/lK. p rom o ter (yellow ). A m picillin  and K anam ycin  resistance  g en es (am p* &  k a n R) a re  show n in red . 
G enera ted  using  pD R A W 32 (see Section  2.11).
f c o R l -1  - CT A A T T .C
Figure 2.2 pQE-60 Vector
T he 3431 bp c lon ing /exp ression  vecto r p Q E -6 0  (see T ab le  2 .3). T he m u ltip le  c lo n in g  s ite  (M C S ) 
enzym es a re  ind ica ted . T h e  6x H is co d in g  sequence  (g reen ) is  situa ted  a t th e  3* en d  o f  th e  M C S , w h ich  in 
tu rn  \% n in iated  dow nstream  o f  th e  T S p rom oter//**  opcron  (yellow ). A m p ic illin  rcs i.n an cc  gene  (a m p ") is  
show n in  red . G enera ted  using  pD R A W 32 (sec Section  2.11).
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EcoKl • 1 • G’AATT C
1 8 1 ' -  G 'O A T C  C  
183" • A 'A O C T ’ t
Figure 2.3 pPC22S Vector
T he 6392  bp c lon ing /exp ression  vector pP C 225  (see T ab le  2 .3 ). T he m u ltip le  c lo n in g  s ite  (M C S ) 
en zy m es a re  ind ica ted . A  1800 bp  sequence  (w h ile  box) is  s itua ted  w ith in  th e  M C S. w hich  in tu rn  is 
s itua ted  dow nstream  o f  th e  P**. p ro m o te r (yellow ). A m picillin  res istance  gene  (am p*) is  show n in red. 
G enera ted  u s in g  pD R A W 32  (see Section  2.11).
fcoRI ■ 1
Figure 2.4 pKV5 Vector
T h e  5 .235  bp  co n stru c t pP R V 5  (see  T ab le  2 .3). pP C 225  con ta in in g  PA P1 O R F w ith  3 ’ 6 x H is  sequence  
fusion, sub-c loned  from  p Q F 6 0 . for exp ression  and  subsequen tly  p u rifica tio n . T he A m picillin  res istance  
g en e  (am p*) is  show n in p ink. G enera ted  using pD R A W 32 (see Section  2 .1 1).
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2 2 Media, Solutions and Buffers
All chemicals and reagents were obtained from Sigma-Aldrich unless otherwise stated 
All chemicals were Analar grade Microbiological media were obtained from Oxoid 
Sterilisation was achieved by autoclaving at 121°C and 15 lb/in2 for 20 min, unless 
otherwise stated
Luna Bertani Broth (LB)
Adjusted to pH 7 0 with NaOH Sterilised by autoclaving For solid broth LB, 15 g/L 
Techmcal Agar No 3 (Oxoid) was included
SOB Broth
After autoclaving, MgCl2 and MgS04 were added to 10 mM of sterile 1 M stock 
solutions
Tryptone
NaCl
Yeast Extract
10 g/L 
10 g/L 
5 g/L
KC1
PH
Tryptone
NaCl
Yeast Extract
20 g/L 
500 mg/L 
5 g/L 
2 5 mM 
70
TE Buffer
Tns-HCl
Na2-EDTA
pH 80
10 mM
1 mM
TAE Buffer (50X)
Tns 242 g/L
Glacial Acetic Acid 57 1 ml/L
EDTA 100 ml/L (of 0 5 M stock) 
80pH
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STET Buffer
Sucrose 8% (w/v)
Tnton X-100 5% (v/v)
Tns-HCI 50 mM
Na2-EDTA 50 mM
pH 8 0
Solution 1 of 1-2-3 Method (see Section 2 4 12)
Glucose 50 mM
Na2-EDTA 10 mM (from 0 5 M stock)
Tns-HCI 25 mM (from 1 M stock)
Solution 2 of 1-2-3 Method (see Section 2 4 12)
NaOH 200 mM
SDS 1% (w/v)
Solution 3 of 1-2-3 Method (see Section 2 4 12)
Potassium acetate 3 M 
pH 4 8
To 60 ml of 5M potassium acetate, 11 5 ml of glacial acetic acid and 28 5 ml of dH20  
were added The resulting solution was 3 M with respect to potassium and 5 M with 
respect to acetate
TB Buffer
Pipes 10 mM
CaCl2 15 mM
KC1 250 mM
pH 67
The pH was adjusted with KOH and then MnCl2 was added to 55 mM The solution was 
filter sterilised through a 0 22 fiM membrane (Millipore) and stored at 4°C
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RF1 Buffer
RbCl 100 mM
CaCl2 10 mM
Potassium acetate 30 mM 
Glycerol 15%(v/v)
pH (with HC1) 5 8
After the pH had been adjusted MnCl2 was added to 50 mM The solution was filter 
sterilised through a 0 22 ¡iM membrane (Millipore) and stored at 4°C
RF2 Buffer
RbCl 10 mM
MOPS 10 mM
CaCl2 75 mM
Glycerol 15% (v/v)
pH 68
The solution was filter sterilised through a 0 22 jiM membrane (Millipore) and stored at
Gel Loading Dye (6X)
Bromophenol Blue 0 25%
Xylene Cyanol 0 25%
Ficoll (Type 400) 15%
Bromophenol Blue and/or Xylene Cyanol were used as appropriate On a 1% agarose 
gel, bromophenol blue and xylene cyanol migrate approximately with the 300 base pairs 
and 4000 base pairs DNA fragments respectively
Ethidium Bromide Stain
A 10 mg/ml stock solution in dH20  was stored at 4°C in the dark For the staining of 
agarose gels, 100 /xl of the stock solution was mixed into 1 L of dH20  The staining 
solution was kept in a plastic tray and covered to protect against light After use 
ethidium bromide stain was collected and filtered through a deactivating filter according 
to the method of Schleicher & Schuell
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2.3 Antibiotics
■ Ampicillin was prepared in CIH2O at a concentration of 100 mg/ml and stored at 
-20°C. The working concentration for E. coli was 100 /ig/ml.
■ Chloramphenicol was prepared in ethanol at a concentration o f 100 mg/ml and 
stored at -20°C. The working concentration for E. coli was 25 /xg/ml.
■ Tetracycline was prepared in 50 % ethanol at a concentration o f 10 mg/ml and 
stored at -20°C. The working concentration for E. coli was 10 /¿g/ml.
■ Kanamycin was prepared in dH20  at a concentration of 100 mg/ml and stored at 
-20°C. The working concentration for E. coli was 30 /ig/ml.
2.4 Isolation and Purification of DNA and RNA
2.4.1 Isolation of Plasmid DNA
Two procedures for the isolation o f plasmid DNA were variably employed. The 1-2-3 
Method (see Section 2.4.1.1) was used routinely. The Genelute Plasmid Miniprep Kit 
(Sigma, see Section 2.4.1.2) was used to prepare consistently pure and supercoiled 
plasmid DNA, mostly for the purpose of DNA sequencing.
2.4.1.1 1-2-3 Method
This method is adapted from the procedure described by Bimboim and Doly (1979). 1.5 
ml of a bacterial culture was centrifuged in a microfuge tube at 13,000 rpm for 5 min to 
collect the cells. The supernatant was discarded and the cell pellet re-suspended in 200 
fiI o f Solution 1. Alternatively, bacterial growth was taken off an LB agar culture plate 
with a sterile loop and re-suspended in 200 /xl of Solution 1. The re-suspension was left 
for 5 min at room temperature. 200 p\ o f Solution 2 was added, the tube was mixed by 
inversion and placed on ice for 5 min. 200 //I of Solution 3 was added and the tube 
mixed by inversion and placed on ice for 10 min. A clot of chromosomal DNA was 
collected by centrifugation at 13,000 rpm for 10 min (Hermle Bench Centrifuge, 
Z160M). The supernatant was removed and placed in a new microfiige tube with 400 fi\ 
o f phenol chloroform isoamylalcohol (25:24:1) and mixed by brief vortcxing. Upon 
centrifugation at 13,000 rpm for 5 min the mixture is divided into an upper aqueous and 
lower organic layer. The aqueous layer was removed to a new microfuge tube with an 
equal volume of isopropanol and mixed by inversion. The tube was left at room 
temperature for 5 min and then centrifuged at 13,000 rpm for 20 min to pellet the 
plasmid DNA. The pellet was washed with 70% ethanol and then dried briefly in a
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SpeedVac (Savant) vacuum centrifuge. The plasmid DNA was resuspended in 50 /¿I of 
TE buffer and 1 ¡l\ of Ribonuclease A (see Section 2.8) was added to digest co-purificd 
RNA. Plasmid DNA was stored at -20°C\
2.4.1.2 GenElute Plasmid Miniprep Kit
This miniprep kit was used according to the manufacturer’s instructions: 1.5 ml of a 
bactcrial culture in a microtiige tube was centrifuged at 13,000 rpm for 5 min (Hermle 
Bench Centriiiige, Z160M) to collect the cells. The supernatant was discarded and the 
cell pellet was completely re-suspended in 200 /zl of re-suspension solution. 200 n\ of 
lysis solution was mixed in by inversion to lyse the cells. 350 //I neutralisation/binding 
buffer was added and mixed by inversion to precipitate cell debris, lipids, proteins and 
chromosomal DNA. The precipitate was collected by centrifugation at 13,000 rpm for 
10 min. The supernatant was transferred to a spin column in a micro frige tube and 
centrifuged at 13,000 rpm for 1 min to bind the plasmid DNA. The flow through was 
discarded and 750 /¿I of washing solution was added followed by further centrifugation 
at 13,000 rpm for 1 min. The flow through was discarded and the column was 
centrifuged at 13,000 rpm for 1 min to dry the spin column. The spin column was 
transferred to a new microfuge tube and 100 //I TE buffer was added. The DNA was 
collected by centrifugation at 13,000 rpm for 1 min.
2.4.2 Isolation of DNA From Agarose Gels
The PerfectPrep Kit (Eppendort see Section 2.4.2.1) was used to purify DNA from 
agarose gels.
2.4.2.1 PerfcctPrep Kit
The kit was used according to the manufacturer’s instructions: The desired DNA band 
was excised from the agarose gel using a scalpel. The gel slice was weighed and placed 
in a micro fuge tube. The tube was incubated at 65°C for 10 min to completely dissolve 
the agarose in the chaotropic (binding buffer) solution. One gel slice volume of 
isopropanol was added and mixed by inversion. The solution was transferred to a filter 
column in a micro fuge tube and centrifuged at 13,000 for 1 min to bind the plasmid 
DNA. The flow through was discarded and 750 /il of washing solution was added 
followed by further centrifugation at 13,000 rpm for 1 min. The flow through was 
discarded and the column was centrifuged at 13,000 rpm for 1 min to dry the spin
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column The spin column was transferred to a fresh microfuge tube and 30 ¡i\ TE buffer 
was added The DNA was eluted by centrifugation at 13,000 rpm for 1 min
2 4 3 Purification and Concentration of DNA Samples
The sample containing the DNA to be precipitated was brought to 400 ¡i\ with dtfeO 
400 fii of phenol chloroform isoamylalcohol (25 24 1) was added and mixed by brief 
vortexing (5 seconds) Upon centrifugation at 13,000 rpm for 5 min the mixture is 
divided into an upper aqueous and lower organic layer The aqueous layer was removed 
to a new micro fuge tube with an equal volume of chloroform and mixed by brief 
vortexing The tube was centrifuged at 13,000 rpm for 5 min and the aqueous layer was 
transferred to a new micro fuge tube A 1/10 volume of 3 M sodium acetate was added 
followed by an equal volume of isopropanol and mixed by inversion The tube was left 
at room temperature for 60 min and then centrifuged at 13,000 rpm for 20 min to pellet 
the DNA The pellet was washed with 70% ethanol and then dried briefly in a 
SpeedVac (Savant) vacuum centrifuge The DNA was resuspended in 20-50 /¿I of TE 
buffer
2 4.4 Isolation of RNA
RNA was isolated using Trizol Reagent (Invitrogen), a mono-phasic solution of phenol 
and guanidine isothiocyanate This was based on the method developed by 
Chomczynski and Sacchi (1987) 100 mg of tissue was homogenised in 1 ml of Trizol 
reagent using a glass-Teflon homogemser (treated with RNase AWAY, Molecular Bio- 
Products, inc) and transferred to a microfuge tube Alternatively, a pellet of cultured 
cells was lysed in 1 ml of Trizol reagent by repeated pipetting The sample was 
incubated at room temperature for 5 min to allow complete dissociation of 
nucleoprotein complexes 200 /¿I of chloroform was added, mixed by brief vortexing 
and mcubated at room temperature for 3 mm The phases were separated by 
centrifugation at 13,000 rpm for 15 min The upper aqueous layer was transferred to a 
fresh microfuge tube 500 fi\ of isopropanol was added and mixed by inversion The 
sample was incubated at room temperature for 10 min to precipitate the RNA and then 
centrifuged at 13,000 rpm for 10 min The supernatant was discarded and the RNA 
pellet was washed with 1 ml of 70% ethanol The RNA pellet was air-dried and 
dissolved in 30 jLil RNase-free water Any possible DNA contamination was eliminated 
by treatment with Deoxyribonuclease I (see Section 2 8)
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2 4 5 Quantification of DNA and RNA
Nucleic Acid concentration was quantified by UV spectrometry A dilution of the 
sample (typically 1/50) in dP^O was measured for absorbance at 260 nm A reading of
1 0 corresponds to 50 ^g/ml of DNA or 40 ¿tg/ml of RNA
2 5 Agarose Gel Electrophoresis
DNA was analysed by migrating electrophoretically through (typically 0 7-2 %) agarose 
gels in a BioRad horizontal gel apparatus Agarose was added to TAE buffer to the 
required concentration and dissolved by boiling The agarose solution was poured into 
plastic trays and allowed to set with a plastic comb fitted to create sample wells TAE 
buffer was used as the running buffer Loading dye was mixed with the DNA samples 
to facilitate loading and to give indication of migration distance during electrophoresis 
When RNA samples were being analysed 0 1% (v/v) DEPC was included in the TAE 
buffer Gels were run at 140 volts for 20-40 mm depending on size of gel Gels were 
stamed for 15 min by immersion in an ethidium bromide staining solution Gels were 
visualised usmg a UV transilluminator coupled with an image analyser to capture the 
image to a PC On every gel 0 5 fig of 1 Kb Plus DNA Ladder (Invitrogen, see Figure 
2 5) was run as a molecular size marker
hi m  hsso
5.000
121000
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Figure 2 5 DNA Ladder 1 Kb Plus (Invitrogen)
1 0% Agarose Gel
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2.6 Competent Cells
The two methods used to prepare competent cells were the rubidium chloride method 
(see Section 2.6.1) and the TB method (see Section 2.6.2). The former method was 
favoured for its reliability.
2.6.1 Rubidium Chloride Method
This is an adaptation o f the method outlined by Hanahan (1985). Sterile conditions were 
used throughout. 10 ml o f LB broth containing the relevant antibiotics was inoculated 
with a single colony o f  the desired bacterial strain from a plate stock and cultured 
overnight at 37°C. A 1 L flask with 200 ml o f LB broth was inoculated with 2 ml o f  the 
overnight culture and incubated at 37°C shaking at 225 rpm (Oribsafe Heated Orbital 
Shaker, Sanyo). When the culture had reached an OD600 o f --0.5 (early-mid exponential 
phase) the flask was cooled in ice water. All subsequent transactions took place at 4°C. 
The culture was transferred to a sterile centrifuge bottle. The cells were collected by 
centrifugation at 3,000 rpm for 5 min (using a Beckman JA-14 rotor). The supernatant 
was decanted and the cells gently re-suspended in 60 ml o f chilled RF1 buffer. The 
suspension was left on ice for 90 min. The cells were again collected by centrifugation 
at 3,000 rpm for 5 min. The supernatant was decanted and the cells gently re-suspended 
in 8 ml of chilled RF2 buffer. Aliquots o f 800 /xl were prepared in sterile 1.5 ml 
microfuge tubes and flash frozen using -70°C ethanol. The competent cells were stored 
at -70°C. Cells were routinely used within a few weeks.
2.6.2 TB Method
This method was developed by Inoue et al. (1990). Sterile conditions were used 
throughout. 10 ml o f  LB broth containing the relevant antibiotics was inoculated with a 
single colony o f the desired bacterial strain from a plate stock and cultured overnight at 
37°C. A 1 L flask with 200 ml o f SOB broth was inoculated with 2 ml o f the overnight 
culture and incubated at 37’C shaking at 225 rpm. When the culture had reached an 
ODftoo o f 0.4, as optimised by Inoue et al. (1990), the flask was cooled in ice water. All 
subsequent transactions took place at 4°C. The culture was transferred to a sterile 
centrifuge bottle. The cells were collected by centrifugation at 3,000 rpm for 5 min 
(using a Beckman JA-14 rotor). The supernatant was decanted and the cells gently re­
suspended in 80 ml o f chilled TB butter. The suspension was left on ice for 10 min. The 
cells were again collected by centrifugation at 3,000 rpm for 5 min. The supernatant was
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decanted and the cells gently re-suspended in 15 ml of chilled TB buffer DMSO was 
added drop-wise to 7% (v/v) The suspension was left on ice for 10 min Aliquots of 
800 fil were prepared in sterile 1 5 ml microfuge tubes and flash frozen using -70°C 
ethanol The competent cells were stored at -70°C Cells were routinely used within a 
few weeks
2 6 3 Transformation of Competent Cells
An aliquot of competent cells was thawed on ice 200 fil of the cell suspension was 
mixed gently with 1-50 ¡i\ of plasmid DNA in a sterile 1 5 ml micro fuge tube The 
mixture was left on ice for 30 min The cells were heat-shocked at 42°C for 30 seconds 
and placed back on ice for 2 min 800 fil of LB broth was added to the cells followed by 
incubation at 37°C for 60 min 100 fil of the transformation suspension was spread on an 
LB agar plate containing the relevant antibiotics and incubated at 37°C overnight
2 6 4 Determining Cell Efficiency
Competent cell efficiency is defined in terms of the number of colony forming units 
obtained per fig of transformed plasmid DNA A 10 ng/¡il stock of pBR322 plasmid 
DNA was diluted to 1 ng/fil, 100 pg/jul and 10 pg/jttl 1 fil of each dilution was 
transformed as described above The cell efficiency was calculated from the number of 
colonies obtained, taking into account the dilution factor and the fraction of culture 
transferred to the spread plate
2 7 Bacterial Storage
Bacterial strains were stored as 40% glycerol stocks 750 fi\ of an overnight culture was 
mixed with 750 ¿¿1 sterile 80% glycerol in a microfuge tube If the bacterial strains 
contained plasmids, the selective antibiotic was included in the culture Duplicate stocks 
were stored at -20°C and -70°C Working stocks streaked on LB agar plates, containing 
antibiotics where appropriate, were stored at 4°C Bacterial samples containing plasmids 
to be sent for commercial DNA sequencing were prepared as stab cultures 1 ml of LB 
agar containing the selective antibiotic was added to a microfuge tube and allowed to 
set The tube was inoculated by stabbing using a sterile pin with bacterial growth taken 
from an LB broth culture
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2 8 Enzymes
All restriction endonucleases, Antarctic Phosphatase, T4 DNA ligase were obtained 
from Invitrogen Life Technologies or New England Bio labs Deoxyribonuclease I 
(Ribonuclease free), Ribonuclease A (Deoxyribonuclease free), REDTaq polymerase 
were obtained from Sigma-Aldrich PfuTurbo DNA polymerase was obtained from 
Stratagene AMV reverse Transcriptase was obtained from Promega Enzymes were 
used with their relevant buffers according to the manufacturers instructions
2 81  Reverse Transcription
1 fig of RNA was combined with 0 5 fig oligo(dT)i5 pnmer (alternatively 1 fi\ of 25 fiM 
specific reverse primer) and the volume made to 5 fil with dUiO The mixture was 
incubated at 70°C for 10 mm and then placed on ice for 5 min To the mixture were 
added dNTP’s to a final concentration of 500 fiM each, 1 unit AMV reverse 
transcriptase and 2 (i\ specific lOx enzyme buffer The volume was brought to 20 ji\ 
with dFbO The first strand was synthesised at 42°C for 60 min followed by inactivation 
of the transcriptase at 95°C for 2 min 1 fi\ of the reaction was used as template for PCR
2 8 2 Polymerase Cham Reaction
PCR reactions (Mullis and Faloona, 1987) were carried out using a Peltier Thermal 
Cycler The standard PCR reaction volume was 50 fil containing 1 /zl template (10-100 
ng), 1-2 5 mM MgCb, 0 5 fiM of each primer, 200 fxM of each dNTP, 1 unit RED7b#
DNA polymerase and 5 fil specific 1 Ox enzyme buffer The standard PCR program was
Stage 1 Step 1 95°Cforl0min
Stage 2 (30 cycles) Step 1 95°C for 1 min
Step 2 Tann for 30 sec
(Tann was routinely 5°C below the Tm of the pnmers)
Step 3 72°C for 1 min per Kb to be synthesised 
Stage 3 Step 1 72°Cforl0min
2 8 3 Alkaline Phosphatase, Calf Intestinal (CIP) Treatment
The standard CIP reaction volume was 20 fi 1 containing 16 fil plasmid preparation (10- 
100 ng)» 1 unit Alkaline Phosphatase enzyme and 2 fil specific lOx enzyme buffer The 
reaction mixture was incubated at 37°C overnight
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2 9 Gene Manipulation
A variety of plasmid-based gene cloning approaches such as described by Maniatis et 
a l , (1982) were used, employing PCR techniques (see Section 2 8 2), restriction 
endonucleases, antartic phosphatase and DNA ligase (see Section 2 8)
2 9 1 TA Cloning of PCR Products
PCR products were cloned using the TA cloning vector pCR2 1 (Invitrogen, Table 2 3, 
Figure 2 1) The cloning method using this vector exploits the fact that thermostable 
polymerases such as Tag DNA polymerase leave 3’ A-overhangs due to their lack of 3’- 
55 exonuclease activity The pCR2 1 vector is provided with a location in the lacZa 
gene open with 3’ T overhangs (see Figure 2 1) PCR products with 3’ A-overhangs can 
be directly ligated into this cloning site The ligation was transformed into E coh 
XLIO-Gold (see Table 2 1) cells as described in Section 2 63 100 /xl of the 
transformation reaction was plated on an LB agar plate containing ampicillin and 
kanamycin (see Section 2 3 for required antibiotic concentrations) The agar plate was 
previously overlaid with 60 /¿I of 40 mg/ml X-gal to test for «-complementation of /3- 
galactosidase X-gal stock was prepared in DMF and stored in the dark at -20°C The 
lacZa gene encodes the o-peptide of /?-galactosidase, which cleaves the X-gal substrate 
yielding a blue product This allows for positive selection of transformants harbouring 
plasmids with PCR product inserts Routinely a small proportion of colonies are blue It 
is assumed that these arise as a result of re-circularisation of the pCR2 1 vector
2 9 2 Site-Directed Mutagenesis
Point mutations were introduced into open reading frames on plasmid constructs by 
PCR amplification using the Quick Change Site-Directed Mutagenesis Kit (Stratagene) 
and complementary primers carrying the desired mutation 50 fi\ reactions were set up, 
containing 10-100 ng of plasmid template isolated from dam+ E coh (e g XL-10 Gold 
strains, see Table 2 1), 0 5 fiM of each primer, 200 ¡iM of each dNTP, 3 ¡i\ Quick 
Change Solution, 2 5 units of PfuTurbo DNA polymerase and 5 ¿il specific lOx enzyme 
buffer The particular PCR program used was
Stage 1 Step 1 95°C for 1 mm
Stage 2(18 cycles) Step 1 95°C for 50 sec
Step 2 60°C for 50 sec
Step 3 68°C for 2 min per Kb of template plasmid
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Stage 3 Step 1: 68°C for 7 min
The template DNA was eliminated by digestion with 20 units o f Dpn I restriction 
endonuclease. Dpn I is biased toward a methylated recognition sequence. It selectively 
digests the template DNA from dam' E. coli strains mentioned above and not the newly 
synthesised DNA. Subsequently the samples were transformed into E. coli XL10-Gold. 
Potential mutants were verified by DNA sequencing.
2.9.3 Random Mutagenesis
Random mutations were introduced into open reading frames on plasmid constructs by 
adding manganese chloride ions to the standard PCR (see Section 2.8.2). 50 /zl reactions 
were set up, containing 1 /¿I template (10-100 ng), 1-2.5 mM MgCb, 0.5 fiM o f each 
primer, 200 /iM o f each dNTP, 0.05mM MnCfeJ unit REDTa^ DNA polymerase and 5 
/il specific lOx enzyme buffer. The random mutagenesis PCR program was:
Stage 1 Step 1: 95°C for 10 min
Stage 2 (30 cycles) Step 1: 95°C for 1 min
Step 2: Tann for 30 sec
(Tann was routinely 5 °C below the Tm o f the primers)
Step 3: 72°C for 1 min per Kb to be synthesised 
Stage 3 Step 1: 72°C for 10 min
2.10 DNA Sequencing
Recombinant clones and potential mutants were verified by DNA sequencing. 
Commercial sequencing services were provided by MWG Biotech AG. Suitable 
sequencing primers (see Table 2.2) for standard vcctors were provided as part o f the 
service. Samples were sent as dried plasmid DNA preparations.
2.11 Bio-Informatics
Nucleotide and Amino Acid sequences were analysed using a variety o f  web-based 
tools. The BLAST programs (Altschul et al., 1997) at the National Centre for 
Biotechnology Information (http://www.ncbi.nlm.nih.gov) were used to identify 
homologous sequences deposited in GenBank (Benson ct al., 1996). Protein sequences 
and structure files were obtained from the Swiss-Prot database (Bairoch and Apweiler,
1996) at (http://us.cxpasy.org) and the Protein Data Bank (PDB, Berman et al., 2000) at
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(http://www.rcsb.org/pdb). Alignments o f DNA and Protein sequences were performed 
using the Mult Alin program (Corpet, 1988) available at 
(http://prodes.toulouse.inra.fr/multalin/multalin.html) and edited using the GeneDoc 
program (Nicholas el al., 1997) available for download at
(www.psc.edu/biomed/genedoc). Plasmid maps were constructed using the pDRAW32 
program available for download at (http://www.acaclone.com). Chemical structures 
were drawn using the ACD/Labs ChemSketch program available for download at 
(http://www.acdlabs.com). DNA sequences were analysed for restriction enzyme sites 
using the Webcutter 2.0 tool at (http://ma.lundberg.gu.se/cutter2). Tertiary protein 
structure was predicted by the automated SWISS-MODEL server (Schwede et a l., 2003, 
http://swissmodel.expasy.org), subsequently analysed and visualised using the 
DeepView software (Guex and Peitsch, 1997) available for download at 
(http://ca.expasy.org/spdbv). Rare codons were analysed using rare codon calculator 
available at http://nihserver.mbi.ucla.edu/RACC/.
2.12 Protein Expression
2.12.1 Standard Expression Culture
100 mL o f LB broth was inoculated with I ml of a stationary phase culture o f  E. coli 
that had been transformed with an expression plasmid. Where 1 L cultures were used, 1 
L of LB broth was inoculated with 10 ml o f a stationary phase culture o f  E. coli. 
Selective antibiotics were included in the LB broth. The culture was incubated at 37°C, 
shaking at 220 rpm, until an optical absorbance (A*™) o f  0.3-0.5 was reached. IPTG 
was added (from 10 mM stock) to a final concentration o f 50 ¿¿M to induce expression. 
The culture was allowed to incubate for 4 hr and was centrifuged at 5,000 rpm for 5 min 
(using a Beckman JA-14 rotor) to pellet the cells. The supernatant was discarded and 
the pellets were stored at -20°C.
2.12.2 Preparation of Cleared Lysate
Expression culture cell pellets were washed in potassium phosphate buffer, pH 8.0 
followed by centrifiigation at 4,000 rpm for 10 min (using a Beckman JA-20 rotor). The 
supernatant was discarded and the cells were re-suspended in 40 ml potassium 
phosphate buffer. pH 8.0. The cells were disrupted on ice with a 3 mm micro-tip 
sonicator (Sonics & Materials Inc.) using 2.5 sec, 40 kHz pulses for 40 sec. The cell 
debris was removed by centrifugation at 4,000 rpm for 20 min at 4°C (using a Beckman
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JA-20 rotor). The eleared lysate was transferred to a fresh universal container and stored 
at 4°C.
2.13 Protein Purification
Immobilised Metal Affinity Chromatography (IMAC) was used to purify recombinant 
bovine and human PAP1 having a C-terminal 6xHis tag (see Table 2.3).
2.13.1 Standard IMAC Procedure
1 ml o f  nickel-nitrilotriacetic acid resin (Ni-NTA. Qiagen) was gently mixed with 10 ml 
o f cleared lysate for 60 min at 4°C. For 1 L cultures 2 ml o f resin was mixed with 30 ml 
o f cleared lysate. The mixture was poured into a 0.7 x 15 cm column, allowing the resin 
to settle. The column was washed four times w'ith 10 ml potassium phosphate buffer, 
pH 8.0 containing 20 mM imidazole and then eluted with 5 ml potassium phosphate 
buffer, pH 8.0 containing 200 mM imidazole. The elute was dialysed overnight against 
1 L potassium phosphate buffer, pH 8.0. Samples taken throughout the procedure were 
analysed by SDS-PAGE (see Section 2.16). Protein concentration was determined by 
the standard BCA assay (see Section 2.14) and PAP1 activity was determined by the 
fluorimetric assay (see Section 2.15).The purified PAP1 sample was aliquoted and 
stored at 4°C or -20°C with 40% glycerol.
2.13.2 Optimised Protein Purification for Protein Crystallisation
100ml crude lysate was mixed with 2 ml nickel-nitrilotriacetic acid resin (Ni-NTA, 
Qiagen) for 60 min at 4°C and subsequently poured into 0.7 x 15 cm column and allowed 
to settle. The flow-through was collected and the column was then washed with six 
different 20mls washes in the following sequence: 50 mM Potassium Phosphate with 
300 mM NaCl, 20 mM imidazole pH 8.0, 50 mM Potassium Phosphate with 2 M NaCl 
pH 8.0, 50 mM Potassium Phosphate with 20 mM /3-ME pH 8.0, 50 mM Potassium 
Phosphate with 2% Tween-20 pH 8.0, 50 mM Potassium Phosphate with 20% ethanol pH 
8.0 and finally 50mM Potassium Phosphate with 40% glycerol pH 8.0. Bound protein 
was then eluted with 3 x 5 ml washes o f 50mM Potassium Phosphate containing 200 mM 
imidazole buffer pH 8.0. The elute was dialysed against 3L ultra pure water overnight at 
4°C. Samples were assayed for PAP1 activity according to Scction 2.15. Protein content 
in each fraction was determined using the coomassie assay according to Section 2.14.
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2 13 3 Recharging of Ni-NTA Resin
This procedure was routinely used before re-using the Ni-NTA Resin The resin was 
poured into a column and washed with 2 column volumes (2cv) of distilled water 
followed by 2cv 50% ethanol The resin was stripped with 3cv 100 mM EDTA, pH 8 0 
The resin was washed with 2cv 500 mM NaCl followed by 2cv distilled water The 
resin was re-charged with 2cv 100 mM N1SO4 The resin was washed with 2cv distilled 
water, transferred to a plastic container and stored at 4°C in 20% ethanol
2 13 4 Preparation of Dialysis Tubing
The required amount of tubing was placed in a 1 L glass beaker and rinsed thoroughly 
with distilled water The beaker was filled with distilled water and -1 g of EDTA was 
added The beaker was brought to boil and boiled for 2 min The water was allowed to 
cool and then poured off The beaker was re-filled with fresh distilled water and boiled 
again for 2 min The water was allowed to cool and poured off The tubing was 
thoroughly rinsed with distilled water The tubing was stored at 4°C in distilled water
2 14 Protein Concentration 
2 14 1 Quantitative Determination By BCA Assay
The Bicinchomnic acid (BCA) assay described by Smith et al (1985) was used for the 
colorimetric detection and quantification of total protein in the range of 20-2,000 /zg/ml 
All samples were dialysed against dH20  and diluted appropriately to achieve a 
concentration within range of the assay 50 /xl of sample was added in triplicate to 200 
/¿I of BCA reagent (Sigma) and incubated at 37°C for 30 min Absorbances were read at 
570 nm on a Tecan Plate Reader Bovine serum albumin (BSA) was used as the 
reference protein BSA standards (0-2 mg/ml) were prepared in dH20  and assayed in 
triplicate to yield a standard curve (see Appendix A) Protein concentration of samples 
was determined from this standard curve
2 14 2 Quantitative Determination By Coomassie Assay
The Coomassie Plus assay (Bradford, 1976) was used for the colorimetric detection and 
quantification of total protein in the range of 100-1,500 ¿ig/ml All samples were 
dialysed against dH20  and diluted appropriately to achieve a concentration within range 
of the assay 50 ¡i\ of sample was added in triplicate to 1 ml of Coomassie Plus reagent 
(Pierce) and mixed gently Absorbances were read at 595 nm on a spectrometer blanked
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Jwith dt^O Bovine serum albumin (BSA) was used as the reference protein BSA 
standards (0-2 mg/ml) were prepared in dHzO and assayed in triplicate to yield a 
standard curve (see Appendix A) Protein concentration of samples was determined 
from this standard curve
2 15 Fluorescence Spectrometry 
2 15 1 AMC Standard Curve
A 100 [iM stock of 7-Ammo-4-Methyl-Coumann (AMC) was prepared in 50 mM 
potassium phosphate buffer, pH 8 0 containing 4% (v/v) methanol This stock solution 
was stored in the dark at 4°C for up to one month AMC standards were prepared by 
dilution of the stock solution with potassium phosphate buffer, pH 8 0 to the range of 0- 
20 fxM 500 fi 1 of each standard was incubated in triplicate at 37°C for 15 mm followed 
by the addition of 1 ml of 1 5 M acetic acid The fluorescence intensities of the 
standards were read using a Perkin Elmer LS50 Fluoresence Spectrophotometer at 
excitation and emission wavelengths of 370 nm and 440 nm respectively Excitation slit 
width was 10 nm while emission slit width was 2 5 nm This AMC standard curve is 
shown in Appendix A
2 15 2 Quantitative Fluonmetnc PAP1 Assay
Quantitative pGlu-AMC degrading PAP1 activity was determined according to the 
method by Fujiwara and Tsuru (1978), as modified by Browne and O’Cuinn (1983) 
PAP1 sample was suitably diluted in 50 mM potassium phosphate buffer, pH 8 0 100 
jil was incubated in triplicate at 37°C for 15 min with 400 ¡x\ of pGlu-AMC substrate 
(final concentration 250 /xM) in 50 mM potassium phosphate, pH 8 0 containing at final 
concentration 10 mM DTT, 2 mM EDTA and 5% (v/v) DMSO Blanks were set up by 
substituting 100 ju.1 50 mM potassium phosphate buffer, pH 8 0 for PAP1 sample The 
reaction was terminated by the addition of 1 ml 1 5 M acetic acid Liberated AMC was 
detected using a Perkin-Elmer LS-50 fluorescence spectrophotometer with excitation 
and emission wavelengths of 370 and 440 nm, respectively The fluorescence readings 
were converted to nanomoles of AMC released per minute by calculations shown in 
Appendix C, using a standard curve of free AMC (Appendix A), prepared as described 
in Section 2 15 1 under identical assay conditions Units of PAP 1 activity were defined 
as nanomoles of AMC released per minute at 37°C (unit = nmoles min'1)
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2 15.3 Quantitative 96-Well Plate Fluorimetnc PAP1 Assay
[
A quantitative version of the above assay was earned out on a 96-well plate 25 /¿I of
i
sample was incubated in tnphcate with 100 fi\ of the substrate solution used in Section 
2 15 2 at 37°C for 15 min The reaction was terminated by the addition of 100 fd 1 5 M 
acetic acid Liberated AMC was detected fluorometncally using a Perkin Elmer LS-50B 
plate reader attachment with excitation and emission wavelengths of 370 and 440 nm, 
respectively
2.15 4 Fluorimetnc Colony Assay
Screening for transformants with PAP1 activity was carried out by a fluonmetric plate 
assay similar to that described by Mulczyk and Szewczuk (1970) Selective agar plates 
with colonies from an overnight transformation were flooded with 250 fiM pGlu-AMC 
substrate in 50 mM potassium phosphate, pH 8 0 with 10 mM DTT, 2 mM EDTA and 
5% (v/v) DMSO After 30 mm incubation at 37°C the plates were viewed under UV 
light A digital camera was used to capture the images to a PC
2 16 SDS-PAGE
Protein samples were analysed by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE), based on the method outlined by Laemmli (1970)
i
i
2 16 1 Preparation of SDS Gels
10% and 15% resolving and 4% stacking polyacrylamide gels were prepared as per 
Table 2 4 Gels were cast using an ATTO vertical mini electrophoresis system Upon 
the addition of the TEMED to the resolving gel it was poured immediately and overlaid 
with 50% ethanol After polymerisation, the overlay was removed Upon the addition of 
the TEMED to the stacking gel it was poured immediately and allowed to polymerise 
around a comb placed into the top of the gel liquid to form loading wells
i
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Table 2 4 Preparation of SDS-PAGE Gels
Solution 10% Resolving 15% Resolving 4% Stacking
Gel Gel Gel
1 5 M  T ris-H C l, pH  8 8 R eso lv ing  G el buffer 1 625 m l 1 625 m l -
0  5 M  T ris-H C l, pH  6 8 S tack ing  G el buffer - - 0 625  m l
dH 20 2 64 m l 1 56  m l 1 538 m l
A cry lam id e /B is-acry lam id e  30% /0  8%  (w /v) 2 17 m l 3 25 m l 0 335 m l
10%  (w /v) A m m on ium  P ersu lpha te 32 5 ^1 32 5 ^1 12 5 |il
20 %  (w /v) SD S 32 5 |il 32  5 ^1 12 5 (nl
T E M E D 3 25 ^1 3 25 nl 2 5 |il
2 16 2 Sample Preparation
20 jul of sample was added to 5 jliI solubilisation buffer (5X) consisting of 50% (v/v) 
glycerol, 2% (w/v) SDS, 5% (v/v) 2-mercaptoethanol, 0 1% (w/v) bromophenol blue 
and 62 5 mM Tris-HCl, pH 6 8 Samples were boiled for 3 minutes and stored on ice 
until application
2 16 3 Sample Application
Routinely 25 ¡x\ of each prepared sample was applied to the SDS PAGE gel 10 fx 1 
relative molecular weight protein marker (Mr) solution (SigmaMarker, Sigma, see 
Figure 2 6) was also applied to the gel consisting of Rabbit Muscle Myosin (205 kDa), 
E coh P-Galactosidase (116 kDa), Rabbit Muscle Phosphorylase b (97 kDa), Rabbit 
Muscle Fructose-6-phosphate Kinase (84 kDa), Bovine Serum Albumin (66 kDa), 
Bovine Liver Glutamic Dehydrogenase (55 kDa), Chicken Egg Ovalbumin (45 kDa), 
Rabbit Muscle Glyceraldehyde-3-phosphate Dehydrogenase (36 kDa), Bovine 
Erythrocyte Carbonic Anhydrase (29 kDa), Bovine Pancreas Trypsinogen (24 kDa), 
Soybean Trypsin Inhibitor (20 kDa), Bovine Milk o-Lactalbumin (14 2 kDa) and 
Bovine Lung Aprotinin (6 5 kDa) Gels were run at 125 V for 1-2 hrs at room 
temperature using Running Buffer containing 25 mM Tris-HCl, 192 mM glycine and 
0 1 % (w/v) SDS
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Figure 2 6 Relative Molecular Mass Protein Marker (Mr)
15%  p o lyacry lam ide  gel
2 16 4 Gel Staining
Polyacrylamide gels removed from the electrophoresis chamber and washed with dt^O 
for 5 mm Routinely, gels were stained for 60 min in a 0 25% (w/v) Coomassie blue 
solution containing 10% (v/v) Acetic Acid/45% (v/v) methanol and then de-stained 
overnight using 10% (v/v) Acetic Acid/45% (v/v) methanol Subsequent soaking m 
dt^O enhanced the protein bands further If this did not sufficiently stain the gel, the 
more intense silver staining method (Blum et a l , 1987) was used as outlined in table 
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Table 2 5 Silver Staining of SDS-PAGE Gels
Step Duration Reagent
Fix 60 m in 50%  ethanol, 12%  acetic  acid, 0 05%  form aldehyde (37%  stock)
W ash 3 x 20 m m 50%  ethanol
P re-T rea t 1 m m 200 \i\ o f  a 5%  N a 2S20 3  x  H 2O  stock  so lu tion  m  100 m l dH 20
R inse 2 x 20 sec dH 20
Im pregnate 20  m m 0 lg  A g N 0 3, 70 [Û fo rm aldehyde in  100 m l dH 20
R inse 2 x 20 sec dH 20
D evelopm en t 10 m m  (m ax ) 3 g N a 2C 0 3 , 50 |lü fo rm aldehyde, 4  \il N a 2S 20 3  x  H 2 0  stock  so lu tion  
m  100 m l dH 20
Stop 5 m m 0 1 M E D I A
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2 16 5 Gel Analysis
Gels were placed between two transparent sheets and scanned using a flatbed scanner 
(Dell Photo 924, All in One) allowing the image to be saved to a PC
2 17 UV Zymography 
2 17 1 Native PAGE
A 15% native polyacrylamide gel was prepared as in Section 2 16 1 with the omission 
of SDS and set up at 4°C with running buffer as m Section 2 16 3 with the omission of 
SDS 20 (X1 of sample was added to 5 fi\ non-denaturing solubilisation buffer consisting 
of 50% (v/v) glycerol, 0 0125% (w/v) bromophenol blue and 62 5 mM Tns-HCl, pH 
6 8 The samples were applied directly to the gel The gel was run at constant 100 V at 
4°C for up to 2 5 hrs
2 17 2 UV Zymogram Development
After native PAGE the gel was gently rinsed with ice cold dH20 and then incubated at 
37°C in 20 ml of 5 ¡iM pGlu-AMC in 50 mM potassium phosphate, pH 8 0 containing at 
final concentration 10 mM DTT, 2 mM EDTA and 5% (v/v) DMSO After 10-15 mm 
the gel was visualised using a UV transilluminator (Image Master VDS) coupled with 
an image analyser to capture the image to a PC
218  PAP1 Characterisation
A range of biochemical and kinetic properties of recombinant PAP1 were determined 
(see Sections 2 18 1 to 2 18 7) including native size, pH optimum, optimum 
temperature, Michaelis constant, turnover number, maximal velocity, inhibition 
constants and effect of inhibitors
2 18 1 Size Exclusion Chromatography
The native molecular mass of recombinant PAP1 under native conditions was 
determined by size exclusion chromatography A 2 5 x 48 cm Sephadex G-100 gel- 
filtration column (Sigma-Aldnch) was equilibrated with potassium phosphate buffer, 
pH 8 0 containing 100 mM NaCl at 4°C The void volume of the column was 
determined by eluting 250 ¿¿1 blue dextran (8 mg/ml) at a flowrate of 0 3 ml/mm 1 ml 
fractions were collected and optical density read at 620 nm To calibrate the column, 
standard molecular mass markers were applied separately to the column and eluted at a
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flowrate of 0 3 ml/min The markers applied were 100 ¿¿1 BSA (66 kDa, 2 mg/ml), 300 
¡i 1 Carbonic Anhydrase (29 kDa, 1 mg/m 1), and 300 (i\ cytochrome c (12 kDa, 2 mg/ml)
1 ml fractions were assayed for protein concentration using the BCA method described 
in Section 2 14 1 100 /il of purified PAP1 (250 ¿ig/ml) was applied to the column 1 ml 
fractions were assayed for activity using the 96-well plate method described in Section
2 15 3 A linear plot of log molecular mass versus Ve/V0 was constructed The relative 
molecular mass of PAP1 was estimated using this plot
2 18 2 Determination of pH Optimum
The pH activity profile of PAP 1 was determined by carrying out the standard activity 
assay as described in Section 2 15 3 at pH range 6 0-10 5 This range was established 
usmg the following buffers 50 mM potassium phosphate for pH range 6 0-8 0, 50 mM 
Tns-HCl for pH range 7 5-9 5 and 50 mM NaOH/glycine for pH range 9 5-10 5 PAP1 
samples were pre-incubated in the above buffers for 10 mm at 37°C prior to addition of 
the substrate solution, also prepared in the respective buffers
2 18 3 Determination of Temperature Optimum
Purified enzyme was assayed in triplicate for 15 minutes at temperatures ranging from 4- 
60°C, after ten minute pre-incubation at the appropriate temperature prior to assay as per 
section 2 15 3 with temperature alteration A plot of residual PAP1 activity (%) verus 
temperature (°C) was constructed
2 18 4 Thermal Stability at 37°C
Purified enzyme was incubated at 37°C for up to three hours Aliquots of enzyme were 
removed at various time points and stored on ice All samples were brought to thermal 
equilibrium for 15 mins at 37°C and assayed under standard conditions according to the 
method described in Section 2 15 3
2 18 5 Inhibition
A selection of compounds (see Table 2 6) were investigated for their effect on the pGlu- 
AMC degrading activity of PAP1 If the effect was inhibitory, the IC50 value was 
determined l e the inhibitor concentration resulting in the PAP1 activity being reduced 
to 50% pGlu-AMC (250 /xM) substrate solutions were prepared in 50 mM potassium 
phosphate, pH 8 0 containing (at final concentration) 10 mM DTT 2 mM EDTA and
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5% (v/v) DMSO and the compounds summarised m Table 2 6 PAP1 samples were pre- 
mcubated with the same relevant compound concentration for 10 min at 37°C PAP1 
activity was assayed in triplicate using these substrate solutions as outlined in Section 
2 153
Table 2 6 Compounds Tested For Inhibition
Inhibitor Assay conc range
(mM)
L-pG lu 0-5
2 -p y rro lidone 0-5
Iodoacetic  A cid 0-5
Io dacetam ide 0-5
2 18 6 Kinetic Studies 
2 18 6 1 Km Determmation For pGlu-AMC
The Michaehs constant (Km) was determined using a range of concentrations of pGlu- 
AMC (10-500 ¡iM \ prepared in 50mM potassium phosphate, pH 8 0 containing at final 
concentration 10 mM DTT, 2 mM EDTA and 5% (v/v) DMSO Purified PAP1 activity 
was assayed in triplicate with each substrate concentration as described in Section 
2 15 3 Km, Vmax (maximal velocity) and Kcat (turnover number) values of PAP 1 for the 
substrate pGlu-AMC were obtained by fitting the data to Lineweaver-Burk, Eadie- 
Hofstee and Hanes-Woolf kinetic models (see Appendix C)
2 18 6 2 Ki Determmation Using Selected Synthetic Peptides
The effect of selected synthetic peptides on the kinetic interaction between PAP1 and 
the substrate pGlu-AMC were determined pGlu-AMC substrate concentrations were 
prepared (10-500 fxM) in 50 mM potassium phosphate, pH 8 0 containing at final 
concentration 10 mM DTT, 2 mM EDTA, 5% (v/v) DMSO along with 250 ¡iM of the 
desired peptide PAP1 activity was assayed in triplicate as outlined in Section 2 15 3 
The data obtained was applied to the Lineweaver-Burk model, whereby the dissociation, 
or inhibition constant (K,), and the type of inhibition observed were determined as 
outlined in Appendix C
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Table 2 7 Peptide Preparation for K, Determinations
Peptide Stock Cone 
(mM)
Solubility Assay Cone 
(HM)
pG lu -A la 10 5%  v/v  D M S O 250
p G lu -P ro 10 5%  v /v  D M S O 250
p G lu -T h r 10 5%  v /v  D M S O 250
p G lu -V al 10 5%  v /v  D M SO 250
p G lu -A la-A la 10 5%  v/v  D M S O 250
pG lu -G lu -A la 10 5%  v /v  D M SO 250
pG lu -H is-P ro -N H 2 (T R H ) 10 5%  v /v  D M SO 250
p G lu -M et-A la 10 5%  v/v  D M SO 250
p G lu -T hr-A la 10 5%  v/v  D M S O 250
219 Crystallisation
2 19 1 Determination of Crystallisation Conditions
Preliminary screening was carried out to determine conditions under which recombinant 
PAP1 could form crystals The sparse matrix screening strategy (Jancarik and Kim, 1991, 
Cudney et a l , 1994) was employed using Crystal Screen 1 and 2 reagent kits (Hampton 
Research) The kits consist of a panel of reagents combining various salts, buffers, 
précipitants and solvents The composition of the Screen 1 and Screen 2 reagents are 
shown in Tables 2 8 and 2 9 respectively
Punfied PAP1 was dialysed extensively into dH2Û and then concentrated to 1 5-12 mg/ml 
using a Speed Vac (Savant) vacuum centrifuge The screening was carried out by the 
hanging drop vapour diffusion method, section 2 19 2 The drops were monitored daily 
using a microscope (lOx magnification) Observations were recorded and images 
transferred to a PC using a digital camera attached to the microscope
2 19 2 Hanging Drop Method
1 ml of each Screen reagent was aliquoted into a separate reservoir of a 24-well sample 
plate Vaseline was applied around the upper edge of each reservoir 2 fil of reagent was 
taken from each reservoir and placed onto a glass cover slide 2 fil of purified PAP1 
sample was mixed with the drop of reagent The slide was inverted and pressed gently 
over the reservoir, creating a seal with the Vaseline and resulting in the drop hanging over 
the reservoir
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Figure 2.7 Schcniatic of Hanging Drop Crystallisation Technique
2.19.3 Crystal Mounting For X-Ray Diffraction
CryoLoops were used to mount, freeze, and secure the crystal during cryocrystallographic 
procedures and X-ray data collection. The nylon loop was first dipped into 0.5% Formvar 
solution (Sigma Aldrich) to form a thin film. The film provides extra support for fragile 
crystals, and can result in much sharper reflections with just slightly higher background. 
After use the loop is cleaned by dipping it in alcohol to dissolve the support.
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Table 2.8 Crystal Screen 1
R e a g e n t S a lt B u f f e r P r e c ip i ta n t
1 0.02 M  Calcium chloride dehydrate 0.1 M Sodium acctatc trihydrate pH 4.6 30 %  v/v 2-mcthyl-2.4-pcntancdiol
2 None None 0.4 M  Potassium sodium tartrate tetnvhydn
3 None None 0.4 M  Ammonium dihydrogen phosphate
4 None 0.1 M  Tris hydrochloride pH 8.5 2 M  Ammonium sulphate
5 0.2 M  iri-Sodium citrate dehydrate 0.1 M  Sodium HEPES pH 7 5 30% v/v 2-mcthyl-2.4-pentancdiol
6 0.2 M  magnesium chloride hexahydratc 0.1 M  Tris hydrochloride pH 8.5 30% w/v polyethylene glycol 4000
7 None 0.1 M  sodium  cacodylate pH 6.5 1.4 M  sodium acetate trihydratc
8 0.2 M  tri-sodium citrate dehydrate 0.1 M  sodium cacodylate pH 6.5 30% v/v iso-propanol
9 0.2 M  ammonium acetate 0.1 M  tri-sodium citrate dihydrate pH 5.6 30% w/v polyethylene glycol 4000
10 0.2 M  ammonium acetate 0.1 M  Sodium acetate trihydratc pH 4.6 30%  w/v polyethylene glycol 4000
I I None 0.1 M  tri-sodium citrate dihydrate pH 5.6 1 M  Ammonium dihydrogen phosphate
12 0.2 M  magnesium chloride hexahydratc 0.1 M  Sodium HEPES pH 7.S 30% v/v iso-propanol
13 0  2 M  tn-Sodium citrate dehydrate 0.1 M  Tris hydrochloride pH 8 5 30% v/v polyethylene glycoi 400
14 0.2 M Calcium chloride dehydrate 0.1 M  Sodium HEPES pH 7.5 30% v/v polyethylene glycol 400
15 0.2 M  ammonium sulphate 0.1 M  sodium cacody la te p I I  6.5 30% w/v polyethylene glycol 8000
16 None 0.1 M So<lium HEPES pH 7.5 1.5 M  lithium sulfate monohydrate
17 0.2 M  lithium sulfate monohydralc 0.1 M  T r i*  hydrochloride pH 8.5 30% w/v polyethylene glycol 4000
18 0 2  M  magnesium acetatc tctrahydratc 0.1 M sodium cacody late pH 6.5 20% w/v polyethylene glycol 8000
19 0.2 M  ammonium  acetate 0 .1 M  Tris hydrochloride pH 8.5 30%  v/v iso-propanol
20 0.2 M  ammonium sulphate 0.1 M  Sodium acetatc tnhydratc pH 4.6 25%  w/v polyethylene glycol 4000
21 0.2 M magnesium acetate tctrahydratc 0.1 M  sodium cacodvlate pH 6.5 30% v/v 2-mcthyl-2,4-pentancdiol
22 0.2 M  sodium acetate tnhydratc 0.1 M  Tris hydrochloride pH 8.5 30% w/v polyethylene glycol 4000
23 0 2  M  magnesium chloride hexahydratc 0.1 M  Sodium IIEPES pH 7.5 30% v/v polyethylene glycol 400
24 0 2 M  Calcium chlonde dehydrate 0.1 M  Sodium acetatc tnhydratc pH 4.6 20% v/v iso-propanol
25 None 0.1 M  imida/olc pH 6.5 I M  Sodium acctatc trihydratc
26 0 2  M  ammonium acetate 0 1 M  tri-sodium citrate dihydrate pH 5.6 30% v/v 2-methyl-2.4-pentancdiol
27 0,2 M  tri-Sodium  citrate dehydrate 0.1 M  Sodium HEPES pH 7.5 20%  v/v iso-propanol
28 0.2 M  sodium acetate trihydrate 0.1 M  sodium cacody late pH 6.5 30% w/v polyethylene glycol 8000
29 None 0.1 M Sodium HEPES pH7.5 0.8 M  Potassium sodium tartrate tctrahydn
30 0.2 M  ammonium sulphate None 30% w/v polyethylene glycol 8000
31 0 2  M  ammonium sulphate None 30% w/v polyethylene glycol 4000
32 None None 2 M  Ammonium sulfate
33 None None 4 M  Sodium formate
34 None 0.1 M sodium acetate trihydratc pH 4.6 2 M  Sodium formate
35 None 0 1 M  Sodium HEPES pH 7.5 0.8 M  Sodium dihydrogen phosphate 
0.8 M  potassium dihydrogen phosphate
36 None 0.1 M  Tris hydrochloride pH 8.5 8%  w/v polyethylene glycol 8000
37 None 0.1 M  Sodium acetate trihydratc pH 4.6 8%  w/v polyethylene glycol 4000
38 None 0.1 M  Sodium HEPES pH 7.5 1.4 M  tri-sodium citrate dihydrate
39 None 0.1 M Sodium HEPES pH 7 5 2%  v/v polyethylene glycol 400 
2 M  ammonium sulfate
40 None 0.1 M tri-sodium citrate dihydrate pH 5.6 20% v/v iso-propanol
20% w/v polyethylene glycol 4000
41 None 0.1 M  Sodium HEPES pi 1 7.5 
0.05 M  mono-Potassium dihydrogen
10% v/v iso-propanol
20%  w/v polyethylene glycol 4000
42 Phosphate None 20% w/v polyethylene Glycol 8000
43 None None 30% w/v polyethylene glycol 1500
44 None N«ine 0.2 M  magnesium formate
45 0.2 M  Zinc acetate dehydrate 0.1 M  sodium cacodylatc pH 6.5 18% w/v polyethylene glycol 8000
46 0.2 M  calcium acetate hydrate 0.1 M  sodium cacodylate pH 6.5 18% w/v polyethylene glycol 8000
47 None 0.1 M  Sodium acetate trihydratc p ll 4.6 2 M Ammonium sulfate
48 None 0.1 M  I ns hydrochlondc pH 8.5 2 M  Ammonium dihydrogen phosphate
49 1 M Lithium sulfate monohydralc None 2%  w/v polyethylene glycol 8000
50 0.5 M  lithium aulfutc monohvdiutc None 15% w/v polyethylene glytol 8000
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Table 2 9 Crystal Screen 2
R __________________ S a lt______________________
1 2 0 M  sodium chloride None
2 0 01 M Hexadecyltriméthylammonium Bromide None
3 None
4 None
5 2 0 M  ammonium sulfate
6 None
7 None
8 1 5 M  sodium chi onde
9 None
10 0 2 M  sodium chloride
11 0 01 M  cobaltous chloride hexahydrate
12 0 1 M cadmium chloride dehydrate
13 0 2 M  ammonium sulfate
14 0 2 M potassium sodium tartrate tetrahydrate
15 0 5 M  ammonium sulfate
16 0 5 M  sodium chloride
17 None
18 0 01 M  feme chloride hexahydrate
19 None
20 None
21 0 1 M  sodium dihydrogen phosphate
0 1 M  potassium dihydrogen phosphate
22 None
23 1 6 Ml ammonium sulfate
24 0 05 M  cesium chlonde
25 0 01 M  cobaltous chlonde hexahydrate
26 0 2 M  ammonium sulfate
27 0 01 M  zinc sulfate heptahydrate
28 None
29 0 5 M ammonium sulfate
30 None
31 None
32 0 1 M sodium chlonde
33 None
34 0 05 M  cadmium sulfate hydrate
35 None
36 None
37 None
38 None
39 0 2 M  magnesium chloride hexahydrate
40 None
41 0 01 M  nickel (11) chlonde hexahydrate
42 1 5 M  ammonium sulfate
43 0 2 M  ammonium dihydrogen phosphate
44 None
45 0 01 M mckcl ( I I )  chlondc hexahydrate
46 0 1 M sodium chlonde
B u ffe r
None
None
None
None
None
None
0 1 M  sodium acetate tnhydrate pH 4 6
0 1 M  sodium acetate tnhydrate pH 4 6
0 I M sodium acetate tnhydrate pH 4 6
0 1 M sodium acetate tnhydrate pH 4 6
0 1 M  sodium acetate tnhydrate pH 4 6
0 1 M tri sodium citrate dihydrate pH 5 6
0 1 M tri sodium citrate dihydrate pH 5 6
0 I M  tri-sodium citrate dihydrate pH 5 6
0 1 M  tn-sodium citrate dihydrate pH 5 6
0 1 M  tri sodium citrate dihydrate pH 5 6
0 1 M  tri sodium citrate dihydrate pH 5 6
0 1 M  MES pH 6 5 
0 1 M MES pH 6 5
0 1 M  MES pH 6 5 
0 1 M  MES pH 6 5 
0 1 M  MES pH 6 5 
0 l M  MES pH 6 5 
0 1 M  MES pH 6 5 
0 1 M MES pH 6 5 
None
0 1 M HEPES pH 7 5 
0 I M HEPES pH 7 5
0 1 M  HEPES pH 7 5
0 1 M  HEPES pH 7 5
0 1 M HEPES pH 7 5
0 I M HEPES pH 7 5
0 1 M  HEPES pH 7 5
0 1 M  HEPES pH 7 5 
0 1 M HEPES pH 7 5
0 1 M  HEPES pH 7 5 
0 1 M tris pH 8 5 
0 1 M  tns pH 8 5 
0 1 M  tris pH 8 5 
0 1 M  tns pH 8 5 
0 1 M  tns pH 8 5 
0 1 M  tns pH 8 5 
0 1 M  tns pH 8 5
0 1 M  bicine pH 9 0___________________
________________ P r e c ip i ta n t____________
10% w/v PEG 6000 
0 5 M  sodium chlonde
0 01 M  magnesium chlonde hexahydrate
25% v/v ethylene glycol 
35% v/v dioxane 
5% v/v iso propanol
1 0 M  imidazole pH 7 0
10% w/v polyethylene glycol 1000 
10% w/v polyethylene glycol 8000
10% v/v ethanol
2 0 M  sodium chlonde 
30 %  v/v MPD
1 0 M  1 6 hexanediol
30% v/v polyethylene glycol 400
30% w/v polyethylene glycol monomethyl ether 20
2 0 M ammonium sulfate
1 0 M  lithium sulfate monohydrate 
2% w/v ethylene imme polymer 
35% v/v tert butanol
10% v/v jeffamine M-600
2 5 M  1 6 hexanediol
1 6 M  magnesium sulfate heptahydrate
2 0 M  sodium chlonde
12% w/v polyethylene glycol 20 000 
10% v/v dioxane 
30% v/v jeffamine M-600 
1 8 M  ammonium sulfate
30% w/v polyethylene glycol monomethyl ether 50i 
25% v/v/ polyethylene glycol monomethyl ether 551 
1 6 M  tn-sodium citrate dehydrate 
30% v/v MPD
10% w/v polyethylene glycol 6000 
5% v/v MPD
20% v/v jeffamine M-600
1 6 M  ammonium sulfate
2 0 M ammonium formate
1 0 M sodium acetate
70% v/v MPD
4 3 M  sodium chlonde
10% w/v polyethylene glycol 8000
8% v/v ethylene glycol
20% w/v polyethylene glycol 10000
3 4 M  1 6 hexanediol 
25% v/v tert-butanol
1 0 M  lithium sulfate monohydrate 
12% v/v glycerol anhydrous 
50% v/v M PD  
20% v/v ethanol
20% w/v polyethylene glycol monomethyl ether 2Q( 
20% w/v polyethylene glycol monomethyi ether 55<
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Table 2 10 CryoScreen 1
Reagent Crvstallant Buffer (0 1 M ) Additive(s)
1 40% (v/v) 2 methyl 2 4-pentanediol phosphate citrate pH 4 2 None
2 40% (v/v) ethylene glycol acetate pH 4 5 None
3 50% (v/v) PEG-200 citrate pH 5 5 None
4 40% (v/v) PEG 300 HEPES pH 7 5 0 2 M  NaCI
5 40% (v/v) PEG-400 citrate pH 5 5 0 2 M  MgCh
6 40%  (v/v) PEG 600 cacodylate pH 6 5 0 2 M Ca(OAc)2
7 40% (v/v) ethanol Tns pH 8 5 0 05 M  MgCl2
8 35% (v/v) 2 ethoxyethanol cacodylate pH 6 5 None
9 35% (v/v) 2 propanol phosphate citrate pH 4 2 None
10 45% (v/v) glycerol imidazole pH 8 0 None
11 35% (v/v) 2-methyl 2 4 pentanediol Tns pH 8 5 0 2 M  (NH 4)2S 04
12 50% (v/v) ethylene glycol acetate pH 4 5 5% (w/v) PEG 1000
13 30% (v/v) PEG 200 MES pH 6 0 5% (w/v) PEG 3000
14 20% (v/v) PEG 300 phosphate citrate pH 4 2 0 2 M (N H 4)2S 04 10% (v/v) glycerol
15 50% (v/v) PEG-400 CHES pH 9 5 0 2 M NaCI
16 30% (v/v) PEG-600 MES pH 6 0 5% (w/v) PEG-1000 10% (v/v) glycerol
17 40% (v/v) 1 2 propanediol HEPES pH 7 5 None
18 35% (v/v) 2 ethoxyethanol imidazole pH 8 0 0 05 M Ca(OAc)2
19 35% (v/v) 2-propanol Tns Ph 8 5 None
20 30% (v/v) 1 >2 propanediol citrate pH 5 5 20% (v/v) 2 methyl-2 4-pentanediol
21 40% (v/v) 1,2 propanediol Acetate pH 4 5 0 05 M  Ca(OAc)2
22 40%  (v/v) ethylene glycol Na/K phosphate pH 6 2 None
23 40% (v/v) 2 methyl 2 4 pentanediol Tns pH 7 0 0 2 M  (N H 4)2S 04
24 40% (v/v) PEG-400 Na/K phosphate pH 6 2 0 2 M  NaCI
25 30% (v/v) PEG-200 TnspH  8 5 0 2 M  (N H 4)2H P 04
26 40% (v/v) PEG-300 CHES pH 9 5 0 2 M NaCI
27 30% (v/v) PEG-400 CAPS pH 10 5 0 5 M  (N H 4)2S 04 10% (v/v) glycerol
28 30% (v/v) PEG 600 HEPES pH 7 5 0 05 M Li2S 04 10% (v/v) glycerol
29 40% (v/v) PEG 300 CHES pH 9 5 0 2 M  sodium citrate
30 35% (v/v) 2 ethoxyethanol citrate pH 5 5 None
31 35% (v/v) 2 propanol citrate pH 5 5 5% (w/v) PEG 1000
32 40% (v/v) 1,2 propanediol CHES pH 9 5 0 2 M  sodium citrate
33 25% (v/v) 1 2 propanediol imidazole pH 8 0 0 2 M  Zn(OAc)2 10% (v/v) glycerol
34 40%  (v/v) 2 methyl 2 4-pentanediol imidazole pH 8 0 0 2 M MgCl2
35 40% (v/v) ethylene glycol HEPESpH 7 5 5% (w/v) PEG 3000
36 50% (v/v) PEG 200 Tns pH 7 0 0 05 M L i2S 04
37 40% (v/v) PEG 300 cacodylate pH 6 5 0 2 M  Ca(OAc)2
38 40%  (v/v) PEG-400 Tns pH 8 5 0 2 M  L i2S 04
39 40% (v/v) PEG-600 phosphate citrate pH 4 2 None
40 40% (v/v) ethanol phosphate-citrate pH 4 2 5% (w/v) PEG-1000
41 25% (v /v ) 1 2 propanediol phosphate-citrate pH 4 2 5% ( w/v) PEG-3000 10% ( v/v) glycerol
42 40% (v/v) ethylene glycol Tns pH 7 0 None
43 50% (v/v) ethylene glycol Tns pH 8 5 0 2 M MgCl2
44 50% (v/v) PEG 200 cacodylate pH 6 5 0 2 M Zn(OAc)2
45 20%  (v/v) PEG-300 Tns pH 8 5 5% (w/v) PEG 8000 10% (v/v) glycerol
46 40% (v/v) PEG -400 MES pH 6 0 5% (w/v) PEG-3000
47 50% (v/v) PEG-400 Acetate pH 4 5 0 2 M  L i2S 04
48 40% (v/v) PEG 600 imidazole pH 8 0 0 2 M Zn(OAc)2
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T ab le  2.11 C ryoScrcen 2
R e a g e n t C r ^ s ta l la n t B u f fe r  (0 .1  M ) A d d it iv e (s )
1 40%  (v/v) 2-mcthyl-2.4-pentanediol cacodylate pH 6.5 5% (w /v) PEG-8000
2 50% (v /v) PEG-200 CUES pH 9 5 None
3 40% (v/v) ethylene glycol phosphatc-citiatc pH 4.2 0.2 M  (N llihSO «
4 40% (v /v) PEG-400 H IT E S  pH 7.5 0 2  M  CaiOAch
5 40% (v/v) PEG-300 Tris pH 7.0 5 % (w /v) PF.G-1000
6 30% (v/v) PEG-600 cacodylatc pH 6.5 1 M  NaCI. 10% (v/v) glycerol
7 40%  (v/v) ethanol TnspH 7.0 None
8 35% (v/v) 2 -ethoxy ethanol Na/K phosphate pH 6.2 0 2  M  NaC I
9 35% (v/v) 2 -propanol imida/olc pH 8.0 0.05 M  7.n(OAcfc
10 40%  (v/v) 1 ¿-propanediol acetate pH 4.5 None
I I 25% (v /v) 1 .2 -propanediol Na'K phosphate pH 6.2 10% (v/v) glycerol
12 40%  (v/v) 1^-propanediol citrate pH 5.5 0.2 M  NaCI
13 35% (v/v) 2-methyl-2.4-pemanediol cacodylatc pH 6.5 0 05 M  Zn(OAc)j
14 40%  (v/v) ethylene glycol im ida/ok pH 8.0 0 2  M  Ca(OAch
15 50% (v /v) PEG-200 Na-K phosphate pH 6 2 0.2 M  Na(T
16 20%  (v/v) PEG-300 imida/olc pH 8.0 1 M  (NH«)iSO«. 10% (v/v) glycerol
17 50% (v/v) PEG-400 MF.S pH 6 0 None
18 40%  (v /v) PEG-300 phosphate-ciIrate pH 4.2 None
19 40%  (v/v) PEG-600 acetate pH 4.5 0.2 M  MgCb
20 50% (v/v) ethylene glycol CHES pH 9.5 0.5 M K/Na tartrate
21 35% (v/v) 2-cthoxycthanol Ir is  pH 8.5 0  2 M  l.i,SO«
22 35% (v /v) 2-propanol cacodylatc pH 6.5 0.2 M  MgCb
23 30% (v/v) 12-propanediol HEPES pH 7.5 20 % (v/v) PEG-400
24 2 5% (v/v) 1.2 -propanediol Tris pH 8.5 0.2 M  MgCb, 10% (v /v) glycerol
25 40% (v/v) 2-mcthyl-2,4-pcmanediol CAPS pll 10 5 None
26 40% (v/v) ethylene glycol MES pH 6.0 0.2 M  Zn(OAch
27 50% (v/v) PEG-200 Tris pH 7.0 None
28 40% (v/v) PEG-300 imida/olc pH 8.0 0.2 M  /.n(OAch
29 30% (v /v) PEG 4 0 0 HEPES pH 7.5 5% (w /v) PEG -3000,10% (v/v) glycerol
30 4 0 % (v/v) PEG-600 citrate pH 5.5 None
31 40%  (v/v) PEG-600 CHES pH 9  5 None
32 35% (v/v) 2-propanol acetate pH 4.5 None
33 45%  (v/v) glycerol cacodylatc pH 6.5 0.2 M  Ca(OAc)j
34 25% (v/v) 1 .2 -propanediol I ns pH 7.0 0.2 M (N llihS O «, I0 % (v /v ) glycerol
35 40%  (v /v) 2-methyl-2,4-pentanediol citrate pH 5.5 None
36 50% (v/v) PEG-200 cacodylatc p ll 6.5 0.2 M  MgCb
37 50% (v/v) ethylene glycol imidazole pll 8.0 rK>ne
38 40%  (v/v) PEG-400 acctate pH 4.5 none
39 30% (v/v) PEG -600 T n sp ll 7.0 0.5 M  (N H 4hS 04. 10% (v /v) glycerol
40 40%  (v /v) 2-mcthyl-2.4-pcn(anedroJ C IIE S  pH 9 5 none
41 50% (v/v) ethylene glycol HEPES pH 7.5 0.2 M  I.ijSO ,
42 30% (v /v) PEG-200 acetate pH 4 5 0.1 M  NaCI
43 40% (v/v) PEG-400 imidazole pll 8.0 none
44 35% (v/v) 2-methyl-2.4-pcntanediol acctate p ll 4.5 10% (v/v) glycerol
45 40%  (v/v) PEG-300 acetate pH 4 5 0 2 M  NaC I
46 30% (v /v) PEG-200 CAPS pll 10 5 0 2  M  (NIUhSO«
47 50% (v /v) PEG-200 HEPES pH 7.5 none
48 50% (v /v) PEG-200 phosphatc-citratc pi 1 4.2 0.2 M  NaCI
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C H A P T E R  T H R E E
Cloning, Expression and Characterisation of Purified Recombinant Bovine PAPI
31 Overview
This chapter describes cloning of the bovine PAP1 gene from eDNA and the subsequent 
expression of recombinant protein utilizing an expression system which was developed 
by Vaas (2005) during the expression of recombinant human PAP1 Various 
biochemical, kinetic and functional studies were then carried out on the purified bovine 
PAP1 enzyme and a comparative study with the recombinant human PAP1 investigated 
This study will allow us to further characterise this family of cysteine peptidases There 
are multiple homologues of this family and it is important to compare them to determine 
functionality and identify essential amino acid residues
3 2 Cloning of Bovine PAP1 Gene
Bovine brain tissue samples were obtained from Kepak, (Co Meath, Ireland) Total 
RNA was isolated from bovine brain tissue as described in Section 2 4 4 Figure 3 1A 
shows analysis of this RNA by agarose gel electrophoresis (see Section 2 5)
The sequence for putative bovine PAP1 mRNA (XM866409, see Figure 3 2) was 
obtained from GenBank (Benson et a l , 1996) The 700 bp sequence contains a 630 bp 
open reading frame (ORF) for bovine PAP1 (Bta-papl) Primers PAPBtA and PAPBtB 
(see Table 2 2) were designed external to this ORF to amplify the putative PAP1 gene 
(see Figure 3 2) as a 648 bp fragment cDNA was generated from the bovine brain RNA 
using the specific reverse primer PAPBtB as described in Section 2 8 1 The cDNA was 
used as template for PCR (see Section 2 8 2) using primers PAPBtA and PAPBtB The 
resulting RT-PCR product, analysed by agarose gel electrophoresis (see Section 2 5), is 
shown in Figure 3 IB A band corresponding to the expected size of 648 bp was 
obtained
The PCR product shown m Figure 3 1C was cloned into the TA cloning vector pCR2 1 
(see Table 2 3, Figure 2 1) as described in Section 2 9 1 Several white colonies were 
purified and plasmid DNA was isolated (see Section 2 4 1) Screening for a TA clone, 
having the desired -700 bp recombinant Bta-papl insert 0rBta-papl), was earned out 
by enzymatic restriction analysis with EcoRl (see Figure 3 3, Section 2 8) EcoRl 
specifically cuts the TA insert out of the pCR2 1 vector Restriction with EcoRl 
produces a band corresponding to the expected -700 bp fragment containing the rBta- 
papl sequence
This clone (pZKl) was analysed by agarose gel electrophoresis (see Figure 3 4) The 
EagI restriction resulted in bands corresponding to 510 and 180 bp, suggesting that the
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rBta-papl sequence had inserted in the opposite orientation to the lacZot ORP of 
pCR2 1 The Ncol restnction similarly supported this opposite orientation The 
successful cloning of rBta-papl was confirmed by DNA sequencing (see Section 2 10) 
The sequence was clearly confirmed to be that of Bovine PAP1 shown in Genbank The 
sequencing data is given in Appendix B A map of pZKl is shown in Figure 3 5
Figure 3 1 Amplification of Bovme PAP1 cDNA
1% agarose  gels (A ) L ane 1, D N A  L adder, L ane 2, R N A  iso la ted  from  bov ine  b ra in  tissue  (B ) L ane 1, 
D N A  L ad d er (s izes as m  F igure 2 6), L ane 2, negative  co n tro l, L ane 3, p ro d u c t o f  R T -P C R  (see S ection
2 8 1 &  2 8 2) on  bov ine  bram  tissue  R N A  usm g p rim ers  P A P B tA  an d  P A P B tB  (see T ab le  2 2, F igure
3 2) T he band  co rrespond ing  to  the  expected  PA P1 p ro d u c t is m d icated  by  b lue  a rro w  (C ) L ane 1, D N A  
L adder, L ane 2, p roduc t o f  P C R  (see S ection  2 8 2) on  p Z K l u sing  p rim ers  P A P B tA  an d  P A P H tB  (see 
T ab le  2 2) T he b an d  co rrespond ing  to  the  expected  PA P 1 p roduc t is in d ica ted  by  b lue  a rrow
B C
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< M _ 8 6 6 4 C 9  : 1 7 T-F T-t - ! - i  r -T T T ^ T T Y T -v - i -v - E ^ t  q q a q c a q c c c a q q a a q q c q q t  q q t  g a t  q a c q q g a t  t  c q q g e c t 1 1 1  g g g g a a c a c a c t  g t  g a a t g c c a g c t q q a t t  q  : 1 0 9
PAPBtaA
< M _ 8 6 6 4 C 9  : c g g t c c a g g a g c t g g a g a a a c t a g g g c t t g g g g a c a g c g t g g a c c t a c a t g t g t a t g a g a t t c c a g t g g a g t a t c a g a c g g t c c a g a g g c t c a t c c c t g c c c t g t g g g a  : 2 1 8
<H 8 6 6 4 0 9  : g a a g c a c a g t c c g c a g c t g g t g g t g c a c g t a g g c g t g t c a g g c a t g g c a a c c g c a g t c a c a c t g g a g a a g t g t g g a c a c a a c a a g g g t t a c a a g g g c c t g g a c a a c t g c  : 3 2 7
< M _ 8 6 € 4 0 9  : c g a t t c t g c c c c g g c t c c c a g t g c t g t g t g g a g g a c g g g c c g g a a a g c a t t g a c t c c a t c a t c g a c a t g g a t g c t g t g t g t a a g a g g g t c a c t a c a c t g g g c t t a g a t g  : 4 3 6
Eagl
« M 8 6 6 4  0 9  :  t g t c a g t g a c c a t t t c a c a a g a t g c a g g c a g g t a c c t c t g c g a c t t c a c c t a c t a t a c c t c r c t g t a c c a g a g t c a c g g c c g c t c a g c c t t t g t t c a c g t g c c c c c t c t  : 5 4 5
< H _ 8 6 6 4  9 9  : g g g c a a g c c g t a c a a t g c a g a c c a g c t g g g c c g g g c a c t t c g g g c c a t c a t t g a g g a g a t g c t g g a c c t c c t a g a g c a g t c a g a a g g c a a a a t c a a c t g t t g c c a t g a a  : 6 S 4
< M _ 8 6 6 4  9 9  : c a c t q a f T T = i - f - K T 7 T - I - 1 T-! « - k - M  V -t-j-i-t- 1 -irlT T I -1 ^  ; 7 0 0
PAPBtaB
F igure 3.2 Bovine PAP1 Putative mRNA Sequence (U —>T)
N u cleo tid e  seq u en ce  X M 8 6 6 4 0 9 : bov ine  p u ta tiv e  PAP1 m R N A . O R F  is  h ig h lig h ted . L oca tion  o f  p r im e rs  P A P H sA  and  P A P H sB  (see  T a b le  2 .2 )  a re  in d ica ted . R estric tion  
s ite s  on  co rre sp o n d in g  D N A  a rc  m arked  in red . Illu stra ted  using  G en D o c  (see  S ec tion  2 .11 ).
M»I
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2000 bp 
1000 bp 
500 bp
500C bp il::
Figure 3.3 Screening for Potential pZKl Clone Using £coRI Restriction Analysis
£ c o R I restric tion  d igest o f  po ten tia l p Z K l c lo n es  analysed  on  1% agarose  gel (see Section  2 .5 ). L ane 1, 
D N A  L adder (s iz e s  a s  in F igu re  2 .6 ); l ^ n e  2, C lone 1 uncut; l.anc  3 , C lo n e  1 E coR I cu t (p o ssessin g  
bov ine  PAP1 insert); l.an e  4 . C lo n e  2 uncut; l.an e  5, C lo n e  2 £ c o R l cu t; I-ane 6, C lo n e  3 uncu t; L ane 7, 
C lo n e  3 £ c« R I cu t; L ane 8, C lo n e  4  uncu t; L ane 9 , C lo n e  4  £ c « R I cu t; I ^ n e  10. C lo n e  5 u n cu t; L ane 11, 
C lo n e  5 E co K \ cu t. l.an e  12, C lone 6  uncut; Lane 13. C lone 6  E co R l  cu t; L ane 14, D N A  L adder.
¡ ¡¿ M S
% I
121100 bp
5 0 0 0  bp
3 0 0 0  bp 
2000 bp
1 00 0  bp
< 0 0  bp
Figure 3.4 Verification Digest of pZKl
R estric tion  d ig es t o f  p Z K l c lo n e  analy sed  on  1% agarose  gel (see S ec tion  2 .5): L ane I ,  D N A  L adder 
(s izes  a s  in  F igu re  2 .5 ); Lane 2, uncu t (p rom inen t co v a len tly  c lo sed , open  c ircu la r and  linear b an d s  a rc  
v is ib le); L ane 3 , jVcoI; L ane 4, E ag l: Iü n e  5. D N A  I-adder.
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HindlU • 1
N c o l - 930  
E c o R I -1 0 0 0
UtcZ a
Figure 3.5 pZKl Plasmid Map
T he rB ta -p a p l  g ene  fragm en t (b lue) is in serted  in opposite  o rien ta tion  re la tiv e  to  th e  L a c Z a  O R F  (g reen), 
w h ich  is  under the contro l o f  th e  Pla c  p rom o ter (yellow ). A m picillin  and  kanam ycin  re s is tan ce  genes 
(a m p K &  k a n R) a re  show n in red . See  F igure  2.1 for m ap  o f  p a ren t v ec to r pC R 2 .1 . Illu stra ted  using  
pD R A W 32 (see  Section  2.11).
3.3 Expression System for Recombinant Bovine PAP1 in E. coli 
The expression system adopted for expression of rfltaPAP16n was developed by Vaas 
(2005) whereby r/Z.vaPAPUH was expressed in E. coli. The plasmids pQE-60 and 
pPC225 were used in this system. The resulting constructs had introduced 6 consecutive 
His codons (His«,) as a 3’ extension to the rHsa-papI ORF. This His-tag did not 
interfere with catalytic activity and was exploited during protein purification.
3.3.1 Sub-Cloning of Bovine PAP1 Gene into E. coli Expression Vector pQE-60
The vector pQE-60 (see Table 2.3, Figure 2.2) features an optimised hybrid promoter- 
operator element (Bujard el a/., 1987) consisting of the phage T5 transcriptional 
promoter and a lac operator sequence, which increases lac protein (Lacl) binding, thus 
enabling repression of this strong promoter. Associated with this operator region is a 
synthetic ribosome binding site (RBS) designed for high translation rates. The 0- 
lactamase gene conferring resistance to ampicillin (ampR) is present on the vector. Most 
significantly, the vector has six consecutive His codons (His6) followed by a stop codon.
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at the 3’ end of the multiple cloning site (MCS) This enables translation of a fusion 
protein having a C-termmal His-tag, which can be exploited during protein purification 
(see Section 3 5)
The rBta-papl sequence was sub-cloned from pZKl into pQE-60 by the strategy 
outlined in Figure 3 6 The pQE-60 MCS conveniently has an Ncol site as the 5’ 
insertion point As can be seen in Figure 3 2 the rBta-papl sequence already features 
this site within the mRNA rBta-papl was amplified by PCR with primers PAPBtA and 
PAPBtB (see Table 2 2) and ligated into vector pCR2 1 as described in Section 2 9 1 
PAPBtA was designed to include the Ncol site at the 5’ end of rBta-papl (see Figure 
3 2) and PAPBtB to add a Bam HI site at the 3’ end, replacing the stop codon rBta-papl 
was excised from this intermediate clone by an Ncol/BamYll restnction and ligated into 
pQE-60, which had been opened by an Ncol/BgUl restnction BamHl and BglU sites 
have compatible ends which, when fused, eliminate the restnction site Cloning into 
pQE-60 thus results in rBta-papl in fusion with a HiS6 ORF (rBtaPAFl^ )
The NcollHmdlll restnction resulted in a band corresponding to the expected 654 bp 
fragment containing the rBta-papl-Hise fusion (see Figure 3 7) EcoRl and Ncol single 
restnctions produced bands corresponding to the expected 4046 bp linearised plasmid
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Figure 3.6 Cloning Strategy for pZK2
O u tlin e  o f  su b -c lo n in g  stra tegy  from  p Z K I to  g en era te  pZ K 2. P C R  (see  Section  2 .8 .2 ) on  p Z K l using  
p rim e rs  P A PB tA  an d  PA PB tB  (sec  T ab le  2 .2 ) g en e ra te s  p roduct co n ta in ing  r B ta -p a p l  w ith o u t stop  codon  
an d  h av in g  N co\ an d  B an  t i l l  s ite  tags, w hich  is  liga ted  in to  p C R 2 .1 . r B ta -p a p l  is  exc ised  from  
m tcrm ed ia te  c lo n e  by  N co \!B a m H \ res tric tion  an d  ligated  into p Q F -6 0  (see  T ab le  2 .3 , F ig u re  2 .2), w hich 
h as  been opened  w ith  N coVBglW  res tric tion . R esu lting  construct, p Z K 2 , h a s  6 x ll is  sequence  c lo n ed  to  3 ’ 
en d  o f  rB ta -p a p l  fo llow ed b y  stop  codon . Illustrated  using  pD R A W 32 (see S ec tion  2.11).
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Figure 3.7 Verification Digest of pZK2
R estric tion  d igest o fp Z K 2  co n stru c t analysed  on 1% agarose  gel (see S ection  2 5) L ane 1, D N A  L adder 
(s izes as in F igu re  2 5), L ane 2, E c o K l , L ane 3, N c o l ,  L ane 4 , N c o \/H in d il l
3 3 2 Sub-Cloning of Bovine PAPI Gene into E  coli Expression Vector pPC225
rBta-papl was sub-cloned from pZK2 into the vector pPC225 (see Table 2 3, Figure
2 3) as outlined in Figure 3 8 pPC225 features the tac transcriptional promoter (Ptac) 
?tac is a hybrid promoter consisting of the -35 region from the tip promoter fused to 
the -10 region (Pnbnow box), operator and RBS (Shine-Dalgamo sequence) from Plac 
DeBoer et al (1983) reported on the high efficiency of Ptac in expressing foreign genes 
in E coli as opposed to the parental promoters Ptac can be repressed by the LacI 
protein pPC225 contains ampR and another useful feature, noted during cloning, was 
that the 1800 bp fragment within the MCS (see Figure 2 3) allowed for easy 
differentiation of linear from uncut vector
An EcoRl/Hindlll restnction enabled the entire rBta-papl-H\% fusion to be transferred 
from pZK2 to pPC225, which had been opened with EcoRliHindlll Figure 3 9 shows a 
restnction digest of this construct, pZK3 Ncol, EcoRl and Hindlll single restnctions 
produced bands corresponding to the expected 5235 bp linearised plasmid (see Figure
3 10A) The EcoRlfHindlll restnction produced a band corresponding to the expected 
680 bp fragment containing the rBta-papl-Hisó fusion (see Figure 3 10B)
pZK3 was subsequently verified by DNA sequencing (see Appendix B) Figure 3 11 
details the rBta-papl region of pZK3 showing the promoter elements, translated 
sequence, restnction sites and the Hisó tag
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Figure 3.8 Cloning Strategy fo r pZK3
Outline of sub-cloning strategy from pZK2 to generate p7JC3. The rBta-papl-W\% fusion is excised from 
pZK2 by restriction with £coR1 and //indili. This 680 bp fragment is ligated into pPC225, which has 
been opened with £coRI and //indili. Resulting construct, p7.K3, has rBla-papl-Hisfc fusion under control 
o fP tac  promoter. Illustrated using pDRAW32 (see Section 2.11).
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EcoRJ -1
Figure 3.9 pZK3 Plasmid Map
The rBta-papI gene fragment is shown in blue which is under the control of the Ptac promoter (yellow). 
His tag fusion is shown in green and Ampicillin resistance gene (ampR) in red. See Figure 2.3 for map of 
parent vector pPC225. Illustrated using pDRAW32 (see Section 2.11).
A
12000 bp
<000 bp 
3000 li» 
2000 i p
1000 bp
B
m .
<000 bp
—  ' m m  m m  m m 3000  tip m . .  ^ m m
3 !  f t * 2000 bp
1000 bp 
<00 bp
4
Figure 3.10 Verification Digest of pZK3
Restriction digest of pZK3 construct analysed on 1% agarose gel (see Section 2.5): (A) Lane I. L)NA 
Ladder (sizes as in Figure 2.5): Lane 2, uncut; l.anc 3, Afcol; I^ ane 4, £coRI; l.anc 5, //indili. (B) l.ane 1, 
DNA Ladder: Lane 2, uncut: lane 3, EcoK\/HinJ\U\ lane4, DNA ladder.
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pZK3 TCTGAAATGAO ITTJlATC XTCOOCT'
•35
H T
• 10
>JTOTOO#LTTOTOAGCGGAT AAC AATTTC AC i — I* t JlOA ATTC ATT 
♦I InMcnpt»» «1«i1 RBS
Eco Ri Wrol
M t Q P R f. A t  c  r
AATTAACCQjgp'tjcagcccaggaaggcggtggtggtgacgggatccg 
RBS rtOa fQf I *1«»1 codon
Y E t P V E Y Q T V O R L I P a L W EO P E G  E  T V M A Î W l A V Q  E L E C L C L G D S V t* L MV
pZK3 gccctttnggggaacacactgtgaatgccagctggategcggtccaggagctggagaaactagggcttggggacagegtggacctaeatgtgtatgagattccagtggagtatcagacggtccagaggcteatccct^ccctgtgggaga
K H î P Q L V V H V G V S G M  A T  A V T L E K C G H  M t C T K C L D M C R F C P C S Q  C C V E D G P E
pZK3 agcacagteegeagctggtggtgeacgtaggcgtgTcaggeatggcaacegcagtcacactggagaagtgtgoaeacaacaagggttacaagggectggacaaetgccgactetgceccg«ctcecagtgetgtgtggaggacgggccgg
Eagl
S I  D î l l D M O A V C K i V T  T L O L O V  S V T I î Q D a G R  Y L C D T T  Y Y T  5 L Y Q S  H C » 
p ao  aaagcattgactccatcatcgacatggatgctgtgtgtaagagggncactacactgggctt agatgtgtcagtgaccatttcacaagatgcaggcaggt acctctgcgacttcacctaciatncctctctgtaccagagtcacggccgct
i V P P L C K Y H A D 0 L I I E  E M L D L L E  <5 î t G K I H E G î H
p2JO cagcctttgttcacgtgccccctctgggcaagccgracaatgcagaccagctggyccgggcacttcgggccatcattgaggagat gctggacctcct agagcagtcagaaggcaaaatcaactgttgccatgaacac GGATCTj
U m
H H H H H HmtRU
omm MopndM
Figure 3.11 pZK3 Sequence Detail
l l i e  rBia-papl and Ptac promoter (black) regions o f  pZK3 are shown in detail. The translation o f  rBia-papl is shown in blue above the ORF. The 6xHis tag sequence is 
shown in green, joined to rBta-papl by a Gly-Ser linker. Two ribosome binding sites (RBS. red) are shown. The first RBS upstream from the rBia-papl start codon was 
subcloned from pZK2 (see Figure 3.6) while the second RBS was present on pPC225 associated with the Ptac promoter. Restriction enzymes are marked in red. For amino 
acid information see Appendix D. Illustrated using GenDoc (sec Section 2.11).
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3 4 Expression of Recom binant Bovine PAP1 in E  coli XL 10-Gold
The expression plasmid pZK3 (see Figure 3 9) was transformed into E coli strains 
XL10-Gold (see Table 2 1), by the method described in Section 2 6 3 
XLIO-Gold strains contain F factors, which carry the /aclq allele The laclq allele is a 
prom oter mutation that expresses the LacI repressor protein at high levels, resulting in 
strong repression o f  the P ta c  promoter unless the inducer IPTG is added, w hich binds 
and inactivates L a d  and thus induces transcription from Y ta c
A number o f  parameters were investigated during the optimisation o f  the expression 
system for recombinant human PAP1 (Vaas, 2005) These parameters nam ely E coli 
strain, effect o f  induction time, effect o f  IPTG and effect o f  somcation tim e were 
optimised Various E coli strains including D H 5a, IN V aF’, BL21, Nova Blue, Rosetta, 
RosettaBlue and XL 10-Gold were analysed for expression Optimal protein expression 
was found when E coli strain XL 10-Gold was utilised
The optimal concentration o f  IPTG for induction was found to be 50 ¡jlM  Relatively 
low levels o f  recombinant protein were obtained when using 0 5 or 1 mM IPTG 
Somcation was found to have a major negative effect on the r/-/vaPAPl6n enzyme 
Somcation time o f  greater than 30 sec was found to result in a sharp reduction o f  
rHsaPAP 1 6h activity Therefore a standard somcation time o f  30 seconds was utilised 
The E coli XLIO-Gold culture (1 litre culture), expressing r£ taP A P l6H (see Section
2 12) was induced with 50 ¡iM IPTG until the A6oo had reached 0 35 and allowed to 
grow for a further 4 hrs as described in Section 2 12  1
3 5 Purification of Recom binant Bovine PAP1
N itnlotriacetic acid (NTA) is a tetradentate chelator, allowing it to occupy four o f  the
2+six ligand binding sites in the coordination sphere o f  Ni , therefore binding the metal 
ion far more stably, retaining it even under stringent wash conditions In the Ni-NTA
2_j_
resin, two ligand binding sites o f  each Ni are free to interact with the six consecutive 
imidazole groups o f  a HiS6 tag Ni-NTA was used in this w ork to purify r5taPAPl6H as 
reported in the following Section 3 5 1
85
3.5.1 IMAC Purification of Rccombinant Bovine PAP1
The standard procedure to purity r/fraPAPUti from cleared lysate, obtained from E. coli 
cultures expressing r/ff/aPAPUn, using Ni-NTA is described in Section 2.13.1. Both 
washing and elution was carried out using free imidazole as a counter-ligand.
Figure 3.12 shows the SDS-PAGE analysis (see Section 2.16) o f  a routine IMAC 
purification o f  r/?taPA Pl6H, using four 20 mM imidazole washes and three 200 mM 
imidazole elutions. The protein concentration and specific activity values for the cleared 
lysate and first elutions are given in Table 3.1. Zymogram analysis (see Section 2.17) 
was carried out on purified r/frcrPAPUn, shown in Figure 3.13.
1 2 3 4 ? 6 7 8 9 10 11 kDa
Figure 3.12 SDS-PAGE of Bovine PAP1 at Each Stage of Purification
Lane 1 and 11, protein molecular marker; lane 2, crude supernatant; lane 3, flow-through; lane 4-7, 
sequential column washings; lane 8-10. elution o f  recombinant bovine PAP1 protein from the column. 
The relevant sizes (kDa) o f  the protein marker are indicated.
8 6
Figure 3 13 Zymogram Analysis of Purified Bovine
Bovine PAP1 activity band is highlighted which correlates with protein band on SDS-PAGE Lane 1, 
protein molecular marker, lane 2, purified bovine PAP1 on SDS-PAGE, lane 3, zymogram o f purified 
bovine PAP1 on Native-PAGE
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Table 3 1 Summary of Recombinant Bovine PAPI Purification,
Volume
(ml)
Total Activity®
(Units)
Total Protein
(mg)
Specific Activity
(Units mg l)
Purification
F acto r
Yield
(%)
C rude PA PI 30 35,197 103 25 340 1 100
P unfied  PA PI 
(Elution 1)
5 9,388 2 6 3,633 106 8 27
a U nits =  nmoles min 1 i e Units are expressed as nanom oles o f  AM C released per m inute at 37°C
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3.6 Biochemical Properties of Recombinant Bovine PAPI
3.6.1 Relative M olecular Mass
As outlined in Section 2.18.1, 100 [i\ o f  purified r^/iiPA PU n, at a concentration o f  200 
jig/ml, was analysed by size exclusion chromatography. Figure 3.14 shows the protein 
concentration profile corresponding to the elution o f  rfftoPAPUii and the protein 
standards BSA, Carbonic Anhydrase and Cytochrome c. Also shown is the profile o f  
PAP1 activity corresponding to the elution o f  r/ta/PA PU n. Figure 3.15 shows a plot o f  
elution volume over void volum e (Vt./Vt>) versus the log o f  molecular weight. From this 
plot the relative molecular weight o f  r/?/aPA Pl6n was determined as 24.7 kDa.
Ynliun«* (ml)
Figure 3.14 Size Exclusion Ch rom atography of r/fraPA Pl6H
Size exclusion chromatography (sec Section 2.18.1) o f  rfl/aPAPlft,,. Void volume o f 36 ml was 
ascertained using blue dextran. Elution o f  r/foiPAPlwi at 74 ml was determined using PAP1 activity assay 
(sec Section 2.15.3) and is represented by fluorescent intensity, shown in red. Elution volumes o f  
molecular weight standards BSA (51 ml). Carbonic Anhydrase (67 ml) and Cytochrome c (94 ml), were 
determined by protein assay (see Section 2.14.1) and used to construct a plot o f  V/V«» versus log MW 
(sec below).
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Figure 3 15 Determ ination of r2?/aPAPl6H Native Size
Plot o f  elution volume over void volume (Ve/V0) versus the log of molecular weight This plot was used 
to establish the relative molecular weight of r#taPAPl6H to be 24 7 kDa
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3 6 2 pH  Profile
The effect o f  pH on the activity o f  ri?taPA Pl6H was investigated as outlined in Section 
2 18 2 Figure 3 16 shows the pH profile for purified ri?taPA Pl6H Prominent PAP1 
activity was detected between pH 7 5-10 0, with activity rapidly dropping o ff outside 
this pH range Bovine PAP1 exhibited its optimum activity within the peak range o f  
9 0-9 5
' p H
Figure 3 16 Effect of pH on rZft«PAPl6H Activity
Effect o f pH on recombinant bovine PAP 1 activity Enzyme activity was measured under standard assay 
conditions over the range pH 6 0-10 5 with buffers as described in materials and methods The buffers 
used were 0, potassium phosphate, o, Tns/HCL and A, glycine/NaOH Error bars represent the SD o f  
triplicate readings
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The effect o f  temperature on the activity o f  r/?faPAPl6H was investigated. As outlined in 
Section 2.15.3, the standard activity assay was carried out at a range o f  temperatures. 
The resulting 15 min temperature profile is shown in Figure 3.17. Maximal activity was 
observed at 37°C.
3.6.3 Tem perature Studies
120 -,
4 24 30 37 40 50 60
Tem|»erature "C
Figure 3.17 Effect o f T em p era tu re  on r^ ia P A P l6n Activity
ITie effect o f  temperature on the activity o f  r/ta/PAPl6H activity was determined by carrying out the 
standard assay (see Section 2.15.3) at 4 to 60°C for 15 min. Error bars represent the SD o f  triplicate 
readings.
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3 6 4 Effect of DTT and EDTA
DTT and EDTA are essential components o f  the standard PAP1 activity assay (see 
Section 2 15 3) In order to optimise the assay concentrations, their effect on 
ri?taPA Pl6H activity was determined Figures 3 18 and 3 19 show the influence o f  DTT 
and EDTA, respectively, on xBta? API ^  activity Bovine PAP1 activity was heavily 
dependent on thiol reducing agent DTT A rapid increase in activity was observed from 
2 mM to 10 mM and above this concentration a plateau effect was observed EDTA had 
an insignificant effect on activity and as a result 2 mM EDTA was used throughout
DTT Concentiiition (mM)
Figure 3 18 Effect of DTT on riftaPAPliH  Activity
The effect o f DTT concentration on the activity o f r5taPAPl6H activity was determined by carrying out 
the standard assay (see Section 2 15 3) using a range of DTT concentrations up to 20 mM Error bars 
represent the SD of triplicate readings
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Figure 3 19 Effect of EDT A on rB ta P A P lm  Activity
The effect o f EDTA concentration on the activity o f r6taPAPl6H activity was determined by carrying out 
the standard assay (see Section 2 15 3) using a range o f EDTA concentrations up to 15 mM Error bars 
represent the SD of triplicate readings
3 6 5 Inhibition Studies
A number o f compounds were analysed for their possible inhibitory effect on 
ri?taPAPl6H activity (see Section 2 18 5) IC50 values were determined, whereby this 
value represents the inhibitor concentration at which 50% of enzymatic activity is lost 
A value o f 0 8mM was determined for the thiol-blocking compound lodoacetic acid (see 
Figure 3 20)
Inhibition by free l- pGlu and the substrate analogue 2-pyrrolidone is shown in Figures 
3 21 and 3 22 IC50 values determined were 1 6 and 0 75 mM, respectively
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Figure 3.20 Effect of lodoacetic Acid on rJfraPAPUn Activity
The effect o f  iodoacetic acid on the activity o f  rfl/aPAPl6M was determined by the procedure outlined in 
Section 2.18.5. using iodoacetic acid at concentrations up to 5 mM. Error bars represent the SD o f  
triplicate readings.
[i-pGlu) (mM)
Figure 3.21 Effect of i.-pGlu on r/fraPAPUii Activity
The effect o f i -pGlu on the activity o f  r/?ftfPAPl6n was determined by the procedure outlined in Section 
2.18.5, using L-pCilu at concentrations up to 5 mM. Error ban represent the SD of triplicate readings.
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2-Pyrrolidone (mM)
Figure 3.22 Effect of 2-Pyrrolidone on r W A P I f H  Activity
The effect o f  2-Pyrrolidinone on the activity o f  r/?taPAPlWJ was determined by the procedure outlined in 
Section 2.18.5, using 2-Pyrrolidone at concentrations up to 5 mM. Error bars represent the SD o f  
triplicate readings.
3.7 Kinetic Studies
Kinetic analysis on purified bovine PAP1 were performed as outlined in Section 2.18.6.
3.7.1 Determ ination of Kinetic Param eters Vm>1 and K*,, for Recombinant 
Bovine PA PI
It was necessary to dilute purified rfltaPAPU n to a concentration o f  1 -5 ng.mY' in order 
to ensure the fluorescent intensity values fell within the measurable range o f  the Perkin- 
Elmer LS-50B plate reader spectrophotometer used in this work (see Section 2.15.3). 
This procedure, which required PAP1 activity to be assayed at various pGlu-AMC 
concentrations, as outlined in Section 2.18.6.1, was carried out with purified 
r/to jP A P l6ii. The resulting Michaelis-Menten curve for purified r# taP A P l6u is shown 
in Figure 3.23.
This data was applied to the three kinetic models described in Appendix C, namely: 
Lineweaver-Burk (see Figure 3.24), Eadie-Hofstcc (see Figure 3.25) and H anes-W oolf 
(see Figure 3.26). From these plots the maximal enzyme velocity (V n^) and the 
M ichaelis constant (Km) were determined, which are given in Table 3.2. Also shown in
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this table is the turnover number (Kcat) for purified rZfraPAPUii, which was determined 
as described in Appendix C. These parameters were also determined using Enzfitter 
software from Biosoft, Cambridge, UK.
[pGhi AMC] (mM)
Figure 3.23 M ichaelis-Menten Curve for Purified rB taP APhu
Plot o f  substrate concentration ([pGlu-AMC]) versus reaction rate, represented by fluorescence intensity 
(Fi). for purified r£taPAPlMi diluted to 2.5 pg/'ml. Data obtained by the procedure described in Section 
2.18.6.1. Lrror bars represent the SD o f  triplicate readings.
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l/[pGlu-AMq
Figure 3 24 Lineweaver-Burk Plot for Purified rI?taPA Pl6H
Data from Figure 3 23 fitted to the Lmeweaver-Burk model for the determination o f  kinetic parameters, 
as outlmed m Appendix C Equation and regression are shown Km and values given m Table 3 2 
Error bars represent the SD of triplicate readings
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Fluoi escence Mensity/ [pQuAMC]
Figure 3 25 Eadie-Hofstee Plot for Purified r2?taPAPl6H
Data from Figure 3 23 fitted to the Eadie-Hofstee model for the determination of kinetic parameters, as 
outlmed in Appendix C Equation and regression are shown Km and Vmax values given in Table 3 2 
Error bars represent the SD o f triplicate readings
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Figure 3 26 Hanes-W oolf Plot for Purified rZ taP A P l6H
Data from Figure 3 23 fitted to the Hanes-Woolf model for the determination o f kinetic parameters, as 
outlmed m Appendix C Equation and regression are shown Km and Vnm values given in Table 3 2 Error 
bars represent the SD of triplicate readmgs
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Table 3 2 Kinetic Parameters Obtamed for rl?taPAPl6H
M ethod K m
¡iM
Vmax 
Units ml"1
o 
—
Lineweaver-Burk 66 3 3 3 6
Eadie-Hofstee 55 2 93 3 25
Hanes-W oolf 50 3 04 3 37
Enzfitter Software 63 3 22 3 57
Average 59 3 12 3 5
[Km and Vmax values obtained from Figures 3 24 to 3 26 calculated as outlined in Appendix C]
3 7 2 Determ ination of K, Values for Pyroglutam yl-Peptides
Determination o f  K, values in the PAP 1-catalysed hydrolysis o f  pGlu-AM C using 
pyroglutamyl-containing peptides was performed according to Section 2 18 6 2 Km (app) 
and Vmax values were determined graphically for each o f  the peptides using the 
Lineweaver-Burk kinetic plot values and the nature o f  inhibition were estimated for 
each peptide Figures 3 27 to 3 33 represent Lineweaver-Burk plots for each peptide 
studied A K, value o f  44 ¡iM was determined for tnpeptide TRH showing the relative 
highest affinity for bovine PAP1 Table 3 3 lists the Km (app) values and the type o f  
inhibition obtained for peptides tested The significance o f  these results is discussed in 
Section 3 8
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Figure 3.27 Kinctic Analysis of the Effect of pGlu-Ala ( • )  on Bovine PAP1 
Catalysed Hydrolysis of pGlu-AMC (■). I ineweaver-Burk reciprocal plot o f fluorescent 
intensity versus [pGlu-AMCJ. Plot illustrates mixed inhibition o f  PAP1 by pGlu-Ala. Error bars represent 
the SD o f  triplicate readings.
I fr/Ju AMC]
Figure 3.28 Kinetic Analysis of the Effect of pG lu-T hr ( • )  on Bovine PAPI 
Catalysed Hydrolysis of pGlu-AM C (■ ). 1 inewea ver-Burk reciprocal plot o f  fluorescent 
intensity versus [pGlu-AMC]. Plot illustrates competitive inhibition o f  PAPI by pGlu- Ihr. Lrror bars 
represent the SD o f  triplicate readings.
102
l/{pC3u- \M (. J
Figure 3 29 Kinetic Analysis of the Effect of pG lu-Pro (• )  on Bovine PAP1 
Catalysed Hydrolysis of pGlu-AM C (■ ) Lineweaver-Burk reciprocal plot o f fluorescent 
intensity versus [pGlu-AMC] Plot illustrates non-competitive inhibition of PAP 1 by pGlu-Pro Error bars 
represent the SD of triplicate readings
l / lp t tu  AMC]
Figure 3 30 Kinetic Analysis of the Effect of pGlu-Val ( • )  on Bovine PAP1 
Catalysed Hydrolysis of pGlu-AM C (■ ) Lineweaver-Burk reciprocal plot of fluorescent 
intensity versus [pGlu-AMC] Plot illustrates mixed inhibition of PAP 1 by pGlu-Val Error bars represent 
the SD of triplicate readings
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l/[pQiHMCl
Figure 3.31 Kinetic Analysis of the Effect of pGlu-Ala-AIa ( • )  on Bovine PAP1 
Catalysed Hydrolysis of pGlu-AM C (■ ) Lineweaver-Burk reciprocal plot of fluorescent 
intensity versus [pGlu-AMC] Plot illustrates mixed inhibition of PAP1 by pGlu-Ala-AIa Error bars 
represent the SD of triplicate readings
1/IpO u a m c i
Figure 3 32 Kinetic Analysis of the Effect of pGlu-Glu-Ala ( • )  on Bovine PA PI 
Catalysed Hydrolysis o f pGlu-AM C (■ ). Lineweaver-Burk reciprocal plot of fluorescent 
intensity versus [pGlu-AMC] Plot illustrates competitive inhibition of PAPI by pGlu-Glu-Ala Error bars 
represent the SD of triplicate readmgs
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F igure 3.33 K inetic A nalysis o f the Effect o f pG lu-H is-Pro-N H 2 ( • )  on Bovine 
PAPI C atalysed H ydrolysis o f pG lu-A M C  (■ ) . Lineweaver-Burk reciprocal plot o f  
fluorescent intensity versus [pGlu-AMC]. Plot illustrates competitive inhibition o f  PAPI by pGlu-His- 
Pro-NHi Error bars represent the SD o f  triplicate readings.
i h>ra<i ,vnk*i
Figure 3.34 K inetic Analysis o f the Effect of pG lu-M et-A la ( • )  on Bovine PAP1 
C atalysed H ydrolysis o f  pG lu-A M C  (■ ). I.ineweavcr-Burk reciprocal plot o f  fluorcsccnt 
intensity versus [pGlu-AMCJ. Plot illustrates mixed mhibition o f PAP1 by pGlu-Met-Ala. Error bars 
represent the SD o f  triplicate readings.
105
0<KS
i / [ p a u  AMC]
Figure 3.35 Kinetic Analysis of the Effect of pG lu-Thr-A la ( • )  on Bovine PAP1 
Catalysed Hydrolysis of pGlu-AM C (■ ) Lmeweaver-Burk reciprocal plot o f fluorescent 
intensity versus [pGlu-AMC] Plot illustrates mixed inhibition o f PAP 1 by pGlu-Thr-Ala Error bars 
represent the SD o f triplicate readings
Table 3 3 K, Values O btained for Pyroglutam yl Peptides
Peptide Km (app) Kj (f iM) Inhibition Type
pGlu-AJa 166 141 Mixed
pGlu-Thr 125 279 Competitive
pGlu-Pro 71 3,300 Non-Competitive
pGlu-Val 83 625 Mixed
pGlu-Ala-Ala 111 366 Mixed
pGlu-Glu-Ala 47 n d Competitive
pGlu-His-Pro-NH2 (TRH) 400 44 1 Competitive
pGlu-Met-Ala 111 366 Mixed
pGlu-Thr-Ala 83 625 Mixed
Activity o f bovine PAP 1 towards pyroglutamyl peptides Enzyme assays were earned out as described in 
Materials and methods [Kmapp values obtained from Figure 3 27 - 3 35 K, calculated as outlmed in 
Appendix C]
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3 8 Com parative Study of Recom binant Bovine PAP1 with Recom binant 
H um an PAP1
Given that a member o f  our research group (Vaas, 2005) had previously cloned, 
expressed and purified the recombinant human PAP1 enzyme it was possible to carry 
out a comparative study with recombinant bovine PA P1
Nucleotide and amino acid sequences o f  both genes were aligned (see Figure 3 36 and 
3 37, respectively)
3 8 1  Expression and Purification
Both r5 faP A P l6H and rHsa?AP16H were then expressed in E coh XLIO-Gold (1 Litre 
Culture, see Section 2 12) and purified using IMAC (see Section 2 13)
SDS-PAGE resolved a band o f -23-24  kDa for both bovine and human PAP1 (see 
Figure 3 38) Following purification, bovine PAP1 produced a yield o f  2 6 mg o f  PAP1 
protein per litre culture Interestingly, the human PAP1 enzyme produced a higher yield 
o f  6 5 mg PAP1 per litre culture (see Table 3 4) Total activity for rHsa?AP\m is almost 
three times greater than ri?taPA Pl6H activity Overall, specific activity for r£ faP A P l6H 
and rHsa?AP\ were 3,633 units mg"1 and 4,623 units m g '1, respectively
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S'm it Codon
1 10 ?0 30 40 50 GO 70 80 90 100 110 120 130
I.................   ♦--------------♦ - + —------»-------------- ♦...................♦---------------              I
HunanPRPl Gflft6CRGGTCCGRGGC RCRGCCCGRTCCCGCCRTGGflGCRGCCGflGGRflGGCGGtGGTflGTGRCGGGflT TIGGCCCT IT TGGGGfWCACRCCGTGflflCGCCftGTIGGfllTGCBGTTCRGGftGC IRGflflflfl 
BovinePflPl GGftftCCGGTCfiGflGGCflCBGCCTGflflCCCGCCfllGGflGCnGCCCRGGflflGGCGGTGGTGGTGRCGGGflT TCGGCCCITI IGGGGflnCRCnCTGTGflflTGCCRGC TGG8T TGCGGTCCRGGRGC IGGflGftfl 
Consensus GaRaCaGGTCdGRGGCRCRGCCcbRarrrGf CRTGGRGCRGCCcRGGRRGGCGGTGGleGTGRCGGGRTTcGGCCCT IT TGGGGRBTRCRCcGTGRRcGCrRGcTGGRHGCaGlcrRGGRGr laGRaRR
131 140 150 160 170 180 190 200 210 220 230 240 250 260
I-------- — ^ ------------♦—---------- ♦-------------- ------------------------------- ♦—--------------            ♦ ---------------1
HunanPBPl GCIRGGCL IIGGCGRCRGCG1GGRCL IGLHIGIGIRCGMGRI1LC6GIIGRGIHCCRRRCRGICLHGRGHC ILHICCUCGCCCIGIGGGHGHHGIHCHGILCRCRGCTGGIGGIGCRIGI GbüGüIGTCR 
BovinePDPl RC1RGGGTI TGGGGRCRGTGTGGACCTRCRTGTGTRIGRGRTTCCMjTGGRGlRTrRGIICGGTrCRGRGGCTCRTCCCIGCrCTGTGGGRGRRGCRCRGTrCSCRGCIGGTGGTGCRCGTflGGCGTGTCfl 
Consensus oCTRGGcC I IGGcGHLRGCGIGGRCL lalRIGlGlRcGHI.RI TCCaGlKGRblHctHdRCdGICCRGRGaCICRICCLcGCtCIGIGGGRGRRbCHCRGILLACHGCIGGlGGTGCRcGlaGGcGIGlLH
261 g79 ?80 290 300 310 320 330 340 350 360 370 380 390
MunonPBPl GGCRTGGCGRCCRCftGTCRCRC TGGnGRflfllGTGGRCRCRflCRRGGGCTnCRRGGGGf TGGRCRRC TGCCGCT TTTGCCCCGGCTCCCRGTGCTGCGIGGRGGRCGGGCCTGRRRGCRITGRCTCCRTCR 
BovinePAPl GGCRTGGCRRtCGCRGTCRCRCIGGHGRNGIGIGGRCRCRRCRAGGGTTRCRRGGGCCTGGRCRACTGCCGflHCTGCCCCGGCTCCCAGTGCTGTGlGGRGGRCGGGCCGGRRRGCRTTGRClCCRTCR 
Consensus GGCRTGGCdflCCeCRGTCRCRCTGGRGRRaTGTGGRCRCRRCRRGGGcTRCRRGGGcf TGGRCRACTGCCGaHcTGCCCCGGCTCCCRGTGCTGcGIGGRGGRCGGGCCeGRflRGCRTTGRC TCCRTCR
391 400 410 4?0 430 440 450 460 470 490 490 500 510 520
|        » ♦ -♦          1   1 1
HunanPRPl TCGRCRTGGRTGCTGTGTGCRRGCGRGICRCCRCGTT&GGCCTGGRTGTGlCGGTGRCCRTCH'Gt RGGRIGCCGGCRGATRTCTCIGCGRCUTRCCTRCTRCRCCICTTTGTRCCRGRGICRCGGTCG 
BovinePRPl ICGACHlüGHIGCTGIGTGTHHüHüGülCHlfHCACIGGGC! IRGRIGIGILHGIGHCCRTT !LR( HRGRIGLRGGCHGGIRCCTCIGCGRCI ICRCCIRCIRTRCClClCIGlRCLHbRGRHCGGCCG 
Consensus TCGRCRTGGRTGCTGIGTGcRRGaGaGTCRCcRCacIGGGCcIaGflTGTGTCaGIGRCCRTcirdf RaGRIGCdGGCRGalRcCTCTGCGRCI TcRCCTRCTRcRCCTCTcTGTRCCRGRGTCRCGGcCG
521 530 540 550 560 570 580 590 600 610 620 630 640 650
I------------   — -----------♦--------------       ♦---------------«---------------    — -----------♦---------------1
HunanPRPl RTCRGCC1TCGTCCRCGTGCCCCCRC1GGGGARGCCGTRCRRCGCGGRCCRGCIGGGCRGGGCRC TGRGAGCCRTCRTIGRGGRGRT6TIGGRCC TCCTGGAGCRGTCRGRGGGCRRRRTCRRCTRTTGC 
BovinePflPl CTCflGCC7TTGTTfflTGTGCCfnf TCTGGGCRRGrfGTflf RRTGfBGflrrRGC TGGiifCGGGrflf TTC66GCCRTCRI TGflGGRGRTGCTGGflCCICCIAGRGrflGTrflGflRGGrflflflflTCRRCTGI IGT 
Consensus alCRGCC! IcGlcCRCGIGCCCCCaClGGGcHRGlLGIHLRRcGCaGRCtHGCIGGGtaGGGCRCIeaGaGtCHICRI IGHÜGRGRTGcIGGRtL ICCIaGRGLHGI L'RGffebGCRHflfllL'HRCfal IGL
651 660 670 680 690 69b
I-------  ♦ --------------  «------------------  1
HummPRPl CACflRRCRCIGRGGGACGCTCRGGTCTCCTAflGnCCTCRTCCTGC 
BovinePflPl CRTGflflCRCIGRlTGCTGCTCRGGCCTCCCflRGRCCTCRTCCTGC 
Consensus CAcaflACflCTGActGacGCTCflGGcCTCCcflRGnCCICfllCCTGC
I
Sfop Codon
Figure 3.36 PAP1 Nucleotide Alignments
Alignment o f  the recombinant bovine PAP I XM866409 (Bovine PAP1) nucleotide sequence with human PAPI AJ278828 (Human PA PI) highlighting the 71 nucleotide 
variations throughout. IT»e sequences were annotated using the Multialign program, (sec Section 2.11).
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Bovine PAP 
Human PAPI
ME Q PR KAVWTGFGPFGE HT VN ASWIAVOE LE K LGLGD 
ME Q PR KAWVTGF GPFGE HT VN ASWIAVQE LE K LGLGD
38
38
Bovine PAP : SVDLHVYEIPVEYQTVQRLI PALWEKHS PQLWHVGVS : 76
Human PAPI : SVDLHVYEIPVEYQTVQRLI PALWEKHS PQLWHVGVS : 76
*
Bovine PAP : GMAT0VT LgKCGHNKGYKGLENCRFCPGSQCCVEDGPE : 1 1 4  
Human PAPI : GMATflVTLgKCGHNKGYKGLDNCRFCPGSQCCVEDGPE : 1 1 4
*
Bovine PAP : SIDSIIDMDAVCKRVTTLGLDVSVTISQDAGRYlWDFT : 152 
Human PAPI : SIDSIIDMDAVCKRVTTLGLDVSVTISQDAGRYl5)FT : 152
*
Bovine PAP : YYTSLYQSHGRSAFVfjJ/PPLGKPYNADQLGRALRAIIE : 1 9 0  
Human PAPI : YYTSLYQSHGRSAF\lS/PPLGKPYNADQLGRALRAIIE : 1 9 0
Bovine PAP : EM LDL LE QSEGKI NBrHgjH : 2 0 9  
Human PAPI : EMLDLLEQSEGKTnS?H2H : 2 0 9
Figure 3.37 PAP1 A m ino Acid A lignm ents
Alignment o f  the recombinant bovine PAP1 XM866409 (bovine pap 1) amino acid sequence with human 
PAP1 AJ278828 (human papl) highlighting the three amino acid variations at positions 81. 205 and 208 
in blue. Active site residues (*) are highlighted in red. The sequences were annotated using the Genedoc 
program (see Section 2.11).
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Table 3 4 Recombinant Bovine and Human PAPI Purification
Total Activity3 Total Protein Specific Activity
(Units) (mg) (Units mg ‘)
Purified Bovine PAPI 9,388 2 6 3,633 8
Purified Human PAPI 30,192 6 5 4,623 1
Summary o f recombinant bovine and human PAP1 purification from 1 L expression runs a Units = 
nmoles mm 11 e Units are expressed as nanomoles o f AMC released per mmute at 37°C
Figure 3 38 SDS-PAGE of H um an and Bovine PAP1 Purification
A SDS-PAGE o f purification of human PAP 1 B SDS-PAGE o f purification o f bovine PAP 1 Lane 1, 
protem molecular marker, lane 2, crude supernatant, lane 3, flow-through, lane 4-7, sequential column 
washings, lane 8-10, elution of recombinant PAP1 protem from the column The relevant sizes (kDa) of 
the protein marker are indicated
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3 8 2 Investigation into Reduced Yields of Bovine PAP1 Protein
Due to the fact that there is 98% identity between the two amino acid sequences (see 
Figure 3 29), it was decided to investigate the reduced yields o f  ri?taPA Pl6H (2 6 mg) 
compared to the high yields o f  rHsa?A?\6H (6 5 mg) Factors such as media (batch to 
batch variation), IPTG, sonication and purification were eliminated from contributing to 
this decrease in both specific activity and total protein concentration as both proteins 
were expressed simultaneously with each other and media from the same batch was 
utilised in the expression process
There are two major elements which could possibly contribute to these reductions 
including rare codon usage (see Section 3 8 2 1 ) and amino acid residue differences (see 
Section 3 8 2 2)
3 8 21  R are Codon Usage
Codon usage can have adverse effects on synthesis and yield o f  recombinant proteins 
Genes in both prokaryotes and eukaryotes show a non-random usage o f  synonymous 
codons meaning that there is a bias for one or two codons for most degenerate codon 
families Certain codons are most frequently used by different genes, for example CCG 
is the preferred triplet encoding pro line
It has been observed that highly expressed genes exhibit a greater degree o f  codon bias 
than do poorly expressed genes This implies that recombinant heterologous genes that 
are enriched with codons which are rarely used by E coh may not be expressed 
efficiently in E coh (Makrides, 1996) Low usage codons in E coh include arginine, 
pro line, leucine and iso leucine
It was decided to compare rare codon content o f  the human PAP1 nucleotide sequence 
with the bovine PAP1 nucleotide sequence in the hope o f  resolving the reduced 
expression level yields in bovine PAP1 Analysis shows that human PAP1 has a greater 
number o f  rare codons than bovine PAP1 Human PAP1 possesses 13 rare codons while 
bovine PA P1 has 11 rare codons (see Figure 3 39)
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a t  g g a g c a g C C C a q q a a g g e g g t g g t g g t g a c g g g a t t c g g c c e t t t t g g g
g a a c a c a c t g t g a  a t g e e a g e t g g a t t g e g g t c c a g g a g c t g g a g a a a C T A
g g g c t  t g g g g a c a g e g t g g a c C T A c a t g t g t a t g a g a t t c c a g t g g a g t a t
c a g a c g g t c c a g a g g c t c a t e c e t g e e c t g t g g g a g a a g c a c a g t c c g c a g
c t g g t g g t g c a c g t a g g c g t g t e a g g c a t g g c a a c c g c a g t c a c a c t g g a g
a a g t g t g g a c a c a a c a a g g g t t a c a a g g g c c t g g a c a a c t g c c g a t t c t g c
g g c t c c c a g t g c t g t g t g g a g g a c ggg c c g g a a a g e a t t g a c t c c a t e
a t e g a c a t  g g a t g e t g t g t g t a a g a g g g t c a c t a c a c t g g g c t t  a g a t g t g
t e a g t g a c e a t t t e a c a a g a t g c a g g c a g g t a c c t c t g c g a c t t c a c c t a c
t a t a c e t c t c t g t a c c a g a g t c a c g g c e g e t e a g e e t t t g t t c a c g t g C C C
c e t c t g g g c a a g c c g t a c a a t g c a g a c c a g c t g g g c e g g g c a c t t e g g g e e
a t e a t  t g a g g a g a t g c t g g a c e t c C T A g a g c a g t e a g a a g g c a a a a t e a a c
t g t t g c c a t g a a c a c t g a
R e d  »  rare  A r g  c o d o n s  A G G .  A G A ,  C G A
Green = rare Liu codon CTA  
Blue =  rare Ile c o i  en ATA
Orange »rane Pro coder» CCC
Figure 3.39 Rare Codon Analysis of Bovine PAP1
Nucleotide sequence coding for rfltoPAPl, as found on pZK3 (sec Figure 3.9).Rarc codons are 
highlighted in red. green and orange (see Section 2.11). http://nihservcr.mbi.ucla.edu/RACC.
3.H.2.2 Site-Directed Mutagenesis of r/?/aPA Pl6l|
Using site-directed mutagenesis (see Section 2.9.2) it was possible to modify each o f  
these three amino acid residues Ala81, Cys205 and Glu208 (see Figure 3.40) 
individually, thus reverting back to amino acid residues which are present in human 
PAP1 amino acid sequence. This may perhaps reveal whether o r not individual amino 
acid residues at positions 81, 205 and 208 are responsible for reduced activity and 
protein expression.
' T     ■ V '* i»,
AJauiuc
TIm co m ic
C V rtC U K
Acjd
T m  usa ic
L v»uk
Figure 3.40 Substitution of  rBtaVA P lft„ Residues AlaHl, Cy*205 and Clu208
Amino acid side-chams o f  the three varied residues AlaXI. Cys205 and Glu208. which were substituted 
with threonine, tyrosine and lysine respectively. For amino acid information see Appendix D. Illustrated 
using ChemSketch (see Section 2.11).
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3 8 2 2 1 Analysis of Recom binant Bovine PAP1 M utants
The mutant plasmid derivatives o f  pZK3 (see Table 3 5) were transformed into E coh 
XL 10-Gold as described in Section 2 6 3 Expression cultures (100 ml) were prepared 
as outlined in Section 2 12 Purified samples were assayed for PAP1 activity (see 
Section 2 15 3) and total PAP1 protein (see Section 2 14) An increased yield o f  bo vine 
PAP1 protein was obtained for r£toPAPl_C205mY6H and increases were also observed 
with specific activity Specific activity dramatically increased for both C-terminus 
mutations r/?taPAPl_C205mY6H and ri?taPAPl_E208mK6H (see Table 3 5)
Figure 3 41 Purification of Bovine PAP1 M utants
Lane 1 and 7, protein molecular marker, lane 2, r/ftaPAPl6H, lane 3, r£taPAPl6H, lane 4, 
r5taPAPl_A81mT6H, lane 5, r5taPAPl_C205mY6H, lane 6, r^^PAPl_E208mK6H The relevant sizes 
(kDa) o f the protein marker are indicated
Table 3 5 Properties of rZ/sflPAPl6H, r2fraPAPl6H and M utan t Derivatives
Enzyme Specific Activity 
(Units m g ')
Total Protein 
(mg)
Temperature
(°C)
Km
G»M)
r/?taPAPl6H 5,321 0 13 37 59
r//saP A P l6H 13,951 0 5 50 53
rl?taPAPl_A81 mT6H 7,376 0 14 37 83
r2tatPAPl_C205mY6n 10,019 0 4 50 50
rBtePAPl_E208mK6H 8,220 0 12 37 45
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3.8.3 Active Site Mutagenesis of Bovine PAP1
Previous work carried out on human PAP1 enzyme indicated that its catalytic triad 
consisted o f  Glu-Cys-His. By sequence alignment (sec Figure 3.37) these residues 
correspond to Glu85, C ysl49  and His 168 in rBta-papl. These three residues occupy the 
identical position in the rHsa-papl sequence.
The catalytic mechanism o f  cysteine peptidases require a nucleophile and a proton 
donor. The nucleophile is the thiol group o f  a Cys residue and the proton donor is 
usually the imidizolium ring o f  a His residue. In some cases a third residue is required 
to orientate the imidazolium ring o f  His (Barrett and Rawlings, 2001).
If  these residues constitute the catalytic site o f  rBta-papl, one would expect the enzyme 
activity to he affected dramatically. Using a site-specific mutagenic approach Glu85, 
C ysl49  and H isI68 were substituted with glutamine, phenylalanine and aspartic acid, 
respectively (see Figure 3.42). This was carried out as described in Section 2.9.2, using 
primers listed in Table 2.2. The choice o f  these amino acid replacements was based on 
altering properties o f  the amino acids. For example, glutamic acid which is an acidic 
amino acid was replaced with the basic amino acid glutamine. The resulting mutant 
constructs are listed in Table 3.6. All mutations caused a com plete loss o f  activity, 
supporting the catalytic significance o f  these residues. SDS-PAGE shows expression o f  
mutant bovine PAP1 proteins at levels comparable to r& aPA PUii (sec Figure 3.43).
GhiUHiK At iH idiil.miuk
CVsIm w  P lw uvM w um
• n r t >   .  - r x
Etetiduic A<patu Acid
Figure 3.42 Substitution of r# /aP A P l6ll residues Glu85, C ysl49 and H isl68
Amino acid sidc-chains o f  the activc site residues Glu85. Cys 149 and His 168, which were substituted 
with glutamine, phenylalanine and aspartic acid respectively. For amino acid information see Appendix 
D. Illustrated using ChemSketch (see Section 2.11).
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Tabic 3.6 r/fraPAPUii Active Site Mutant Derivatives
M utation Plasmid Enzyme
E85 to 0 pZK3 L;85mQ rÆfaPAPl_E85mQ6H
C149 to F pZK3 C149mF rfl/aPAPl_C149mF6H
H168 to D pZK3_H168mD rBtaPAP 1 _H 168m Dtii
kDa 1 2 3 4 5 6
Figure 3.43 Purification of Active Site rlfraPA Plfii M utants
Lane 1 and 6, protein molecular marker; lane 2. rfltaPAPlwl; lane 3, rfl/aPAPl_E85mQw,; lane 4. 
r£wPAPl_C149tnF6H, lane 5, r£/tfPAPl_H168mD6H.The relevant sizes (kDa) o f  the protein marker arc 
indicated.
3.9 Discussion
3.9.1 Cloning, Expression and Purification of Bovine PAPI
The 680 bp bovine PAPI gene was successfully cloned from bovine mRNA (plasmid 
pZK.1, see Figure 3.5). Bovine PAPI was then expressed in an E.coli based system 
which was developed by Vaas (2005) which was used to express recombinant human 
PAPI. At that time it was hoped that human PAPI could be expressed in E.coli since it 
shared many biochemical characteristics and sequence homology with its prokaryotic 
counterparts.
The bovine PAPI gene was cloned into the TA cloning vector pCR2.1 and subsequently 
cloned using the Nco\ and BamH\ sites into the pQE60 vector. This construct (pZK2) 
was sub-cloned, utilizing the pQE-60 encoded EcoR\ and // in d ili sites, into the 
expression vector pPC225. This generated a pZK.3 expression plasmid having the gene 
for recombinant Bos taurus in ftision with a His#, ORF (rfltaPA PU n) (see Figure 3.9). 
rfltaPAPUn was purified by metal affinity chromatography as reported in Section 3 .5 .
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SDS-PAGE o f  recombinant bovine PAP1 resolved a band with an estimated size o f  24 
kDa (Figure 3.12). This agrees well with previously reported data (Cummins and 
O ’Connor, 1996). This expression run yielded 2.6 mg o f  bovine PAP1 protein and a 
specific activity o f  3,633 units.mg ' 1 (see Table 3.1). Zymogram analysis which was 
carried out on purified preparation displayed a clear band which correlates with SDS- 
PAGE analysis (see Figure 3.13).
3.9.2 Biochem ical and  K inctic Analysis o f Bovine PAP1
Size exclusion chromatography (see Section 2.18.1) has indicated that rBtaPAP 16» has a 
relative molecular mass o f  24.7 kDa (see Section 3.6.1). Thus value correlates very well 
with results obtained from SDS-PAGE (see Figure 3.12) and zymographic analysis (see 
Figure 3.13). This agrees well with findings reported by Dando et al., (2003) who found 
human PAP I to have a relative molecular mass o f  24 kDa. From this it can be 
concluded that recombinant bovine PAP1 is active as a monomeric enzyme.
Bovine PAP1 displayed an optimum pH o f  9.0-9.5 (see Figure 3.16). This compares 
well with data obtained from other researchers which examine the effect o f  pH on PAP1 
activity. Cummins and O ’Connor (1996) found optimal pH o f  bovine brain to be 8.5 
and Dando et al., (2003) obtained maximal activity in the range o f  pH 7.0-9.0 for 
human PAP1. Awade et al., (1992) found bacterial PAP1 to display an optimum pH 
between 7.0-9.0.
Optimum temperature for maximal bovine PAP1 activity was found to be 37°C (see 
Figure 3.17). The optimal temperature for human PAP1 activity was found at 50°C 
(Dando et al., 2003), however bovine PAP1 displayed 50 % reduced activity at 50°C 
and 60°C. Cummins and O ’Connor (1996) found that incubating purified bovine 
enzyme at 37°C for 45 min had no apparent effect on PAP1 stability. However, when 
incubatcd at 40°C and 50°C for the same incubation period PAP1 activity decreased by 
17 %  and 65 % respectively.
As with all cysteine peptidases (Cummins and O ’Connor, 1998), bovine PAP1 
displayed an absolute requirement for a thiol-reducing agent for recombinant bovine 
PAP1 enzyme activity. The thiol group is a very reactive functional group. In vivo, this 
group can form complexes with various metal ions and is readily oxidised, forming 
cysteinc disulphidc bonds. I hiol-rcducing agents such as DTT are required to prevent 
oxidation from occurring. Optimum activity was obtained using 10 mM DTT (see 
Figure 3.18). The thiol-dependent nature o f  r£ /aP A P l6„ was demonstrated by complete
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PAP1 activity inhibition by 5 mM iodoacetic acid, an IC50 value o f  0.8 mM was 
obtained (see Figure 3.20).
The chelating agent EDTA, although not a requirement for PAP1 activity (see Figure 
3.19), was routinely including in the standard PAP1 activity assay (see Section 2.15.3), 
as a stabilising agent for DTT, according to the modified method described by Browne 
and O ’Cuinn (1983).
Inhibitors i.-pGlu (IC 50 = 1.6 mM, Figure 3.21) and 2-pyrrolidone (IC 50 = 0.75 mM, see 
Figure 3.22) proved to have an inhibitory effect on bovine PAP1 activity due the 
competitive binding into the catalytic site. (Tsuru e/ al.. 1978, Mudge and Fellows, 
1973).
The kinetic parameters o f  purified recombinant bovine PAP1 were determined (see 
Table 3.2). A Km value o f  59 /¿M was determined for the recombinant bovine PAP1 
using various pGlu-AMC substrate concentrations ranging between 10 and 500 ¡xM. 
This compares well with Dando et al., (2003) whom obtained a Km value o f  50 /iM for 
human PAP1. It is interesting to note that Cummins and O 'C onnor (1996) obtained a 
Km value o f  16 //M for bovine PAP1 which was purified from bovine brain tissue.
Vma* and Kca, values obtained for bovine PAP1 were 3.15 units.mg ' 1 and 3.5 s*1 
respectively.
Kinetic studies were carried out with a number o f  pyroglutamyl peptides which were 
tested with the recombinant bovine enzyme (see Table 3.3). When initial kinetic 
analysis was carried out, K, values were determined for only three pyroglutamyl 
peptides, namely pGlu-His-Pro-NH2 (TRH), pGlu-Ala and pGlu-Val. From this data, it 
was assumed that PAP1 activity possesses a higher affinity for the hydrolysis o f  
tripeptide substrates over dipeptide substrates. However, this does not appear to be the 
case with the pyroglutamyl peptides listed in Table 3.3.
Bovine PAP1 has a higher affinity for dipeptides pGlu-Ala (see Figure 3.27) and pGlu- 
Thr (see Figure 3.28) than for tripeptides pGlu-Ala-Ala (see Figure 3.31) and pGlu-Thr- 
Ala (see Figure 3.35). The addition o f  the alanine residue to each o f  the dipeptides 
appears to affect enzyme/substrate binding causing an increase in the K, values 
determined and overall decreasing the affinity o f  bovine PAP1 for these tripeptides. 
Dipeptides pGlu-Glu and pGlu-Met would have been interesting candidates for this 
work. A K, value for pCilu-Glu-Ala (see Figure 3.32) could not be determined, while a 
K, o f  366 //M was determined for pGlu-Met Ala (see Figure 3.34).
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Poor affinity o f  PAP1 has been observed for pyroglutamyl peptides which possess a 
valine residue positioned directly adjacent to the pyroglutamyl residue, while lowest 
affinity has been reported for dipeptide pGlu-Pro which is not hydrolysed by PAP1, 
with one notable exception being Klebsiella cloacae PAP1 (Fujiwara et a l , 1978)
A K, o f  625 fxM was obtained for pGlu-Val showing mixed inhibition (see Figure 3 30) 
The dipeptide pGlu-Pro produced a K, value o f  3,300 fiM and uncompetitive inhibition 
can be seen in Figure 3 29
TRH produced the lowest K, o f  44 1 /¿M (indicating the relative highest affinity) and 
behaved as a competitive inhibitor (see Figure 3 33) We can conclude from this that the 
high affinity observed is not due to the fact that TRH is a tnpeptide but most probably 
due to the identity and sequence o f  the amino acid residues in the second (P2) and third 
(P3) positions o f  the peptide
A comparison with published data from Cummins and O ’Connor (1996) o f  the kinetic 
constants (K,) which were evaluated for bovine PAP1 (purified from bovine brain 
tissue) with different substrates unveil a number o f  interesting observations 
K, values for a number o f  bioactive peptides were determined for purified bovine PAP1 
which include LHRH (pG lu-H is-Trp-Ser-Tyr-G ly-Leu-A rg-Pro-G ly-N ^), Acid TRH 
(pG Iu-H is-Pro-O H ), TRH (pG lu-H is-Pro-N H 2) and Anorexigemc Peptide (pG lu-H is- 
Gly-OH) All o f  the aforementioned peptides produced K, values ranging between 20 
and 50 /xM It is interesting to note that that all o f  the above peptides commence w ith 
pGlu-His followed by a tryptophan residue (LHRH), a proline residue (Acid TRH and 
TRH) and a glycine residue (Anorexigemc Peptide)
Bombesin (pGlu-G]n-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-M et-NH2) was 
also analysed and produced a Kj o f  64 fiM
From reported findings and the data obtained from this research, kinetic analysis would 
seem to show that bovine PAP1 has greatest affinity for a hydrophilic amino acid 
residue in the P2 position (e g pGlu-His, pGlu-Gln) with less affinity for hydrophobic 
amino acid residues in this position (e g pGlu-Ala, pGlu-Val, pGlu-M et)
Ultimately, the H 1S6 tag did not prevent the exhibition o f  characteristic mammalian 
PAP1 enzymatic activity, as shown by specific cleavage o f  pGlu from pGlu-AM C and 
sensitivity to the thiol reducing agent DTT W e cannot eliminate completely the 
possibility that the His6 tag exerts some degree o f  an effect on the catalytic properties o f  
the enzyme However, if  such an effect exists it may be quite minimal As described, the 
prim ary sequence o f  bovine PAP1 differs from that o f  human PAP1 by only three
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residues, leading one to expect no substantial differences in kinetic properties. Kinetic 
and biochemical parameters reported for recombinant human PAP1 having no Hist tag 
(Dando el ai, 2003) correlate very closely to those presented here for recombinant His6- 
tagged bovine PAP1. Furthermore, the value for Km obtained here (59 pM ) fits well into 
the range o f  Km values (15-150 jiM) and various biochemical parameters reported for 
diverse mammalian native PAP1 enzymes (Cummins and O 'C onnor, 1996).
3.9.3 C om parative  S tudy of Bovine PAP1 w ith H um an PAP1
The comparative study which was carried out as described in Section 3.8 has shown that 
there is little variation at the amino acid level between rBta-papl and rUsa-papl (see 
Figure 3.37). In fact there are only three amino acid variations at positions 81, 205 and 
208. There are 71 nucleotide variations (see Figure 3.36), however, the majority o f  these 
proved to be silent mutations when the amino acid residues were aligned. In view o f  the 
fact that there is little variation between the two amino acid alignments and that the 
bovine PAP1 sequence possessed 98% identity w ith the human PAP1 sequence, one 
would have expected to find properties o f  both to be similar given that both were 
expressed, purified and assayed under the same conditions. However, this was not the 
case with results which were obtained for PAP1 activity and protein concentration (see 
Table 3.4).
Total activity and total protein for rHsaPAP 1 tH arc almost three times greater than 
rBta?A?\w total activity and total protein. Overall, specific activity for r/tazPA Pl6H and 
r//$aP A P l6H were 3,633.8 units.mg ' 1 and 4,623.1 units.mg ', respectively.
SDS-PAGE produced a band o f  ~23-24kDa for both bovine and human PAP1 (see 
Figure 3.38).
As a result o f  reduced bovine PAP1 protein yields w hen compared to human PAP1 
yields, both rare codon usage and different amino acid residues were investigated. 
Reduced protein yields could also be due to  the differing nucleotide bases upstream 
from the ATG start codon which may be affecting protein translation efficiency (see 
Figure 3.36). Analysis revealed that rare codon usage does not contribute to the reduced 
yield o f  protein seen in bovine PAP1 (see Figure 3.39). If  findings highlighted that 
bovine PAP1 possessed a greater number o f  rare codons than human PAP1, one could 
assume that the rare codon usage could be a contributing factor to reduced expression 
levels o f  bovine PAP1 as described in Section 3.8.2.1.
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Utilising site-directed mutagenesis (see Section 2 9 2) amino acids Ala81, Cys205 and 
Glu208 were substituted with Thr, Tyr and Lys respectively (see Figure 3 40) After 
examining the position o f  these residues in the bovine PAP1 amino acid sequence it is 
clear that both Cys205 and Glu208 are positioned at the C-terminal end, while Ala81 is 
closely located to active site residue Glu85 (see Figure 3 37) From this, one could 
speculate that the residue change at position 81 could be responsible for the reduced 
r# taP A P l yields Alanine could be causing a change in the structure o f  the hydrophobic 
pocket to occur, thus decreasing the amount o f  substrate being hydrolysed and as a 
result reducing rifraPA Pl total activity and protein
The pZK3 derivates (see Table 3 5) were expressed in E coh XL10-Gold (see Section 
2 12) and subsequently purified (see Figure 3 41, Section 2 13)
It is evident that the potential susceptibility o f  the cysteine residue at position 205 is 
having an adverse affect on bovine PAP1 protein yields and activity (see Figure 3 41, 
Table 3 5) Substitution with a tyrosine residue has resulted in a dramatic increase in 
total protein and activity Optimal temperature has increased from 37°C to 50°C 
Presence o f  a cysteine residue at position 208 may have resulted in the bovine PAP1 
structure to change conformation This in turn may have resulted in bovine PAP1 
becoming prone to proteolytic degradation and protein instability Disulphide bonds 
between cysteine residues may also have been introduced, supporting the above theory 
o f  a change occurring in the bovine PAP1 structure These findings suggest that the C- 
terminal region o f  PAP 1 plays a role in PAP1 protein expression and PAP1 enzymatic 
activity
The orientation o f  the catalytic triad (Glu-Cys-His) o f  bovine PAP1 is identical to 
human PAP1 Amino acid residues Glu85, C ysl49  and His 168 are fully conserved in 
both sequences (see Figure 3 37) M utation o f  the residues Glu85, C ysl49  and H is l68 
individually (see Section 3 8 3) in r£ taP A P l6H resulted in complete loss o f  catalytic 
activity, strongly implicating them m the catalytic triad o f  r5 taP A P l6H
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CH APTER FO UR
Biochemical, Kmetic and Functional Analysis of Recom binant H um an PA PlU sing 
Site-Directed and Random  Mutagenesis
4 1 Overview
This chapter describes further characterisation o f  human PAP1 To date, there has been 
no publication o f  the three-dimensional (3D) structure for human or other eukaryotic 
PAP1 enzymes However, the 3D structures o f  four prokaryotic PAP1 enzymes have 
recently been solved using X-ray crystallography These PAP1 structures, namely for B 
amylohquefaciens (ZtawPAPl) (Odagaki et a l , 1999), T htorahs (77/PAP1) (Singleton 
et a l , 1999a, 1999b), P furiosus (i^wPAPl) (Tanaka et a l , 2001) and P honkoshu 
(Pho?AV\) (Sokabe et a l , 2002) Hsa?A?\ has considerable homology to prokaryotic 
PAP1 enzymes, displaying greatest homology w ith Bam?A?\ Based on this homology 
a 3D structure model o f  Hsa?API (see Figure 4 1 ) was created by SW ISS-M ODEL (see 
Section 2 11), using the prokaryotic structures as templates
This series o f  mutants are biochemically charactensed in this work The active site 
residue glutamic acid at position 85 o f  human PAP1 is investigated A second series o f  
mutants are generated using random  mutagenesis which are also characterised both 
biochemically and kinetically Kinetic analysis was also carried out on human PAP1 
using a number o f  pyroglutamyl peptides
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/fai PA PI
Bam PAPI Pfu PAPI 77/PA PI
Figure 4.1 / / aw PA PI 3D m odel com pared  w ith s tru c tu ra l tem plates (V aas, 2005)
Ribbon diagram o f the 3D //saPAPl model, which was predicted using the SWISS-MODEL server (see 
Section 2.11), taking the structures o f  Bam?AP\, PfuPAP\ and 77/PAP 1 as templates, a  -helices arc 
coloured red and /3-strands are coloured blue. 3 N-terminal and 24 C-terminal Hsa?AP\ residues were 
excluded from the model. The residues o f  ÆamPAPl, /yùPAPl and 77/PAP 1 correlating to the excluded 
C-terminal residues form o-helices. indicated by arrows. Generated using DeepView (sec Section 2.11).
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4 .2  H u m a n  P A F 1 K in c tic  A n a ly s is
Kinetic analysis was performed (see Section 2.18.6.2) using a number o f  pyroglutamyl 
peptides (see Table 2.7). The significance o f  these results is discussed in Section 4.6.
I IjrfJu AMI'I
Figure 4.2 Kinctic Analysis of the Effect of pGlu-Ala ( • )  on Human PAPI 
Catalysed Hydrolysis of pGlu-AM C (■ ) . Lincwcaver-Burk reciprocal plot o f  fluorescent 
intensity versus [pGIu-AMCj. Plot illustrates competitive inhibition o f  PAPI by pGlu-Ala. Error bars 
represent the SD o f triplicate readings.
I iprju-AMn
Figure 4.3 Kinctic Analysis of the fcffcct o f pG lu-T hr ( • )  on Human PAPI 
Catalysed Hydrolysis of pGlu-AM C (■ ). Li ne weaver-Burk reciprocal plot o f  fluorescent 
intensity versus [pGlu-AMCJ. Plot illustrates competitive inhibition o f  PAPI by pGlu-Thr. Ettot bars 
represent the SD o f  triplicate readings.
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l/tl«» AlHT]
Figure 4 4 Kinetic Analysis of the Effect of pG lu-Pro (• )  on H um an PAP1 
Catalysed Hydrolysis of pGlu-AM C (■ ) Lmeweaver-Burk reciprocal plot o f fluorescent 
intensity versus [pGlu-AMC] Plot illustrates uncompetitive inhibition o f PAP 1 by pGlu-Pro Error bars 
represent the SD o f triplicate readings
l/ll«CJu AMC]
Figure 4 5 Kinetic Analysis of the Effect of pGlu-Ala-Ala ( • )  on H um an PA PI
Catalysed Hydrolysis of pGlu-AM C (■ ) Lineweaver-Burk reciprocal plot o f fluorescent 
intensity versus [pGlu-AMC] Plot illustrates competitive inhibition of PAPI by pGlu-Ala-Ala Error bars 
represent the SD o f triplicate readings
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MpQu-AMq
Figure 4 6 Kinetic Analysis of the Effect of pGlu-Glu-Ala (• )  on H um an PAP1 
Catalysed Hydrolysis of pGlu-AM C (■ ) Lineweaver-Burk reciprocal plot o f fluorescent 
intensity versus [pGlu-AMC] Plot illustrates mixed inhibition o f PAP 1 by pGlu-Glu-Ala Error bars 
represent the SD o f triplicate readings
Mpcau Ai\iq
Figure 4 7 Kinetic Analysis of the Effect of pGlu-His-Pro-NH2 ( • )  on H um an PAPI 
Catalysed Hydrolysis of pGlu-AM C (■ ) Lineweaver-Burk reciprocal plot o f fluorescent 
intensity versus [pGlu-AMC] Plot illustrates competitive inhibition o f PAPI by pGlu~His-Pro-NH2 Error 
bars represent the SD of triplicate readings
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l / [pQu \MC|
Figure 4 8 Kinetic Analysis of the Effect of pGlu-M et-Ala (•)  on H um an PAPI 
Catalysed Hydrolysis of pGlu-AM C (■ ) Lineweaver-Burk reciprocal plot o f fluorescent 
intensity versus [pGlu-AMC] Plot illustrates competitive inhibition o f PAPI by pGlu-Met-Ala Error 
bars represent the SD o f triplicate readings
l / [pai l  AAR]
Figure 4 9 Kinetic Analysis of the Effect of pG lu-Thr-A la ( • )  on H um an PA PI 
Catalysed Hydrolysis of pGlu-AM C (■ ) Lineweaver-Burk reciprocal plot o f fluorescent 
intensity versus [pGlu-AMC] Plot illustrates competitive inhibition o f PAPI by pGlu-Thr-Ala Error bars 
represent the SD of triplicate readings
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Table 4 1 K, Values Obtained for Pyroglutamyl Peptides
Peptide Km (app)
(MM)
K,
d m
Inhibition Type
pGlu-Ala 111 204 Competitive
pGlu-Thr 66 781 Competitive
pGlu-Pro 50 n d Uncompetitive
pGlu-Ala-Ala 166 107 Competitive
pGlu-Glu-Ala 200 83 Mixed
pGlu-His-Pro-NH2 (TRH) 333 44 Competitive
pGlu-Met-Ala 111 204 Competitive
pGlu-Thr-Ala 125 166 Competitive
Activity o f  human PAP1 towards pyroglutamyl peptides Enzyme assays were carried out as described in 
Materials and methods [Kmapp values obtamed from Figure 4 2  -  4 9  calculated as outlined in 
Appendix C]
4 3 H um an PAP1 Site-Directed M utagenesis
A series o f  site-directed mutants were generated by a previous member o f  this research 
group to carry out a functional analysis study on human PA P1 (Vaas, 2005) The nine 
active mutants are listed in Table 4 2 and are also highlighted on Hsa?API 3D model 
(see Figure 4 10) Majority o f  mutations were made to the substrate binding pocket o f  
human PAP1, with mutations also been made to the extended outer loop and the C- 
termmal end The mutations were based on a study which was previously carried out on 
BamPAPl (Ito et a l, 2001) This study highlighted that PhelO, Phel3  and Phel42  play 
an essential role in the substrate binding pocket o f  BamPAPl These residues 
correspond to Phel3 , P h e l6 and T yrl47  in HsaPAPl Asp97 and Asn98 which are 
located on the outer edge o f  the binding pocket were also mutated On an extended loop 
o f //s a P A P l the m otif Seri 15-Ilel 16-Aspl 17 was changed to Ala-Tyr-Phe, the latter 
three amino acids being commonly found in prokaryotic PAP1 enzymes The 3D model 
structure for HsaPAPl which is based on three o f the prokaryotic sequences failed to 
include the C-terminal 24 amino acid residues from the model As a result, a deletion 
mutation was produced, where the 9 terminal amino acids were deleted from the 
HsaPAPl sequence
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1 m ill. **.£ m u m m  u c i 1» au> cs  
Mutation
V1 i i i . w i  n r  I6M 
Plasmid Enzyme
F13 to Y pRV5_F13My r//.vaPAPl_Fl3mY6„
F 16 to Y pRV5_F16mY rtfsaPAP 1_F 16m YW|
Y 147 to F pRV5_Y147mF rHsaPAP 1 _ Y I47mF6H
N98 to 0 pRV5_N98mQ r//.vaPAPl_N98mQ6H
N98 to V pRV5_N98mV rHsaPAP 1 _N98m V6H
SI 15 to A. 1116 to Y. D 117 to F pRV5_SlDl 15mAYF r//wPAP 1 SID 115mA YFmj
0 18 0  toE pRV5_Q180mE rHsaPAP 1 Q 180m
0 1 8 0  to E, N177 to Y pRV5_Q 180mE.N 177m Y rHsaPAP 1 _Q 180m E.N 177m Y6„
C-tcrminal deletion: G201 to H209 pRV5 A3’ r//saPAPI_AC*M
[For amino acid information see Appendix D.J
A m i 77
S c r 115
Figure 4.10 H saP\?\ 3D M odel Show ing Residues T arg e ted  F o r M utagenesis 
(V aas, 2005)
Ribbon diagram of die ffsuP AP1 model. Residues targeted for si to-specific mutagenesis are visualised 
in red. Residues affected by unintentional mutagenesis are marked in green. For amino acid information 
see Appendix D. Generated using DecpView (see Section 2.11).
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4.3.1 Biochcmical Analysis of Human PAP1 M utations
4.3.1.1 Effect of Tem perature
The effect o f  temperature on human PAP1 and the mutants listed in Table 4.1 was 
investigated as outlined in Section 2.18.3. Figures 4.11 - 4.13 illustrate the effect o f  
temperature on each o f  the mutants compared to the human PAP1 wild-type fo rm  The 
significance o f  these results is discussed in Section 4.6.
4 24 30 3*’ 40 50 «50
Tttnpri atia e "c
F ig u r e  4 .11  P lo ts  o f  M u ta n t R e la t iv e  E nzy m e  A c t iv it ie s  V e r su s  T e m p e r a tu r e
Figure 4.11 shows the eiTcct o f  temperature on mutants r//.wPAPl A3'6H. r//.vaPAPl_F13mY6ii and 
r//.v«PAP I F 16m Ym,. Black bars represent r/Z.vaPAPl«, activity. Enzyme activities arc expressed as a 
percentage o f the fluorescence observed at 37°C. Error bars represent the SD o f  triplicate readings.
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apR V5_5l80m E
OpRV5_QliOmE.N|77(nY
Tein|jei a(iu e C
F igure  4.12 Plots of M u tan t Relative Enzym e A ctivities V ersus T em p era tu re
Figure 4.12 shows the effect o f  temperature on mutants r/fcaPAPl N98mV6„, r//MPAPl_Q180mE<,„ 
and rHsaPAPI_Q 180mI:.N 17 7m Y w  Black bars represent rHsaPAP\w activity. Enzyme activities arc 
expressed as a percentage o f  the fluorescence observed at 37°C. Fjror bars represent the SD o f  triplicate 
readings.
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QpRV5_N98mQ
*  100
<
*>
r
Figure 4.13 Plots o f M utan t Relative Enzym e A ctivities V ersus T em p era tu re
Figure 4.13 shows the effect o f  temperature on mutants rtfwPAPl SIDI ISAYF«,, 
r//saPAP1 _Y 147m F<,h and r//s«PAPl_N98mQ6„ Black bars represent r//saPAPlN, activity. Enzyme 
activities are expressed as a percentage o f  the fluorescence observed at 37°C. Error bars represent the SD 
o f  triplicate readings.
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4.3.1.2 Therm al Stability a t 37°C
Thermal stability studies were carried as described in Section 2.17.3 and the 
significance o f  these results is discussed in Section 4.6.
T im e  ( m i i i s )
Figure 4.14 Relative Human PAPI Enzymatic Activity Versus Time
Figure 4.14 .shows the effect o f  temperature on wild type r/fcaPAPl«*, r//.v«PAPl_F13mY6H and 
r//saPAPl _A3'6H activity. Enzyme activities are expressed as a percentage o f the fluorescence observed 
at 0 minutes. Error bars represent the SD o f  triplicate readings.
T im e  ( in iu s )
Figure 4.15 Relative Human PAPI Enzymatic Activity’ Versus Time
ligure 4.15 shows the cfTect o f  temperature on wild type r//MfPAPlftH, r//saPAPl_F16mY6H and 
r//vaPAPl_N98mQ<,H activity. Enzyme activities are expressed as a percentage o f the fluorescence 
observed at 0 minutes. Error bars represent the SD o f triplicate readings.
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T i m e  ( in iu v )
Figure 4.16 Relative H um an PA PI Enzym atic A ctivity V ersus T im e
Figure 4.16 shows the effect o f  temperature on wild type r//saPAPlW), r//suPAPl_N98mV6H and 
r//j<iPAPl QlSOmE«! activity. Enzyme activities are expressed as a percentage o f the fluorescence 
observed at 0 minutes. Error bars represent the SD o f triplicate readings.
T im e  ( m it is )
Figure 4.17 Relative H um an PAP1 Enzym atic Activity V ersus Tim e
Figure 4.17 shows the effect o f  temperature on wild type r/*wPAPl(,H. r//$aPAP 1 _Q 180mE,N 177m Y^h 
and r//5aPAPl S1D115AYF6H activity. Enzyme activities are expressed as a pcrccntagc o f  the 
fluorescence observed at 0 minutes. Error bars represent the SD o f triplicate readings.
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Time (miiis)
Figure 4.18 Relative Human PAPI Enzy matic Activity Versus Time
Figure 4.18 shows the effect of temperature on wild type r/ftaPAPl^and r//.vaPAPl_Y147mF6H activity. 
Lnzymc activities are expressed as a percentage of the fluorescence observed at 0 minutes. Frror bars 
represent the SD of triplicate readings.
4.3.1.3 Inhibitors
4.3.1.3.1 Determination of 1C , 0  V alues
The cffect o f  thiol-directed inhibitors iodoacetamide and substrate analogue 2- 
pyrrolidone on wild-type and its mutant forms listed in Tabic 4.2 were investigated as 
outlined in Section 2.18.5. Figures 4.19 -  4.28 illustrate the effect o f  these inhibitors on 
each o f  the mutant activities. The significance o f  these results is discussed in Section 
4.6.
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[ f u h i b i K N  I ( t n . M )
[In h ib ito r] (inINI)
Figures 4.19 and 4.20 Inhibitor Profile Effects of lodoacetam ide and 2-Pyrrolidone 
on r/ZsaPAPUn and rf/saPAPl_A3*6it*
Plots o f  relative enzyme activity versus iodoacctamide and 2-pyrrolidone concentrations. Figure 4.19 
shows the effect o f  these inhibitors on wild type r//5aPAPl6M activity, whereas Figure 4.20 illustrates the 
effect o f  inhibitors on r//saPAPl_A3'Mi activity. Enzyme activities are expressed as a percentage of 
uninhibited enzyme. Error bars represent the SD o f  triplicate readings.
136
[Inhibitor] (rnM)
[Inhibitor] (nM )
Figures 4.21 and 4.22 Inhibitor Profile Effects of lodoacetam ide and 2-Pyrrolidone 
on r//.vflPAPl F13mY6n a n d  r/fvaPA Pl FlómYéH
Plots o f  relative enzyme activity versus lodoacotamidc and 2-pyrrolidonc concentrations. Figure 4 .2J 
shows the cffcct o f  these inhibitors on r//v«PAPl_F13mY6ii activity, whereas Figure 4.22 illustrates the 
effect o f  inhibitors on r//sflPAPl_F16mYwt activity. Enzyme activities arc expressed as a percentage o f  
uninhibited enzyme. Error hars represent the SD o f  triplicate readings.
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(In h ib ito r ] (m M )
(In h ib ito r] (m M )
Figures 4.23 and 4.24 Inhibitor Profile Effects of Iodoacetam ide and 2-Pyrrolidone 
r//.vtfPAPl_N98mQ6|, .and r//.vaPAPl N98mV6H. Plots o f  relative enzyme activity versus 
iodoacetamide and 2-pyrrolidone concentrations. Figure 4.23 shows the effect o f  these inhibitors on 
r/fcaPAPI_N9ftmQM| activity, whereas Figure 4.24 illustrate» the cfTcct o f  inhibitors on 
r//saPAPl_N98mV6H activity. Enzyme activities are expressed as a percentage o f  uninhibited enzyme. 
Error bars represent the SD o f triplicate readings.
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[In h ib ito r ]  (in.M)
[In h ib ito r ] (inM )
Figures 4.25 and  4.26 Inh ib ito r Profile Effects o f Iodoacetam ide and  2-Pyrro lidone 
on r // \a P A P l Q 180m E6n .and  r//.vaPA Pl Q180m E,N177m Y 6n.
Plots o f  relative enzyme activity versus iodoacetamide and 2-pyrrolidinone concentrations. Figure 4.25 
shows the effect o f  these inhibitors on r//vaPAP 1_Q 180mE«i activity, whereas Figure 4.26 illustrates the 
effect o f  inhibitors on rHv/jPAPiyiSOmL.NiyVmYoH activity. Enzyme activities are expressed as a 
percentage o f uninhibited enzyme. Error bars represent the SD o f triplicate readings.
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f ln l iib ito r l  (m M )
Figures 4.27 and 4.28 Inhibitor Profile Effects of lodoacctam ide and 2-Pyrrolidone 
on r//.vaPAPl SID1 15AYF6h and r//« iPA Pl_Y 147m F6„ .
Plots o f  relative enzyme activity versus iodoacetamide and 2-pyrrolidone concentrations. Figure 4.27 
shows the effect o f  these inhibitors on r//saPAPl_SIDl 15AYF6h activity, whereas Figure 4.28 illustrates 
the effect o f inhibitors on r//.w/PAPl_Y147mF6H activity. Enzyme activities are expressed as a percentage 
o f  uninhibited enzyme. Error bars represent the SD o f  triplicate readings.
Table 4.3 Biochemical Properties of rffcaPA PU u Site-Directed M utants
Mutant Temp
°C
PH Iod
IC}Q
2-Pyr
IC ,.
r/ZsaPAPUn (wild type) 50 8.5 1.1 1.2
r/ZwiPAP 1 _A3’én 50 8.0 2.0 1.0
r/Isa? AP1 F 13m Ymi 37 9.0 1.0 2.8
r//saPAPl_F16mY6H 50 8.5 1.4 4.1
r//saPAPl_N98m06ii 50 8.5 1.3 1.5
r//.vaPAPl_N98mV6H 50 8.5 3.4 1.3
rHsaPAP\_Q 180m Efc» 37 8.5 0.8 1.5
r/isaPAP 1 _Q « 80m E,N 177m Y6„ 50 9.5 1.8 1.6
rHsaPAP 1 SID 115m A YF6„ 50 9.0 2.0 1.4
r//.wPAPI_Y147mF6H 37 8.5 1.2 1.5
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4 4 Investigation of H um an PAP1 Active-Site Residue Glutam ic Acid
Site directed mutagenesis followed by functional characterisation is a widely used 
approach to obtain information on the structure-function relationship o f  proteins Active 
site residues C ysl49 and His 168 were investigated by Vaas, 2005, utilising a site- 
directed mutagenesis approach C ysl49 and H is l68 were substituted with tryptophan 
and aspartic acid, respectively Both mutations caused a complete loss o f  PAP 1 activity, 
supporting the catalytic significance o f these residues in human PAP1 
It is unknown whether or not the third active site residue Glu85 is required for human 
PAP1 activity or whether, like prokaryotic PAP1, its purpose is to help onentate the 
lmidazohum ring o f  the histidine residue (Doran and Carey, 1996)
In this work, this residue was substituted individually with three differing amino acid 
residues The choice o f  amino acid replacements was based on altering amino acid 
properties Glu85 was substituted with aspartic acid, lysine and glutamine (see Figure 
4 29) Codon changes were introduced on the expression plasmid pRV5 (see Figure 2 4) 
by the method described in Section 2 9 2 , using primers listed in Table 2 2 
Incorporation o f  diagnostic restriction sites into primers were considered for this work 
but similar work previously carried out m our laboratory reported that the use o f  silent 
codon mutations resulted in a significant drop in recombinant protein production (Vaas, 
2005) As a result o f  this, diagnostic restriction sites were not utilised
Figure 4 29 Substitution of r/fcaP A P l6H Active Site Residue Glu85 W ith
Glutamine, Lysine and A spartic Acid Amino acid side-chatns o f Glutamic Acid 85 which 
were substituted with Glutamine, Lysine and Aspartic Acid respectively For ammo acid information see 
Appendix D Illustrated ing ChemSketch (see Section 2 11)
NH
Gliifmii*. Ami
(\cidic <$.
Ih  dioplulic)
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141
4 4 1 Analysis of Recom binant H um an PAP1 Active Site M utants
The mutant plasmid derivatives o f  pRV5 (see Table 4 4) were transformed into E coh 
XL 10-Gold as described in Section 2 6 3 Expression cultures (100 ml) were prepared 
as outlined in Section 2 12 1 All mutants were purified using the IMAC procedure as 
described in Section 2 13 1 and were subsequently assayed for PAP1 activity (see 
Section 2 15 3 and 2 15 4) Increased activity was detected for r/fo¿zPAPl_E85mD6H 
while no activity was detected rHsa? A? 1 _E85mK6H and rHsa?AP I E85mQéh (see 
Figure 4 30, Table 4 5) SDS-PAGE analysis (see Section 2 16) shows that the purified 
mutants were expressed at levels comparable to rHsaPAPlm (see Figure 4 31) Purified 
samples were also analysed using Native-PAGE (see Section 2 17 1 ) Kinetic 
parameters were determined for rHsa?AP\_ES5mDeu (see Section 2 18 6 , Table 4 7)
Table 4 4 pRV5 Active Site M utant Derivatives
Mutation Plasmid Enzyme
Wild Type pRV5 rHsa? API 6H
E85 to D pZK_E85mD rIls a? A? l_E85mD6H
E85 to K pZK_E85mK ri*aPAPl_E85mK6H
E85 to Q PZK_E85mQ rHsa? AP l_E85tnQ6H
-ve
Figure 4 30 A gar Plate Activity Assay for PAP1 Activity
Agar plate assay (see Section 2 15 4) highlighted active mutant r/frtfPAPl_E85mD6H (1A & 1C) and 
inactive mutants r/feaPAPl_E85mK<sH (2A & 2C) and r/feaPAPl_E85mQ6H (3 A & 3C) Negative control 
is positioned in lane B
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Table 4 5 Human PAP1 Active Site Mutant riisaPAPl_E85mD6H
Total Activity Total Protein Specific Activity
(Units) (mg) (Units mg')
r//saPAPl6H 2,656 98 0 55 4770 06
r/*aPAPl_E85mD6H 1,872 14 0 37 4,968 55
LDa
20^
66
36
29
24
20
14
Figure 4 31 SDS-PAGE of Hum an PAP1 Active Site M utants
Lane 1 & 6, protein molecular marker, lane 2, purified r//saPAPl6H, lane 3, purified 
rHsaPAPl_E85mD6H, lane 4, r//5aPAPl_E85mK6H, lane 5, r/*aPAPl_E85mQ6H The relevant sizes 
(kDa) of the protem marker are mdicated
Figure 4 32 Native-PAGE of Hum an PAP1 Active Site M utants.
Lane 1, purified r/fraPAPl6H, lane 2, purified r//saPAPl_E85mD6H, lane 3, r//sflPAPl_E85mK6H and 
lane 4, r//stfPAPl_E85mQ6H
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Table 4 6 r//saPAPl E85mD6H Biochemical and Kinetic Parameters
Biochemical Parameters Kinetic Parameters
Enzyme Temp pH Km K<;at
°C y M s 1
rHsa?AP\ m 50 8 5 53 3 75
r//saPA Pl_E85m D 6H 50 9 5 109 1 7
4 5 Random Mutagenesis of Human PAP1
Random mutagenesis is another powerful tool for studying structure-fiinction 
relationships and for modifying proteins to improve or alter their biochemical and 
kinetic properties The most commonly used random mutagenesis technique is error 
prone PCR (Leung, 1989) Error prone PCR generates random mutants of the target 
gene which are introduced under PCR conditions that reduce the fidelity o f nucleotide 
incorporation (Yuan-zhi, 2006) Fidelity of DNA is reduced by use of error prone DNA 
polymerases and/or modifying PCR reaction conditions The mutated PCR products are 
then cloned into an expression vector, pPC225 (see Figure 2 3) and the resultant mutant 
libraries are screened for changes in enzyme activity Random mutagenesis enables 
researchers to identify interesting mutations in the absence of structural information and 
often yields unique mutations which could not have been predicted (Fujn, 2004)
4 5 1 PCR and Screening For Potential ZfsaPAPl Random Mutants
PCR reactions were set up as described in Section 2 9 3 using pRV5 (see Figure 2 4) 
plasmid DNA and primers PAPHsA and PAPHsB (see Table 2 2) The strategy in 
Figure 4 33 was utilised for random mutagenesis Vector pPC225 (see Figure 2 3) was 
used for this procedure Quantities of MnCk included in the PCR reaction were varied 
from 0 05 to 2 0 mM PCR products were obtained when 0 05, 0 1 and 0 2 mM MnCl2 
were used (see Figure 4 34) However, when 2 mM MnCl2 was utilised in the PCR 
reaction, a PCR product was not obtained An EcoRI/Hindlll restriction enabled the 
PCR product to be ligated with pPC225, which had been opened with EcoRl/Hindlll 
These ligations were subsequently transformed into Ecoh  XL10-Gold (see Section 
2 6  3) Screening for potential random mutants was done by EcoRl/Hindlll restriction 
analysis (see Figure 4 35) and comparing wild-type PAP1 enzymatic activity to mutant 
activities This proved to be unsuccessful and a new approach was adopted It appeared
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that the vector pPC225 was re-circularising and as a result failed to ligate with the 
restricted PCR products.
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Figure 4.33 Strategy Used for r/Z.vaPAPl Random ¿Mutagenesis
PCR (see Section 2.9.3) on pRV5 using MnClj and primers PAPHsA, PAPHsB (see Tabic 2.2) followed 
by phenol extraction and ¿coRI/Z/mc/III restriction generates product which is ligated into pPC225 
(opened with EcaRUHindiW. Ligation is transformed (see Section 2.6.3) into E.coii XLIO-Gold and 
screened for random mutants. Illustrated using pDRAW32 (see Section 2.11).
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Figure 4 34 Random Mutagenesis PCR Products
1% agarose gel Lane 1, DNA Ladder (sizes as in Figure 2 6), Lane 2, PCR negative control, Lane 3, PCR 
product using 0 05 mM M nCb, Lane 4, PCR product using 0 1 mM MnCl2, Lane 5, PCR product using 
0 2 mM MnCh
1 2  * -1 '  6 9 10 i i  12 H
1000tp
500 bp
N o  P A P I  
Inserts
Figure 4 35 Restriction Analysis of Potential Random Mutants
EcoFI/Hindlll restriction digest o f potential random mutant clones analysed on 1% agarose gel (Section 
2 5) Lane 1, DNA Ladder (sizes as in Figure 2 6), Lane 2 - 1 3 ,  EcoKUHindlW restriction analysis on all 
potential clones
Alkaline phosphatase treatment (see Section 2 8 3) was used as an intermediate step in 
this procedure Alkaline phosphatase catalyses the removal of 5' phosphate groups from 
DNA The CIP-treated fragments lack the 5’ phosphoryl termini which are required by 
the ligases As a result, this treatment prevents self-ligation o f the vector and thereby 
greatly facilitates ligation o f other DNA fragments into the vector The modified 
strategy for random mutagenesis is shown in Figure 4 36
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F ig u re  4.36 M odified  S tra teg y  fo r  r//.vaPA P1 R an d o m  M utagenesis
PCR (see Section 2.9.3) on pRV5 using MnClj and primers PAPHsA, PAPHsB (see Table 2.2) followed 
by phenol extraction and £c0RI//ft/i</Ul restriction generates product which is ligated into pPC225 
(opened with EcoRI/Htndlll, and CIP Created). Ligation is transformed (see Scction 2.6.3) into E co li 
XI. 10-Gold and screened for random mutants. Illustrated using pDRAW32 (see Section 2.11).
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Figure 4 37 Restriction Analysis of Potential Random Mutants Using Modified 
Strategy EcoKL/HindUl restriction digest of potential random mutant clones analysed on 1% agarose 
gel (see Section 2 5) Lane 1, DNA Ladder (sizes as in Figure 2 6), Lane 2, Clone 1 uncut, Lane 3, Clone 
1 EcoW H indU l cut, Lane 4, Clone 2 uncut, Lane 5, Clone 2 EcoKUHindlR cut, Lane 6, Clone 3 uncut, 
Lane 7, Clone 3 EcoRI/Hindlll I cut, Lane 8, Clone 4 uncut, Lane 9, Clone 4 EcoRI/H w dill cut, Lane 10, 
Clone 5 uncut, Lane 11, Clone 5 EcoBl/HindUl cut, Lane 12, Clone 6 uncut, Lane 13, Clone 6 
Eco?MHind\\\ cut, Lane 14, Clone 7 uncut, Lane 15, Clone 7 EcoBJiHindlll cut
A series o f potential //saPAPl random mutants were generated using this modified 
strategy EcoRl/HindlU  restriction analysis show presence o f the PAPI 680 bp fragment 
(see Figure 4 37) and varied PAPI activity levels were also detected (see Section 
2 15 3) The successful products of vHsa?API random mutants were confirmed by 
DNA sequencing (see Section 2 10) The sequencing data is given in Appendix B 
rH sa?A ?\ random mutants which were obtained from this work are listed in Table 4 8 
and are also highlighted on /fraPAPl 3D model (see Figure 4 38)
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Table 4.7 Random Mutagenesis Plasmids and Enzymes
M utation Plasmid Enzyme
G35 to T pZK_G35mD rHsaPAP 1 _G3 5m D6H
N90 to D pZK_N90mD rHsaPAP 1 _N90m D6„
M192 to T PZK_M192mT r//5flPAPl_M192mTfcH
K94 to R PZK_K94mR r//5flPAPl_K94mR<,„
A 165 to V PZK_A165mV rHsaPAP 1 A 165m V6H
P48 to R pZK_P48mR r//5aPAPl_P48mR6„
A 184 to P pZK_A 184mP r//.voPAPl_A184mP6„
P48 to 0 .  DI43 to H pZK_P48mQ,D143mH r//.vflPAP 1 _P48mQ.D143mH6„
P67 to R pZK_P67mR r//.vtfPAP 1_M 122mVW|
M 122 to V PZK_M122mV r//.vaPAPl_M122mV6H
G77 to D pZK_G77mD rHsaPAP 1 _G77mD<,(J
Figure 4.38 HsaPAPX Model Highlighting Targeted Residues During Random 
Mutagenesis Generated using Deep View (see Section 2.11).
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4.5.2 Analysis of Recombinant Human PAP1 Random Mutants
Expression cultures (100 ml) were prepared as outlined in Section 2.12. All random 
mutants were purified using nickel-affinity chromatography (see Section 2.13.1). 
Mutants were assayed for PAP1 activity (see Section 2.15.3) and protein concentration 
(see Section 2.14.1). Figure 4.39 displays SDS-PAGE analysis (see Section 2.16) of 
purified random mutants.
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Figure 4.39 Purification of r//.vflPAPl6n Random Mutants
Lane 1, protein molecular marker; Lane 2, r//5flPAPl61l; Lane 3. r//.vflPAPl_A165mV6H; Lane 4. 
r//.vaPAPl_G35mD6n, Lane 5. r//.v«PAPl_G77mD6n. Lane 6, r//saPAPl_K94mR6H, Lane 7, 
r//v«PAPl_P67mR6n; Lane 8. rHsaVAP 1 _M  122mV6H; Lane 9, r/Zw/PAPl_M192mT6it. Lane 10. 
r//.v«PAPl_P48mR6||, l.ane 11. r//jflPAPl_P48mR,D143mH6H,Lane 12. r//saPA Pl N90mD(lH; Lane 13, 
rW!saPAPl_AI84mT6n.The relevant sizes (kDa ) o f  the protein marker are indicated.
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Table 4.8 Biochemical and Kinetic Parameters of r//saPAPl6H Random Mutants
Enzyme pH Temperature Specific Activity Km Kcat
(°C) (units mg*) 0*M) (s ')
rHsaPAPlsH 85 50 r 8770 3 53 2 07
r/ZsaPAPl _G35mD6H 90 50 4257 7 67 031
r/foaPAPl _N90mD6H 85 50 3063 2 76 0 44
rHsaPAP 1_M 192mT6H 85 50 1049 5 65 1 76
r//saPAPl_K94mR6H 85 50 3492 3 85 0 78
rHsaPAP 1 A165m V6H 80 60 2286 6 79 3 1
rHsaPAP l_P48mR6H 85 50 1334 4 71 1 5
i7/saPAPl_A184mP6H 90 50 3723 8 78 1 65
r//saPAPl_P48mQ,D143mH6H 85 50 978 3 56 0 88
rHsaPAP l_P67mR<)n 85 50 6615 37 52 0 77
r/fcflPAPl_M122mV6H 90 50 9167 7 83 2 26
r/*aPAPl_G77mD6H 85 50 2617 7 64 1 55
r/feaPAPl_N22mH(,H 85 50 1676 1 79 0 72
10000 T
M iration
Figure 4 40 Effect of Mutations on Specific Activity
Values for specific activity (units mg ]) taken from Table 4 8
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M ntation
Figure 4 41 Effect of Mutations on Km
Values for Km (/¿M) taken from Table 4 8
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Figure 4 42 Effect of Mutations on Kcat
Values for K^at (s ') taken from Table 4 8
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4.6 Discussion
4.6.1 Human PAP1 Kinetics Using Pyroglutamyl Peptides
Kinctic analysis o f a series o f pyroglutamyl peptides has indicated that purified human 
PAP1 has a greater affinity for tripeptides over dipeptides (see Table 4.1). It is 
interesting to note that the same scries o f  pyroglutamyl peptides were utilised to analyse 
purified bovine PAP1 and different effects have been observed for both enzymes.
A K, value o f 44 pM (see Figure 4.7) was determined for TRH showing the relative 
highest affinity for human PAP1. Kj values o f 204 and 781 were determined for 
dipeptides pGlu-Ala and pGlu-Thr, respectively (see Table 4.1). Addition o f an alanine 
residue to each o f the aforementioned peptides resulted in a dramatic decrease o f K* 
values, indicating an increase o f affinity for human PAP1. Tripeptides pGlu-Ala-Ala 
and pGlu-Thr-Ala yielded K, values o f 107 and 166 nM, respectively. Competitive 
inhibition was found for all four peptides (see Figures 4.2 -  4.9). The total opposite 
effect was found for bovine PAP1 (see Chapter 3.0). Uncompetitive inhibition was 
found for pGlu-Pro (see Figure 4.4), however a K, value could not be determined. 
Greatest affinity was shown for tripeptides pGlu-His-Pro-NH: (TRH) (44 ¿zM) and 
pGlu-Glu-Ala (83 /zM). When compared, both tripeptides have a hydrophilic residue in 
the P: position which agrees with results obtained for bovine PAP I (see Chapter 3.0). 
Amino acid residue in the Pj position o f a tripeptide also affects affinity o f PAP1. This 
is clearly demonstrated with findings obtained using dipeptide pGlu-Thr and tripeptide 
pGlu-Thr-Ala (see Table 4.1). Overall, it can be concluded that greatest affinity is 
observed with tripeptides as opposed to dipeptides. However, the type o f amino acid 
residue in both the P2 and P3 positions affect human PAP1 affinity for the peptide. From 
human, bovine and previous research (see Chapter 3.0), it appears that a hydrophilic 
residue is preferred at the P2 position; however the preferred amino acid type at the P3 
position has yet to be determined.
4.6.2 Biochemical Analysis of Human PAP1 Mutants
A series o f active mutants which were previously generated were biochemically 
characterised (see Table 4.2, Figure 4.10). Optimum temperature studies (see Section
2.18.3) found that the majority o f  the active mutants displayed an optimum temperature 
o f 50°C, while three mutants, namely rMraPAPl_F13mY6n, r/AuPAPl Q180m£6H and 
TllsaPAP\ Y147mF6n were optimally active at 37°C (sec Figures 4.11 -  4.13). As the 
temperature increases, the rate of most chemical reactions increases. However, due to
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the  instability o f  most protein m olecules, the enzym e is inactivated at higher 
tem peratures (Elliott and E lliott, 2005). Therm ostability  studies at 37°C (see  Section 
2 .18.4) revealed that none o f  the nine active m utants display increased therm ostability  
w hen com pared to  wild type PAP1 during the 0-90 m inute period (see F igures 4 .14 - 
4.18). M utants r//.vaPAPl_F13m Y6n and r//saPA Pl_N 98m Q 6H  show increased stability  
during  the 90 -  180 m inute period. r/ZwiPAPl S ID 1 15AYF6H lost 60%  enzym e activ ity  
after 15 m inutes and rapidly declines thereafter show ing poor therm ostab ility  at 37°C 
(see Figure 4.17).
Enzym e activity  is influenced by pH in several ways. The stability  o f  the pro tein  is 
influenced by the sta te  o f  its ionisable groups and on the function o f  the ac tivc  s ite  m ay 
be likew ise dependent on this (E lliott and Elliott, 2005). O ptim um  pH for th is  scries o f  
active m utants was found to range betw een 8.0 and 8.5, w'hile m ajority o f  m utants 
d isplayed an optim um  pH o f  8.5 (see Table 4.3).
IC 50 values w ere determ ined (see Section 2.18.5) for these active m utants (see  Table
4.3) using inhibitors iodacetam ide and 2-pyrrolidone. IC 50 values o f  1.1 /zM and 1.2 //M  
w ere determ ined for wild type PAP1 using the aforem entioned inhibitors, respectively. 
A ctive m utants produced IC 50 values ranging betw een 0.8 and 2.0 /¿M using thiol 
inhibitor iodacetam ide. r//w iPA Pl_N 98m V 6ii produced an IC 50 value o f  3.4 /¿M. 
Sim ilar results w ere obtained w ith substrate  analogue 2-pyrrolidone w ith two o f  the  nine 
active m utants producing higher IC50 values than wild type PAP1 (see Figures 4.21 and 
4.22, T able 4.3). V alues o f  2.8 and 4.1 /iM  w ere determ ined for m utants 
r/Y.s-tfPAPl F13mYfen and r//.vaPA Pl_F16m Y ftn respectively.
T hese d ifferences could be due to structure o f  the substrate binding pocket being 
m odified due to these m utations and as a result has increased IC 50 values being 
determ ined signifying a reduced potency by these inhibitors tow ards pRV5 derivatives 
(see T able 4.3).
4 .6 .3  Investiga tion  in to  the  A ctive S ite o f  H u m an  PAP1
Investigation into hum an PAP1 active site residue Glu85 revealed that an ac id ic  residue 
is required at this position to  retain PAP I activity. Substitution o f  GIu85 w ith  another 
acidic residue, nam ely aspartic acid resulted in a slight increase in PAP1 specific 
activity. How ever, when basic am ino acid glutam ine and neutral am ino acid lysine w ere 
substituted, com plete loss o f  PAP1 activity  w as found for bo th  pRV5 derivatives (see 
Figure 4.30, Table 4.5). SD S-PA G E analysis (see Section 2.16) show s that the  purified
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mutants were expressed at levels comparable to rHsa?AP\eu (see Figure 4 31) Native- 
PAGE analysis highlights a gel shift for inactive mutants rHsaPAPl_E85mK6H and 
vHsaPA?I E85mQan when compared to wild type PAP1 (see Figure 4 32) Mutation o f 
this residue to either a lysine or glutamine residue likely results in some adjustment of 
its protein structure, influencing the hydrophobic pocket and as a result rendering 
rHsaPA? 1 6h mutants inactive The native gel shows presence of multiple protein bands 
at the top o f the gel are most probably due to protein aggregation due to overloading of 
sample
4 6 4 Human PAP1 Random Mutagenesis
Random mutagenesis PCR is a widely employed technique for the study of structure- 
function relationships Thermostable DNA polymerase from Thermus aquaticus (Taq- 
Pol) was chosen for random mutagenesis (see Section 2 9 3) Due to the relatively high 
fidelity of this polymerase, an additional component was included in the PCR reaction 
Various concentrations o f MnCl2 were included to reduce this high fidelity and as a 
result, generate a series of random mutants Other approaches which could have been 
taken to reduce fidelity of DNA polymerase include the variation of dNTP 
concentration in the PCR reaction (Yuan-zhi, 2006) Also, a low fidelity DNA 
polymerase could have been utilised as opposed to Taq-Pol, e g Pyrococcus funosus  
(Pfu-Pol), where the proof-reading exonuclease has been disabled (Biles, 2004)
When analysing protein structure-function relationships, the desired mutation frequency 
is one amino acid change (1-2 nucleotide changes) per gene (Vartanian et al, 1996)
This mutation frequency was optimised by addition of MnCl2 to PCR reaction The 
optimal MnCk concentration for a single amino acid change was 0 05 mM Numerous 
ammo acid changes were obtained when 0 1 and 0 2 mM MnCl2 were utilised 
The main problem which was encountered during random mutagenesis was the 
recirculansation of expression vector pPC225 (see Figure 2 3) which was resolved by 
including CIP treatment as an additional step (see Section 2 8 3) Problems of this 
nature have previously been reported during random mutagenesis (Fujn, 2006) Due to 
low ligation efficiencies during random mutagenesis, this group simplified steps o f this 
method by using error prone rolling circle amplification (RCA) This method consists 
of a one RCA step followed by direct transformation of the host strain to generate 
random mutants
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Figure 4 43 Schematic Diagram of Error-Prone RCA in Comparison With the 
Conventional Random Mutagenesis Method (Fuju, 2004).
In total, twelve human PAP1 random mutants were generated (see Table 4 7) Three 
silent mutants were also generated and it was interesting to note that in all three 
mutants, a cysteine residue was targeted
It has been reported that during random mutagenesis PCR, mutations o f the type T/A -  
to- X occur far more frequently than others (Lin-Goerkr, 1997) However, this was not 
the case with the human PAP1 random mutants generated from this work as only 16% 
of the mutations are o f this nature (see Table 4 7)
Due to availability o f a 3-D model for Hsa?AP\ (see Figure 4 1) it was possible to 
visualise the positions o f the targeted residues for random mutagenesis on the model 
(see Figure 4 38) Majority of the targeted residues reside within the hydrophobic 
pocket region which include N90, A165, D143, P67, N122 and G77 Both G35 and K94 
are positioned on the outer loop of the pocket, while A184 is located at the edge o f the 
hydrophobic pocket Although M l92 is located at the C-termmal end, it was impossible 
to visualise it on the model due to the end twenty-four C-terminal amino acids being 
eliminated from the model
Table 4 8 shows that there is little variation in pH and temperature amongst the pRV5 
derivatives All random mutants are within an 8 0-9 0 pH range An optimum 
temperature of 50°C was determined for mutants with the exception o f
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rHsaFA? 1 _A 165mV6h An optimum temperature of 60°C was obtained for this mutant 
As a result, residue substitution from an alanine to a valine was found to increase the 
thermostability of the enzyme Random mutant specific activity (see Figure 4 40) and 
protein expression (see Figure 4 39) levels vary considerably Lowest specific activity is 
observed for r#saPAPl_P48mQ,D143mH6H This dramatic decrease in specific activity 
of 978 3 units mg 1 suggests that this mutation is having a direct influence on the shape 
of the substrate binding pocket Due to the occurrence o f two mutations it is unclear 
which substitution is actually causing the decrease Increased expression levels are 
observed for r/&aPAPl_G35mD6H, r/fraPAPl_P48mR6H and r/fc<zPAPl_N90mD6H, 
while decreased levels are displayed for enzymes rKsaPAP\_A\65mV6H, 
r/&flPAPl_M122mV6H and r//saPAPl_M192mT6H (see Figure 4 39) It is interesting to 
note that in both cases of the latter two random mutants a methionine residue has been 
targeted Methionine residues are hydrophobic, non-polar residues that may play a role 
in the expression of human PAP1 protein Substitution of the methionine at position 122 
with a valine residue does not have a major effect on specific activity (9,167 units mg'1) 
However when methionine at position 192 was substituted with a threonine amino acid, 
specific activity is drastically reduced (1,049 units mg l), which may be due to the 
threonine residue causing a change in the hydrophobic pocket These differing levels of 
PAP1 protein expression and PAP1 activity are due to either position occupied by the 
methionine residues within the PAP1 amino acid sequence or properties o f the ammo 
acid residues used for substitution during random mutagenesis
Ammo acid, valme, although smaller possesses similar properties to methionine being 
hydrophobic and non-polar This alone may cause or may result m specific activity 
remaining similar to wild type PAP1 The decrease in specific activity observed for 
rllsaPAP 1 _M 192mT6H may be due to the hydrophilic or polar nature of the threonine 
residue used for substitution It is interesting to observe that Ml 92 is located at the C- 
terminal end which would agree with findings from PAP1 bovine study which has 
shown that residues at the C-terminal region are important for protein expression (see 
Chapter 3 0)
Km values (see Figure 4 41) obtained for this series of mutants are m the range between 
52 and 85 fxM suggesting that the random mutants have resulted in little change 
occurring with regards to substrate affinity Koat values (see Figure 4 42) vary 
considerably, majority o f mutants have Kcat values between 1 0 and 2 0 There are only 
two mutants which possess a turnover number that is slightly higher than wild type
157
PAP1 Both r//5,aPAPl_P67mR6H and r//saPAPl_M122mV6H produced Kcat values of 
2 77 and 2 26 s \  respectively
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CHAPTER 5.0 
Human PAPI Crystallisation Study
5 .1  C r y s t a l l o g r a p h y
Crystallography is the science o f determining the arrangement o f atoms, molecules or 
ions in solids. In older usage, it is the scientific study o f crystals. A crystal is a 
homogenous solid formed by a repeating, three-dimensional pattern o f atoms, ions or 
molecules and having fixed distances between constituent parts.
The crystallisation process is composed of two major events, n u c l e a t i o n  and c r y  s t a l  
g r o w t h .  Nucleation is the stage when solute molecules dispersed in the solvent start to 
gather to create clusters. These stable clusters constitute the nuclei (consisting o f  1 0 3 -  
1015). However when the clusters are not stable, they redissolve. Therefore, the clusters 
need to reach a critical size in order to become stable nuclei. It is at the stage of 
nucleation that the atoms arrange in a defined and periodic manner that defines the 
crystal structure.
The crystal growth is the subsequent growth of the nuclei that succeed in achieving the 
critical cluster size. Supcrsaturation is the driving force o f the crystallisation, hence the 
rate o f nucleation and growth is driven by the existing supersaturation in the solution. 
Depending upon the conditions, either nucleation or growth may be predominant over the 
other, and as a result, crystals with different sizes and shapes are obtained. Once the 
supcrsaturation is exhausted, the solid-liquid system reaches the equilibrium and the 
crystallisation process is complete (http://www.structmcd.cirm.ac.uk).
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F ig u re  5.1 C ry s ta l F o rm a tio n
The unit ccll is the basic building block for a crystal.The unit cell is a spatial arrangement o f  atom s which 
is tiled in three-dimensional space to the crystal (http://www.structurmed.cirm.cam.ac.uk).
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5 11 Principles of X-ray Crystallography
X-ray diffraction is the major technique in crystallography in which the pattern 
produced by the diffraction of X-rays through the closely spaced lattice o f atoms in a 
crystal is recorded and then analyzed to reveal the nature of that lattice This generally 
leads to an understanding of the material and molecular structure of a substance The 
spacing in the crystal lattice can be determined using Bragg’s law The electrons that 
surround the atoms, rather than the atomic nuclei themselves, are the entities which 
physically interact with the incoming X-ray photons This technique is widely used in 
chemistry and biochemistry to determine the structures o f an immense variety of 
molecules, including inorganic compounds, DNA and proteins X-ray diffraction is 
commonly carried out using single crystals of a material (Fersht, 2003)
5 1 2  Diffraction
Crystallographic methods now depend on the analysis of the diffraction patterns that 
emerge from a sample which is subjected to X-ray beams The beam is not always 
electromagnetic radiation, although X-rays are the most common choice Crystalline 
material has regularity in structure in 3-D form and it is this regularity that enables 
diffraction (http //www-structmed cirm ac uk) X-ray diffraction is an analytical 
technique which uses a beam of X-rays to probe repeating planes o f atoms The 
reflection of X -rays o f repeating planes o f atoms creates a series o f spots called a 
diffraction pattern The orientation o f the X-ray and the crystal is o f utmost importance 
As the angle between the X-ray beam and the crystal face is varied, the diffraction 
pattern will change as well By collecting data from a series of orientation angles (e g , 
0°, 90°), the three dimensional atomic structure can be calculated In order to collect 
good X-ray diffraction data, chemists use only single crystals with minimum defects 
Modem methods, which employ automated diffractometers and high speed computers, 
have made diffraction studies a very powerful technique for determining the structure of 
crystalline solids A schematic of an X-ray diffractometer is shown in Figure 5 3 Once 
structural knowledge is known, function can then be resolved and at a later stage move 
onto designing specific therapeutic agents The Protein Data Bank (PDB) at 
http //www rcsb org is a freely accessible repository for the structures of proteins and 
other biological macromolecules
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Figure 5.3 Schematic of X-Ray Diffractometer
The main components are an X-ray source, a goniometer (or crystal orientator). a detection system, and a 
computer control system. The X-ray source is a high-vacuum tube, and the X-ray beam passes out o f  the 
tube through a thin window. A single crystal is generally mounted on the end o f  a glass fiber. This fiber is 
then attached to a metal pin which is secured to the goniometer head. The goniometer precisely orients 
the sample in the X-ray beam. As the X-rays pass through the crystal, the detector collects information to 
generate a diffraction pattern. Finally, the computer control system processes the information from the 
detector, and the structure o f  the crystal is solved (http://www.chem.wisc.edu).
5.1.3 Protein Crystallography
More than a century ago, haemoglobin from the blood of various invertebrates and 
vertebrates were the first proteins to be crystallised. This was followed by the 
crystallisation o f hen egg albumin and a series of plant proteins (Greige, et al, 1995). 
Proteins, like many molecules, can be prompted to form crystals when placed in the 
appropriate conditions as described above. The goal is usually to produce a well-ordered 
crystal that is lacking in contaminants and large enough to provide a diffraction pattern 
when hit with X-ray (http://www-structmed.cirm.ac.uk). This diffraction pattern can then 
be analyzed to discern the protein’s three-dimensional structure.
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A B
Figure 5.4 Overview of Protein Crystallography
The three key stages o f  protein crystallography are shown. A: Formation o f single crystal; B: Protein 
diffraction pattern, C:3-D structure o f protein (http://www-structmed.cirm.ac.uk).
Protein crystallisation is inherently difficult because o f the fragile nature o f protein 
crystals. Unlike most small molecule crystals which typically grow well and are hard, can 
be easily manipulated, the crystals o f protein molecules are for the most part relatively 
brittle, soft and comprise on average 50% solvent although this may vary from system 
with extremes between 25 - 90% depending on the particular macromolecule and as a 
result require careful handling. The large size o f the protein molecules and their water of 
hydration and solvation make them much more sensitive to distorting forces. The overall 
aim o f protein crystallisation is to obtain a 3-D structure o f  protein o f  interest. 3-D 
structures allow one to understand biological processes at the most basic level: which 
molecules interact, how they interact and how enzymes catalyse reactions.
5.1.4 Protein Crystallisation Overview
Crystallization o f biological macro molecules has often been considered unpredictable 
but follows the same principles as the crystallisation of small molecules. It is a similarly 
multi-parametric process. Differences arise from conventional crystal growth due to 
biochemical properties o f proteins. In general, the crystallisation trials need more 
protein sample than conventional biochemical analyses as milligrams o f sample arc 
required. Highly purified (-99% purity) proteins are essential for protein crystallisation. 
Conventional chromatography in the past necessitated the use o f up to a 5000-fold 
purification step unlike the typical 20 to 50 fold purification step used today. 
Expression systems now can facilitate the 5 -  10 mg sample needed to commence the 
crystallisation trials. The characterisation o f the protein and assessment o f the sample 
homogeneity is o f utmost importance. Typically SDS-PAGE or isoelectric focusing are
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commonly used for the determination o f purity and homogeneity o f  the sample. The 
challenge o f protein crystallography involves appropriate selection o f experimental 
parameters. Manipulation of numerous variables is then carried out. Variables include 
protein sample concentration, crystallisation method, buffer concentration, temperature, 
pH and drop volume. Typically, concentrated solutions o f protein are mixed with 
various solutions, which usually consist o f a buffer to control the pH o f the experiment, 
a precipitating agent to induce supersaturation and other salts or additives, such as 
detergents or co-factors. The process of crystallising macromolecules can be divided 
into three discrete stages. These are (1) screening for useful crystallization conditions; 
(2 ) optimisation o f one or more initial conditions to produce single crystals suitable for 
X-ray diffraction analysis and (3) reproducible production o f single crystals for X-ray 
data collection. Typically protein crystallographcrs can screen hundreds or thousands o f 
conditions before a suitable condition is found that leads to a crystal o f suitable quality.
E x p r e s s i o n
I
P u r i f i c a t i o n
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P r o t e i n  C o n c e n t r a t i o n
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D i f f r a c t i o n
Figure 5.5 Processes Involved in Protein Crystallisation
Schematic diagram highlighting the various processes involved in protein crystallisation.
5.1.5 Protein Crystallisation Applications
The crystallisation o f proteins currently has three major applicatioas: (1) structural 
biology and drug design, (2) bioseparations, and (3) controlled drug delivery 
(http://www.che.utolcdo.cdu). In the first application, the protein crystals are used with
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the techniques of protein crystallography to ascertain the three-dimensional structure of 
the molecule Obtaining high quality diffractive crystals is the bottleneck in protein 
structure determination This structure is indispensable for correctly determining the 
often-complex biological functions of these macromolecules The design of drugs is 
related to this, and involves designing a molecule that can exactly fit into a binding site 
of a macromolecule and block its function in the disease pathway Producing better 
quality crystals will result in more accurate 3D protein structures, which in turn means 
its biological function can be known more precisely, also resulting in improved drug 
design
Bioseparations refers to the downstream processing o f the products o f fermentation 
Typically the desired product of the fermentation process is a protein, which then needs 
to be separated from the biomass Crystallisation is one o f the commonly employed 
techniques for separating the protein A majority o f small molecular weight drugs are 
produced in crystalline form because of the high storage stability, purity, and 
reproducibility of the drug properties (Hanock and Zografi, 1997) There are hundreds 
o f macromolecular therapeutic agents used in clinical trials or approved as drugs 
However, only insulin is produced and administered in a crystalline form (Jen and 
Merkle, 2001) The entire procedure is performed using yeast cells as a growth medium, 
as they secrete an almost complete human insulin molecule with perfect three 
dimensional structure This minimises the need for complex and costly purification 
procedures (http //www medicinenet com) According to Margolin and Navia (2000) the 
crystallization of macromolecular pharmaceuticals can offer significant advantages, 
such as a) protein purification by crystallization as mentioned above, b) high stability 
of the protein product compared with soluble forms, c) crystals are the most 
concentrated form of proteins, which is beneficial for storage, formulation, and for 
drugs that are needed in high doses (e g , antibiotics)
The latest application of protein crystals is as a means of achieving controlled drug 
delivery Most drugs are cleared by the body rapidly following administration, making 
it difficult to achieve a constant desired level over a period of time When the drug is a 
protein (such as insulin), administering the drug in the crystalline form shows promise 
of achieving such controlled delivery and clinical trials are already underway to test it 
The challenge here is to produce crystals of relatively uniform sizes so that the dosage 
can be prescribed correctly
165
5.1.6 P ro b lem s w ith  P ro te in  C ry s ta llisa tio n
Many problems can be encountered during the crystallisation process. Protein storage is 
very important and processes such as oxidation, deamination, proteolysis and 
aggregation can lead to a general decrease in the quality o f  the overall protein sample. 
Storage under N2 and at low temperature (-20°C or lower) can assist the long term 
storage. Proteins behave best at the pH and ionic strength o f their host conditions and 
this usually means pH slightly above neutral and intermediate ionic strength. These 
may not be ideal for crystallization but dialysis can be performed prior to the 
crystallization trials. Anti-microbial agents such as N aty can be used or filtration using 
0 .2 2  /xm filters to stop the proliferation of microbes which can easily degrade the 
protein under study. Low temperature is advantageous as it helps stabilise the protein 
and also inhibit microbial growth. Freezing samples should only arise once as repeated 
freeze and thaw cycles arc detrimental, but glycerol can help in the process.
Vibration can cause excess nucleation, leading to the formation of large numbers o f low 
quality crystals. Protein to protein interactions arc needed for nucleation, if this doesn’t 
happen crystallisation will never occur. A number o f factors can be responsible for the 
inability o f protein to form proper contacts such as glycosylation, proteolytic 
degradation, aggregation, interference from N- or C-terminals and oxidation of cysteine 
residues (http://www.hamptonresearch.com).
Macromolecule crystals are much more sensitive to post-growth treatment, and this 
provides additional obstacles to structure determinations. For example, many proteins 
arc very sensitive to radiation used in X-ray crystallography, which is an essential tool 
in the structure determination of proteins. In some cases the crystal sensitivity is 
unmanageable and the diffraction quality o f crystals deteriorates rapidly and as a result 
can severely limit the amount o f data that can be obtained from a single crystal. 
Quiocho and Richards initially described the concept o f cross-linked protein crystals in 
1964. They stabilized carboxypeptidase A crystals by glutaraldehyde treatment for X- 
ray structure analysis. There arc only minor changes in the diffraction pattern o f 
crosslinked protein crystals compared with that of the native crystals (Quiocho and 
Richards, 1964; Fitzpatrick el al.. 1993; Lusty, 1999). Crosslinked crystals render it 
possible to study the protein structure in organic solvents, which cannot be done with 
native crystals (Fitzpatrick el al., 1993). Lusty (1999) desenbed the use o f  crystal cross- 
linking together with cryocrystallography, which is a common way to increase the 
stability o f crystals towards the radiation. In cryocrystallography, crystals arc treated
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with a cryoprotectant (e g , sugar solutions, ethylene glycol, PEG, glycerol) and cooled 
rapidly to cryogenic temperatures (e g , with nitrogen gas around 100 K) However, the 
crystals often suffer damage on cooling Lusty proved that glutaraldehyde cross-linking 
protected the crystals from the damage on cooling without any effect on the diffraction 
properties
5 2 Human PAP1 Crystallisation
There are major gaps in our understanding o f protein functions, in particular o f those 
involved in development and in neurological function These proteins are very often 
involved in neuronal functions and the diseases concerned are some of the most 
prevalent in mankind A non-exhaustive list includes cerebrovascular disease, 
Parkinsons, epilepsy, schizophrenia, depression, manic depression, Alzheimers Drugs 
for neurological disorders are rare, the drug regimes are difficult to optimise and the 
commitment to follow a drug regime often for years and often with major side effects is 
a next to impossible in many cases New improved drugs are required and hence 
structure determinations of molecules o f the brain are major scientific as well as 
medical challenges over the next few decades
Crystallography allows scientists, through the study of protein crystals, to determine the 
3D molecular structures o f proteins Such molecules will help shed light on some o f the 
deepest mysteries of humanity, including memory, cognition and desire These 
structures will provide opportunities for treating those suffering from neurodegenerative 
disease due to ageing, genetic disposition, allergies, infection, traumas and 
combinations thereof Such CNS protein structures are one o f the major challenges o f 
biomacromolecular crystallography into the 21st century With an improved 
understanding of the molecular structures and interactions o f proteins, drug designers 
may be able to develop new drug treatments that target specific human, diseases 
At present, there is a varied view as to the exact physiological function o f PAP1 and 
numerous researchers have suggested possible roles for PAP1 as discussed in Section 
1 3 5 To date, the 3D structure o f human or other eukaryotic PAP1 enzymes have not 
been solved The 3D structures of four prokaryotic PAP1 enzymes have been solved 
using X-ray crystallography as discussed in Section 13 11 With the availability of 
highly purified Hsa?A? \ , an attempt to crystallise recombinant human PAP1 and 
obtain 3D structure was the main objective o f this work
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5 2 1 Human PAP1 Crystallisation Study Carried Out in DCU
5 2 11 PAP1 Expression and Purification
rHsaPAPlen was expressed in E coh XL 10-Gold as outlined in Section 2 12 Cells 
were harvested from a 1 L expression culture and re-suspended in 100 ml 50 mM 
potassium phosphate buffer, pH 8 0 A purification scheme using nickel affinity 
chromatography was optimised for this study due to the requirement of highly purified 
protein sample for crystallisation (see Section 2 13 2) Seven (20 ml) washes were 
employed followed by three (5 ml) elutions as shown below in Figure 5 6
Figure 5 6 SDS-PAGE of Purified Human PAP1
Lane 1, protein molecular marker, lane 2, crude lysate, lane 3, flow through, lane 4, wash 1, lane 5, wash 
2, lane 6, wash 3, lane 7, wash 4, lane 8, wash 5, lane 9, wash 6, lane 10, elution 1, lane 11, elution 2, 
lane 12, elution 3 The relevant sizes (kDa) of the protein marker are mdicated
was dialysed against 3L of ultra pure water overnight at 4°C and concentrated using 
rotor vacuum until desired protein concentration was achieved Protein concentration 
was monitored using coomassie assay (see Section 2  14 2 ) Screening o f crystallisation 
conditions for rHsaPAPlen was conducted by employing hangmg drop vapor diffusion 
experiments Hampton Research kits utilised for screening included Crystal Screen 1 
and 2 (see Table 2 8 and 2 9) Various temperatures used were 4, 20, 37 and 60°C and 
protein concentrations included 1 5, 3, 5, 6  5, 7 and 12 mg Crystal trays were stored in 
areas free from disturbance to avoid vibrations which could induce excess nucleation 
and result in formation of poor quality crystals
1 6 8
5.2.1.2 C ry s ta ls  O b ta in e d  F rom  DCU S tudy
Once crystallisation trials were set up, samples were monitored daily for the first week 
as majority o f  crystal nucléation and growth occurred during this time frame. Crystals 
were examined using a ZEISS-AXIOKOP microscope using lOx magnification in all 
cases. Protein crystal images obtained from this study are shown in Figures 5.6 -  5.9. 
All important information was recorded and tabulated (for example see Table 5.1) such 
as date, buffer, sample concentration, temperature, method utilised and status o f each 
sample. For all data recorded during this crystallisation study see Appendix E.
A  B
C
Figure 5.6 Images of Crystals Obtained for Human PAP1 Using a Protein 
Concentration of 1.5 mg.
All samples were set up a! 24°C using Screen I and images were recorded using a lOx magnification. For 
components o f  Screen 1 see Table 2.8. Image A: Reagent 1. 172 hrs. Image B: Reagent 24. 172 hrs. 
Image C: Reagent 45. 360 hrs.
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A B
F ig u re  5.7 Im ages o f  C ry s ta ls  O b ta in e d  fo r  H u m a n  PAP1 U sing  a P ro te in  
C o n c e n tra tio n  o f 3 mg.
All samples were set up at 24°C using Screen 1 and images were recorded using a lOx magnification. For 
components o f  Screen I see Table 2.8. Image A: Reagent 1, 144 hrs, Image B: Reagent 24, 72 hrs, Image 
C: Reagent 45, 240 hrs.
F ig u re  5.8 Im ages o f  C ry s ta ls  O b ta in e d  fo r  H u m a n  PA P1 U sing  a P ro te in  
C o n c e n tra tio n  o f  5 mg.
All samples were set up at 24°C and images were recorded using a lOx magnification. For components o f 
Scrccn 1 and 2 see Tabic» 2.8 and 2.9. Image A: Screen 1. Reagent 1,42 hrs, Image B: Scrccn 1. Reagent 
18, 480 hrs. Image C: Screen 1. Reagent 45, 66 hrs, Image D: Scrccn 2, Reagent 27. 72 hrs. Image E: 
Screen 2. Reagent 27, 144 hrs.
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A B
F ig u re  5.9 Im ages o f  C ry s ta ls  O b ta in e d  fo r  H u m an  PA P1 U sing  a  P ro te in  
C o n c e n tra tio n  o f  12 mg.
All samples were set up at 24°C using Screen 1 and images were recorded using a lOx magnification. For 
components o f  Screen 1 see Iable 2.8. Image A: Reagent 1 ,48 hrs. Image B: Reagent 18, 144 hrs.
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T a b ic  5.1 D ata  C ollection  F o r  H u m an  PAP1 C ry s ta llisa tio n  S tu d y .
Crystal Screen 1 was utilised (see Table 2.8) and a FAP1 protein concentration of'5mg/ml was used. For 
further crystallisation data reports see Appendix E.
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5 2 2 PAP1 Crystallisation Study at the University of Toronto, Canada.
As part of this research, a crystallisation study was carried out in the the University o f 
Toronto, Canada (UTC) Wild type PAP1 and a range of PAP1 mutants listed in Table 
5 2 were examined With access to a sophisticated diffractometer (Rigaku), it was 
possible to analyse promising crystals and progress one step further than previous work 
carried out in DCU
Table 5 2 List of Enzymes Which Were Subjected To Crystallisation Trials at the 
University of Toronto, Canada
Final protein concentration (mg) of each sample is also tabulated
P h sin ld Enzvme F lin i P i otein C’oncenti ation 
(mg)
pRV« IS
pRY^_C149m\V i HsaY AP 1_C 14 9i i AV6H 12
pR \ s_N98mQ \HsaV -\Pl_N98mQ6H 29
pRYS_N9$niY lifrivP APl_N9SmV6H *9
pRV^_F16nA 9
pR \ «J i  147mF iH s a ? W l_ \  147mF6H 20
pR Y ^S ID l 1 sinAYF i/f.ir/PAPl_M Dll ^mAYF6H 27
5 2 21 PAP1 Protein Expression and Purification (UTC)
Wild type human PAP1 and a range of PAP 1 mutants were expressed and purified by the 
methodology outlined in Sections 2  12  and 2 13 2 respectively Following overnight 
dialysis at 4°C in 3L ultrapure water, PAP1 protein samples were concentrated using 
Amicon Ultra centrifuge tubes from Millipore Concentrations ranged from 9 -  29 mg 
(see Table 5 2)
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Figure 5 10 Purification of rHsaYAYlm  Mutants for Crystallisation Study at the 
University of Toronto, Canada Lane 1, protein molecular marker, Lane 2, r//saP A P l6H, Lane 3, 
r/*aPA Pl_C 149m W 6H, Lane 4, r//saPA P l_N98mQ6H, Lane5, vHsa?AP 1_F 16mY6H, Lane 6, 
rHsa? A P 1 _Y 147m F6H The relevant sizes (kDa) of the protein marker are indicated
5.2 2 2 Crystals Obtained From Study at the University of Toronto, Canada
Crystallisation kits used included Crystal Screen 1 and 2 and CryoScreen 1 and 2 (see 
Tables 2 8 - 2 1 1 )  All plates were set up at room temperature according to methodology 
in Section 2  19 2 As with DCU study samples were monitored, images and data were 
recorded and promising crystals were selected for latter diffraction
1 7 4
F ig u re  5.11 Im ages o f C ry s ta ls  O b ta in e d  fo r W ild  T y p e  H u m an  PAP1 in U T C
All samples were set up at 24°C using Screen 1 and images were recorded using a lOx magnification. For 
components o f  Screen 1 see Table 2.8. Image A: Reagent 1. 50 hrs; Image B: Reagent 24, 78 hrs; Image 
C: Reagent 45, 68 hrs; Image D: Reagent 45. 100 hrs.
F ig u re  5.12 Im ages o f  C ry s ta ls  O b ta in e d  fo r  M u ta n t F o rm s o f  H u m a n  PA F1 in
UTC.A11 samples were set up at 24°C and images were recorded using a lOx magnification. For 
components o f  Screen I and 2 see Table 2.9. Image A: r//.wPAPI _C149mW6„, Screen 1, Reagent 48 ,48  
hrs: Image B: r//saPAPl_C149m W 6H. Reagent 48. 78 hrs; Image C: r//vaPAPl_Y147m F6l,. Screcn 2.
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Reagent 3, 68 hrs; Image D: r//saPAPl_Y147m F6H. Screen I, Reagent 3, 48 hrs; Image E: 
r//* iP A P I_ S im  15AYF6H. Screen 2. Reagent 48.
5.3 Diffraction Of Human PAP1 Cry stals
A range o f crystals were selected for diffraction analysis depending on size and 
morphology. Crystals which were flat edged and relatively large in size were chosen. 
These crystals were mounted using cryo-loops as described in Section 2.19.3, were 
exposed to X-rays and the following diffraction patterns were produced as a result.
Figure 5.13 Wild Type PAP1 Diffraction Pattern Using 90° Angle
These crystals were obtained using reagent 45 from screen I. An image o f this crystal type is shown in 
Figure 5.11C.
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F ig u re  5.14 W ild  T y p e  PAP1 D iffraction  P a tte rn  U sing  0° Angle
These crystals were obtained using reagent 24 from screen 1. An image o f this crystal type is shown in 
Figure 5.11D.
F ig u re  5.15 W ild  Type PAP1 D iffraction  P a tte rn  U sing 90° A ngle
These crystals were obtained using reagent 24 from screen l.An image o f  this crystal type is shown in 
Figure 5.11D.
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F ig u re  5.16 r//.v aP A P l_ C 1 4 9 m \V 6n PAP1 D iffrac tio n  P a tte rn  using  a 90° A ngle
These crystals were obtained using reagent 45 from screen 1. An image o f  this crystal type is shown in 
Figure 5.12A.
F ig u re  5.17 r//.v aP A P l_ C 1 4 9 m \V 6ii PAP1 D iffrac tio n  P a tte rn  using  a 90° A ngle
This image was obtained by zooming in on the above Figure. These crystals were obtained using reagent 
45 from screen 1. An image o f  this crystal type is shown in Figure 5.12A.
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5.4 D iscussion
Crystallisation of human PAP1 began with the optimisation o f  a purification scheme 
which could produce a highly purified sample o f PAP1 protein. Figure 5.6 displays a 
prominent purified human PAP1 band in lane 10. Presence o f a contaminant band is 
also visible at the 55 kDa region. Previous experiments carried out have indicated that 
presence o f  this band is strain dependent (data not shown). This band only appeared 
when PAP1 expression was performed using E.coli XL 10-Gold, however did not 
appear when DH5a or BL21 cells were utilised. However, due to reduced PAP1 
expression levels in the aforementioned E.coli strains, XL 10-Gold was used throughout 
this work.
Once a purified PAP1 sample was obtained it was subsequently subjected to dialysis 
overnight to remove salts. A major problem at this stage was protein precipitating out 
o f solution due to prolonged dialysis. After concentrating human PAP1 protein to the 
desired concentration crystallisation trials were set up as described in Section 2.19.2. 
Various crystallisation conditions including reagent, temperature, protein concentration, 
drop volume, reservoir volume and pH were optimised. The hanging drop method was 
used throughout. This diffusion technique is the most popular method for the 
crystallisation o f macro molecules. Typically the drop contains a lower reagent 
concentration than the reservoir. To achieve equilibrium, water vapour leaves the drop 
and eventually ends up in the reservoir. As the water leaves the drop, the sample 
undergoes an increase in supersaturation. Equilibration is reached when the reagent 
concentration in the drop is approximately the same as that in the reservoir.
A range o f differing crystal types were obtained from this study (see Figure 5.6 -  5.9). 
Best quality crystals were produced at room temperature and using a PAP1 protein 
concentration o f 5 mg. The most promising reagents which produced best quality 
crystals were 1, 18 and 45, all o f which were part o f Crystal Screen 1 (see Table 2.8). 
Flat slate-like and oval-shaped crystals were obtained using Reagent 1 (sec Figures 
5.8A) and Reagent 18 (see Figure 5.8B), respectively. Reagent 45, composed o f 0.2 M 
zinc acetate dehydrate, 0.1 M sodium cacodylate pH 6.5 and 18% w/v polyethylene 
glycol 8000 appeared to be the most promising reagent which produced multiple floral 
shaped crystals with flat edges (see Figure 5.8C). It was interesting to note that 
BumVAPI, which displays most homology with Hsa?A?\ from the four prokaryotic 
PAP1 forms, was successfully crystallised using similar crystallisation conditions (see 
Section 1.3.11.1). Pentagonal shaped crystals were obtained for Bam?A?\ using a
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buffer which was composed o f 0 05 M sodium cacodylate/KH2P0 4 , 0 1 M magnesium 
acetate, pH 6  5 and 10% w/v polyethylene glycol 4000 Focusmg on Reagent 45, an 
attempt was made to alter each of the three components of the reagent by producing 
laboratory based reagent variants However, this proved to be unsuccessful as dagger- 
like crystals appeared in the controls This study could not progress any further due to a 
lack o f resources in DCU
Later it was agreed that purified PAP1 samples o f various concentrations would be sent 
to Dr John Gallagher (on sabbatical leave) in the University o f Toronto, Canada 
Access to a diffractometer in HSC (a major resource lacking in DCU) would verify 
whether we were producing salt or protein crystals However, problems were 
encountered during transportation with PAP1 protein precipitating out o f solution This 
occurred in all PAP1 samples with protein concentrations greater than 1 5 mg 
Permission was granted to visit the HSC, Toronto to carry out the work in full there 
Agar slants o f recombinant wild type PAP1 along with PAP1 mutants listed in Table 
5 2 were sent to Toronto Figure 5 10 shows purified preparation from each PAP1 
sample Higher protein concentrations were achieved in the UTC than previous work 
carried out in DCU, with protein concentrations reaching as high as 29 mg 
Approximately, one thousand samples were set up using various PAP1 protein samples 
and crystallisation screens Crystal Screen 1 and 2  along with CryoScreen 1 and 2 (see 
Tables 2 8 - 2 1 1 )  were used for this work
Various crystal morphologies were obtained from this study Figure 5 11 displays 
crystal images obtained for human wild type PAP1, many of which were very similar to 
those obtained from DCU study Floral-like crystal from Figure 5 11C was subjected to 
X-ray diffraction (see Section 2 19 3) Diffraction pattern for this crystal clearly 
demonstrates that this sample is in fact salt (see Figure 5 13) Salt unit cells are much 
smaller than protein unit cells, as a result a well dispersed pattern of dots is displayed 
for salt while a more clustered pattern of dots is typically obtamed from protein 
crystals Results have also shown that crystals from figure 5 1 ID are also salt The 
diffraction image in Figure 5 14 displays presence o f heavy ice rinks and a small 
number of well dispersed dots are visible in Figure 5 15 at the 90° angle Ice nnks are 
due to the crystallisation o f water which is present in the protein sample Crystals 
obtained for PAP1 mutants are highlighted in Figure 5 12 Some crystals were too small 
in size for diffraction analysis The only PAP1 mutant which was subjected to
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diffraction was rHsaPAP 1 _C 149mW6H (see Figure 5 12A) and diffraction patterns in 
Figures 5 16 and 5 17 prove that these crystals are also salt
Following lengthy discussions with protein crystallisation experts in Canada, it was 
suggested that the C-terminal His-tag of PAP1 may be causing the improper 
crystallisation o f PAP 1 to occur Interference from His-tags can be responsible for the 
inability o f protein to form proper protein to protein mteractions which are essential for 
protein crystallisation It is also possible that post-translational modifications of the 
His-tag are occurring leading to an increase in size and charge of the human PAP1 
protein It is interesting to note that all four prokaryotic forms o f PAP 1 (see Section 
13 1 1 ) which were successfully crystallised were purified using conventional 
chromatography as none of which possess any form of His-tag As a result, a new 
strategy for human PAP1 crystallisation was developed for future human PAP1 
crystallisation studies involving the use of an N-terminal His-tag and a new protein 
expression vector, pQE30-Xa (see Chapter 6  0)
181
CHAPTER 6.0 
Summary & Recommendations
In this research thesis, the gene for bovine PAP1 was cloned into an E.coli expression 
system, enabling expression and purification o f the recombinant enzyme. Biochemical 
and kinetic characterisation o f the enzyme was undertaken. Residues of the catalytic 
triad were investigated using site-directed mutagenesis for residue substitution. K, 
values were determined using various pyroglutamyl peptides. With the availability o f 
recombinant human PAP1 in our research group, a comparative study was carried out 
using both bovine and human recombinant PAP1 which revealed some interesting and 
significant differences at the molecular, biochemical and kinetic levels (see Chapter 
3.0).
Kinetic analysis was carried out on recombinant human PAP1 using a range of 
pyroglutamyl peptides. Residues o f the catalytic triad were also investigated. A 
structure/function relationship was investigated by generating a series o f active mutants 
using random mutagenesis. All mutants were characterised both biochemically and 
kinetically (see Chapter 4.0).
An attempt to crystallise human PAP1 was carried out utilising sparse matrix screening 
method. Crystallisation studies were conducted in both DCU, Ireland and in the 
University o f Toronto, Canada (sec Chapter 5.0).
Additional studies on both recombinant human and bovine PAP1 could provide a 
further insight and deeper understanding of these two enzymes.
It would be interesting to continue kinetic research for bovine and human PAP1 using 
pyroglutamyl peptides (see Sections 3.8 and 4.6, respectively). The findings of this 
work and from previous PAP1 research (Cummins and O’Connor, 1996), it appears that 
a hydrophilic residue is the preferred type at the P2 position, however, the preferred 
choice at the P? position has yet to be determined. A new range o f  pyroglutamyl 
tripeptides such as pGlu-His-Ala and pGlu-His-Met need to be synthesised for this 
study.
Random mutagenesis o f  human PAP1 has highlighted some interesting residues, in 
particular, two methionine residues which were mutated to valine and threonine, 
respectively as discussed in Section 4.6. There are four methionine residues in the 
human PAP1 amino acid sequence at positions 1, 78, 122 and 192. An interesting study 
for this area would comprise o f each methionine residue being substituted with an 
alanine residue, thereby retaining the hydrophobic, non polar properties of methionine 
to explore the significance o f each methionine residue in PAP1 protein expression. 
Following mutagenesis, all resultant mutants including wild type PAP1 should be
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subjected to native-PAGE to check if they possess differing mobilities which could 
suggest that they are folded differently.
Although numerous attempts were made, crystallisation o f human PAP1 proved to be 
unsuccessful as discussed in Section 5.4. It is believed that the C-terminal 6 xHis tag of 
PAP1 is causing improper crystallisation to occur. Consequently, a new method has 
been proposed to crystallise human PAP1 lacking the His6 tag using expression vector 
pQE30-Xa (see Figure 6 .1).
W
pQe-30 xo 
3 5 kb
Cdtl
F ig u re  6.1 Q E 30-X a V ec to r w ith  N -te rm in a l H is-T ag
PT5: T5 promoter, lac O: lac opcron, RBS: ribosomal binding site. ATG: start codon, 6xHis: 6xHis tag 
sequence, MSC: multiple cloning site with restriction sites indicated Col El: Col E l origin o f  
replication, Ampicillin: ampicillin resistance gene. Factor Xa Recognition Site: factor Xa Protease 
recognition site (Qiagen. 2003).
The pQE30-Xa expression vector encodes a Factor-Xa Protease recognition site 
between the N-terminal His* tag sequence and the multiple cloning site. Factor Xa 
Protease recognises the amino acid sequence Ile-Glu-Gly-Arg and cleaves the peptide 
bond at the C-terminal o f the arginine residue. If the human PAP1 gene is cloned blunt - 
ended at the 5' end using the Stul restriction site o f the vector, the subsequent Factor Xa 
cleavage of purified recombinant protein results in a PAPI protein which is His-tag free 
(Qiagen, 2003). Human PAPI crystallisation studies may prove to be more successful if 
this strategy is incorporated into the next PAPI crystallisation study.
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Appendix A 
Standard Curves
f
18
16
5 14
soo 1000 1500
BSA  jig/ml
2000 2S00
BSA standard curve for quantitative BCA assay
Standard curve o f BSA (ng/ml) versus absorbance at 570 nm for the determination o f protein 
concentration by the BCA assay described in Section 2 14 1
BSA 0ig/ml)
BSA standard curve for quantitative Coomassie assay
Standard curve o f BSA (ng/ml) versus absorbance at 595 nm for the determination o f protein 
concentration by the quantitative Coomassie assay described in Section 2 14 2
203
4MC (|lM)
AMC standard  curve
Standard curve o f AMC (|wM) versus fluorescence intensity as described in Section 2 15 1, for the 
determination o f AMC released by PAP 1 activity
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Appendix B 
Sequence Data
>pZKl forward read. MWG
CCGCCAGTGTGCTGGAATTCGGCTTCAGCAAGGATCCGTG1TCATGGCAACAGTTGATTT 
TGCCTTCTGACTGCICTAGGAGGTCCAGCATCTCCTCAA TG ATGGCCCG AAGTGCCCGGC 
CCAGCTGGTCTGCATTGTACGGCTTGCCCAGAGGGGGCACGTGAACAAAGGCTGAGCGGC 
CGTGACTCTGGTACAGAGAGGTATAGTAGGTGAAGTCGCAGAGGTACCTGCCTGCATCTT 
GT G A A A T GGT C ACTG AC AC AT CT A AGCCC AGT GT AGTG ACCCTCTT AC AC AC AGC ATCC A 
TGTCGATGATGGAGTCAATGCnTCCGGCCCGTCCTCCACACAGCACTGGGAGCCGGGGC 
AGAATCGGCAGTTGTCCAGGCCCTTGTAACCCIT GTTGTGTCCACACTTCrCCAGTGTGA 
CTGCGGTTGCCATGCCTGACACTCCTACGTGCACCACCAGCTGCGGACTGTGCTTCTCCC
a c a g g g c a g g g a t g a g c c t c t g g a c c g t c t g a t a c t c c a c t g g a a t c t c a t a c a c a t g t a
GGTCC ACGC1GTCCCC A AGCCCTAGTTTCTCC AGCTCCTGG ACCGC A ATCC AGCTGGC AT
TCACAGTGTGITCCCCAAAAGGGCCGAATGCCGTCACCACCACCGCCTTCCTGGGCTGCT
CCATGGCGGGTTCAAGCCGAATTCTGCAGATATCCATCACACTGGCGGCCGCTCGAGCAT
GC ATCT AG AGGGCCC A ATTCGCCCT AT AGTG AGTCGT ATT AC AATTCACT GGCCGTCGTT
TTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACAT
CCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATTGCCCTTCCCAACAG
TTGCGCAGCCTGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATTAGCGCGGCGGGGTG
TGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCG
CTTTCTTCCCTTCTTTCTCGC
>pZK I reverse read. MWG
CCCTCTAGATGCATGCrCGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGGCTTG
AACCCGCCATGGAGCAGCCCAGGAAGGCGGTGGTGGTGACGGCATTCGGCCCTTTTGGGG
AACACACTGTGAATGCCAGCTGGATTGCGGTCCAGGAGCTGGAGAAACTAGGGCTTGGGG
ACAGCG TGGACCTACATGTGTATGAGATTCCAGTGGAG7 ATCAGACGGTCCAGAGGCTCA
TCCCTGCCCTGTGGGAGAAGCACAGTCCGCAGCTGGTGGTGCACGTAGGAGTGTCAGGCA
TGGCAACCGCAGTCACACTGGAGAAGTGTGGACACAACAAGGGTTACAAGGGCCTGGACA
ACTGCCGATTCTGCCCCGGCTCCCAGTGCTGTGTGGAGGACGGGCCGGAAAGCATTGACT
CCATCATCGACATGGATGCTGTGTGTAAGAGGGTCACTACACTGGGCrTAGATGTGTCAG
TGACCATTTCACAAGATGCAGGCAGGTACCTCTGCGACTTCACCTACTATACCTCTCTGT
ACCAGAGTCACGGCCGCTCAGCCTTTGTTCACGTGCCCCCTCTGGGCAAGCCGTACAATG
CAGACCAGCTGGGCCGGGCACTTCGGGCCATCATTGAGGAGATGCTGGACCTCCTAGAGC
AGTCAGAAGGCAAAATCAACTGTTGCCAIGAACACGGATCCTTGCTGAAGCCGAATTCCA
GCACACTGGCGGCCGTT ACT AGTGG ATCCGAGCl CGGTACC AAGCIT'GGCGT AATCATGG
TCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCC
GGAAGCAT A A AGTGT AA AGCCTGGGGTGCCT A ATGAGTG AGCTAACTCACATT AATTGCG
TTGCGCTCACTGCCCGCTTTCCAC.TCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATC
GGC A ACGCGCGGGG AG AGGCGGTTT GCGT ATGGGCGCT CTT CGGCTTCTCGCTC ACTG AC
TCGCTGC GCT C GGT C GTT CGGCT
>pZK2_forward read. MWG
A ATCAT A AAAAATTT ATTT GCTTTGTGAGCGGATAAC AATTTC AC AC AG AATTC ATT AAAG A
GC»AGAAATrAACCATGGAGCAGCCGAGGAAGGC”GGTGGTAGTGACGGGATTTGGCCCTTTT
GGGGAACACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTG
GCGACAGCGTGGACCTGCA1GIGTACGAGA nCCGGTTGAGTACCAAACAGTCCAGAGACT
CATCCCCGCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGC
ATGGCGACCACAGTCACACTGGAGAAATGTGGACACAACAAGGGCIACAAGGGGCTGGACA
ACT GCCGCTTTTGCCCCGGCTCCC AGT GCTGCGTGG AGG ACGGGCCTG A AAGC ATTG ACT CC
ATCATCGACATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGAC
CAT C1CGC AGG ATGCCGGC AG AT ATCTCTGCG ACTTT ACCT ACT AC ACCT CTTT GT ACC AG AG
TCACGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGC
TGGGCAGGGCACTGAGAGCCATCATTGA
>pZK2 revcrse read, MWG
AGCCGAGG/VAGGCGGTGGTAGTGACGGAATTTGGCCCTITTGGGGAACACACCGTGAACGC 
LAG TTGGA IT GCACITCAGGAGC1 AG AAAAGCr AGGCCTTGGCG AC AGCGTGGACCTGC AT 
GTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAA 
GCACAGTCCACAGCTGGTGGTGCATG r GGGGGTGTCAGGCATGGCGACCACAGTCACACTG 
GAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCT 
CCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTG
206
TGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAG
ATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGT
CCACAGTGCCCCCACTGGGGAAGCCAGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAG
CCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCAC
AAACACGGATCTCATCACCATCACCATCACTAAGCTTAATTAGC
>p2K3_forward read, MWG
TTAGTGATGGTGATGGTGATGAGATCCGTGTTCATGGCAACAGTTGATTTTGCCTTCTGA
CTGCTCTAGGAGGTCCAGCATCTCCTCAATGATGGCCCGAAGTGCCCGGCCCAGCTGGTC
TGCATTGTACGGCTTGCCCAGAGGGGGCACGTGAACAAAGGCTGAGCGGCCGTGACTCTG
GTACAGAGAGGTATAGTAGGTGAAGTCGCAGAGGTACCTGCCTGCATCTTGTGAAATGGT
CACTGACACATCTAAGCCCAGTGTAGTGACCCTCTTACACACAGCATCCATGTCGATGAT
GGAGTCAATGCTTTCCGGCCCGTCCTCCACACAGCACTGGGAGCCGGGGCAGAATCGGCA
GTTGTCCAGGCCCTTGTAACCCTTGTTGTGTCCACACTTCTCCAGTGTGACTGCGGTTGC
CATGCCTGACACTCCTACGTGCACCACCAGCTGCGGACTGTGCTTCTCCCACAGGGCAGG
GATGAGCCTCTGGACCGTCTGATACTCCACTGGAATCTCATACACATGTAGGTCCACGCT
GTCCCCAAGCCCTAGTTTCTCCAGCTCCTGGACCGCAATCCAGCTGGCATTCACAGTGTG
TTCCCCAAAAGGGCCGAATGCCGTCACCACCACCGCCTTCCTGGGCTGCTCCATGGTTAA
TTTCTCCTCTTTAATGAATTCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCAC
ACATTATACGAGCCGATGATTAATTGTCAACAGCTCATTTCAGAATATTTGCCAGAACCG
TTATGATGTCGGCGCAAAAAACATTATCCAGAACGGGAGTGCGCCTTGAGCGACACGAAT
TATGCAGTGATTTACGACCTGCACAGCCATACCACAGCTTCCGATGGCTGCCTGACGCCA
GAAGCATTGGTGCACCGTGCAGTCGATAAGCCCGGATCGCTCTAGAGCGATCCTCT
>pZK3_reverse read, MWG
GGTGGTGCACGTAGGAGTGTCAGGCATGGCAACCGCAGTCACACTGGAGAAGTGTGGACA
CAACAAGGGTTACAAGGGCCTGGACAACTGCCGATTCTGCCCCGGCTCCCAGTGCTGTGT
GGAGGACGGGCCGGAAAGCATTGACTCCATCATCGACATGGATGCTGTGTGTAAGAGGGT
CACT ACACTGGGCTTAGATGTGTCAGTGACCATTTCACAAG ATGC AGGCAGGTACCTCTG
CGACTTCACCTACTATACCTCTCTGTACCAGAGTCACGGCCGCTCAGCCTTTGTTCACGT
GCCCCCTCTGGGCAAGCCGTACAATGCAGACCAGCTGGGCCGGGCACTTCGGGCCATCAT
TGAGGAGATGCTGGACCTCCTAGAGCAGTCAGAAGGCAAAATCAACTGTTGCCATGAACA
CGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGCGGATGAGAGAAGATTT
TCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGCCTG
GCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGAAGTGAAACGCCGTA
GCGCCGATGGTAGTGTGGGGTCTCCCCATG
>pZK3_E85mD_forward read, MWG
GGCCCAGTGTGCTGGAATTCGGCTTCAGCAAGGATCCGTGTTCATGGCAACAGTTGATTT
TGCCTTCTGACTGCTCTAGGAGGTCCAGCATCTCCTCAATGATGGCCCGAAGTGCCCGGC
CCAGCTGGTCTGCATTGTACGGCTTGCCCAGAGGGGGCACGTGAACAAAGGCTGAGCGGC
CGTGACTCTGGTACAGAGAGGTATAGTAGGTGAAGTCGCAGAGGTACCTGCCTGCATCTT
GTGAAATGGTCACTGACACATCTAAGCCCAGTGTAGTGACCCTCTTACACACAGCATCCA
TGTCGATGATGGAGTCAATGCTTTCCGGCCCGTCCTCCACACAGCACTGGGAGCCGGGGC
AGAATCGGCAGTTGTCCAGGCCCTTGTAACCCTTGTTGTGTCCACACTTCTCCAGTGTGA
CTGCGGTTGCCATGCCTGACACTCCTACGTGCACCACCAGCTGCGGACTGTGCTTCTCCC
ACAGGGCAGGGATGAGCCTCTGGACCGTCTGATACTCCACTGGAATCTCATACACATGTA
GGTCCACGCTGTCCCCAAGCCCTAGTTTCTCCAGCTCCTGGACCGCAATCCAGCTGGCAT
TCACAGTGTGTTCCCCAAAAGGGCCGAATGCCGTCACCACCACCGCCTTCCTGGGCTGCT
CCATGGCGGGTTCAAGCCGAATTCTGCAGATATCCATCACACTGGCGGCCGCTCGAGCAT
GCATCTAGAGGGCCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTGGCCGTCGTT
TTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACAT
CCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATTGCCCTTCCCAACAG
TTGCGCAGCCTGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATTAGCGCGGCGGGGTG
TGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCG
CTTTCTTCCCTTCTTTCTCGC
> pZK3_E85mD_reverse read, MWG
ACGTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGGCTTG
AACCCGCCATGGAGCAGCCCAGGAAGGCGGTGGTGGTGACGGCATTCGGCCCTTTTGGGG
207
AACACACTGTGAATGCCAGCTGGATTGCGGTCCAGGAGCTGGAGAAACTAGGGCTTGGGG
ACAGCGTGGACCTACATGTGTATGAGATTCCAGTGGAGTATCAGACGGTCCAGAGGCTCA
TCCCTGCCCTGTGGGAGAAGCACAGTCCGCAGCTGGTGGTGCACGTAGGAGTGTCAGGCA
TGGCAACCGCAGTCACACTGGAGAAGTGTGGACACAACAAGGGTTACAAGGGCCTGGACA
ACTGCCGATTCTGCCCCGGCTCCCAGTGCTGTGTGGAGGACGGGCCGGAAAGCATTGACT
CCATCATCGACATGGATGCTGTGTGTAAGAGGGTCACTACACTGGGCTTAGATGTGTCAG
TGACCATTTCACAAGATGCAGGCAGGTACCTCTGCGACTTCACCTACTATACCTCTCTGT
ACCAGAGTCACGGCCGCTCAGCCTTTGTTCACGTGCCCCCTCTGGGCAAGCCGTACAATG
CAGACCAGCTGGGCCGGGCACTTCGGGCCATCATTGAGGAGATGCTGGACCTCCTAGAGC
AGTCAGAAGGCAAAATCAACTGTTGCCATGAACACGGATCCTTGCTGAAGCCGAATTCCA
GCACACTGGCGGCCGTTACTAGTGGATCCGAGCTCGGTACCAAGCTTGGCGTAATCATGG
TCATAGCTGnTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCC
GGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCG
TTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATC
GGCAACGCGCGGGGAGAGGCGGTTTGCGTATGGGCGCTCTTCGGCTTCTCGCTCACTGAC
TCGCTGCGCTCGGTCGTTCGGCT
>pZK3_C149mF_forward read, MWG
CCGCCAGTGTGCTGGAATTCGGCTTCAGCAAGGATCCGTGTTCATGGCAACAGTTGATTT
TGCCTTCTGACTGCTCTAGGAGGTCCAGCATCTCCTCAATGATGGCCCGAAGTGCCCGGC
CCAGCTGGTCTGCATTGTACGGCTTGCCCAGAGGGGGCACGTGAACAAAGGCTGAGCGGC
CGTGACTCTGGTACAGAGAGGTATAGTAGGTGAAGTCGCAGAGGTACCTGCCTGCATCTT
GTG AAATGGTCACTG ACAC ATCT AAGCCCAGTGT AGTGACCCTCTT ACAC ACAGC AT CCA
TGTCGATGATGGAGTCAATGCTTTCCGGCCCGTCCTCCACACAGCACTGGGAGCCGGGGC
AGAATCGGCAGTTGTCCAGGCCCTTGTAACCCTTGTrGTGTCCACACTTCTCCAGTGTGA
CTGCGGTTGCCATGCCTGACACTCCTACGTGCACCACCAGCTGCGGACTGTGCTTCTCCC
ACAGGGCAGGGATGAGCCTCTGGACCGTCTGATACTCCACTGGAATCTCATACACATGTA
GGTCCACGCTGTCCCCAAGCCCTAGTTTCTCCAGCTCCTGGACCGCAATCCAGCTGGCAT
TCACAGTGTGTTCCCCAAAAGGGCCGAATGCCGTCACCACCACCGCCTTCCTGGGCTGCT
CCATGGCGGGTTCAAGCCGAATTCTGCAGATATCCATCACACTGGCGGCCGCTCGAGCAT
GCATCTAGAGGGCCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTGGCCGTCGTT
TTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACAT
CCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATTGCCCTTCCCAACAG
TTGCGCAGCCTGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATTAGCGCGGCGGGGTG
TGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCG
CTTTCTTCCCTTCTTTCTCGC
> pZK3_C149mF_reverse read, MWG
TGCATGCTCGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGGCTTGAACCCGCCATG
GAGCAGCCCAGGAAGGCGGTGGTGGTGACGGCATTCGGCCCTTTTGGGGAACACACTGTGA
ATGCCAGCTGGATTGCGGTCCAGGAGCTGGAGAAACTAGGGCTTGGGGACAGCGTGGACCT
ACATGTGTATGAGATTCCAGTGGAGTATCAGACGGTCCAGAGGCTCATCCCTGCCCTGTGGG
AGAAGCACAGTCCGCAGCTGGTGGTGCACGTAGGAGTGTCAGGCATGGCAACCGCAGTCAC
ACTGGAGAAGTGTGGACACAACAAGGGTTACAAGGGCCTGGACAACTGCCGATTCTGCCCC
GGCTCCCAGTGCTGTGTGGAGGACGGGCCGGAAAGCATTGACTCCATCATCGACATGGATG
CTGTGTGTAAGAGGGTCACTACACTGGGCTTAGATGTGTCAGTGACCATTTCACAAGATGCA
GGC AGGT ACCTCTGCGACTTCACCT ACT AT ACCTCTCTGT ACCAGAGTCACGGCCGCTC AGO
CTTTGTTCACGTGCCCCCTCTGGGCAAGCCGTACAATGCAGACCAGCTGGGCCGGGCACTTC
GGGCCATCATTGAGGAGATGCTGGACCTCCTAGAGCAGTCAGAAGGCAAAATCAACTGTTG
CCATGAACACGGATCCTTGCTGAAGCCGAATTCCAGCACACTGGCGGCCGTTACTAGTGGAT
CCGAGCTCGGTACCAAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTAT
CCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCT
AATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAAC
CTGTCGTGCCAGCTGCATTAATGAATCGGCAACGCGCGGGGAGAGGCGGTTTGCGTATGGG
CGCTCTTCGGCTTCTCGCTCACTGACTCG
>pZK3_H168mD_forward read MWG
GCCAGTGTGCTGGAATTCGGCTTCAGCAAGGATCCGTGTTCATGGCAACAGTTGATTT
TGCCTTCTGACTGCTCTAGGAGGTCCAGCATCTCCTCAATGATGGCCCGAAGTGCCCGGC
CCAGCTGGTCTGCATTGTACGGCTTGCCCAGAGGGGGCACGTGAACAAAGGCTGAGCGGC
208
CGTGACTCTGGTACAGAGAGGTATAGTAGGTGAAGTCGCAGAGGTACCTGCCTGCATCrr
GTGAAATGGTCACTGACACATCTAAGCCCAGTGTAGTGACCCTCTTACACACAGCATCCA
TGTCG ATGAIGG AGTCAATGCITTCCGGCCCGTCCTCCAC ACAGC ACTGGG AGCCGGGGC
AGAA rCGGCAGTTGTCCAGGCCCriG rAACCCTTGTTGTGTCCACACTTCTCCAGTGTGA
CTGCGGrrGCCATGCCTGACACTCCTACGTGCACCACCAGC TGCGGACTGTGCTTCTCCC
ACAGGGCAGGGATGAGCCTCTGG ACCGTCTG AT ACTCCACTGG AATCTC AT ACACATGT A
GGTCCACGCTGTCCCCAAGCCCTAGTTTCTCCAGCTCCTGGACCGCAATCCAGCTGGCAT
TCACAGTGTGTTCCCCAAAAGGGCCGAATGCCGTCACCACCACCGCCTTCCTGGGCTGCT
CCATGGCGGGTTCAAGCCGAATTCTGCAGATATCCATCACACTGGCGGCCGCTCGAGCAT
GCATCTAGAGGGCCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTGGCCGTCGTT
TTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACAT
CCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATTGCCCTTCCCAACAG
TTGCGCAGCCTGAA rGGCGAATGGACGCGCCCTGTAGCGGCGCATTAGCGCGGCGGGGTG
TGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCG
CTTTCTTCCCTTC1TTC
> pZK3_H 168mD reverse read, MWG
TCTAGATGCATGCTCGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGGCTTGAAC
CCGCCATGGAGCAGCCCAGGAAGGCGGTGGTGGTGACGGCATTCGGCCCTTTTGGGG
AACACACTGTGAAIGCCAGCTGGA ITGCGGTCCAGGAGCTGGAGAAACTAGGGCrrGGGG
ACAGCGTGGACCTACATGTGTATGAGATTCCAGTGGAGTATCAGACGGTCCAGAGGCTCA
TCCCTGCC’CTGTGGGAGAAGCACAGTCCGCAGCTGGTGGTGCACGTAGGAGTGTCAGGCA
TGGCAACCGCAGTCACACTGGAGAAGTGTGGACACAACAAGGGTTACAAGGGCCTGGACA
AC TGCCGAITCTGCCCCGGCTCCCAGTGCTGTGTGGAGGACCÌGGCCGGAAAGCATTGACT
CCATCATCGACATGGATGCTGTGTGTAAGAGGGTCACTACACTGGGCTTAGATGTGTCAG
TGACCATTTCACAAGATGCAGGCAGGTACCTCrGCGACTTCACCTACTATACCTCTCTGT
ACCAGAGTCACGGCCGCTCAGCCTTTGTTCACGTGCCCCCTCTGGGCAAGCCGTACAATG
CAGACCAGCTGGGCCGGGCACTTCGGGCCATCATTGAGGAGATGCTGGACCTCCTAGAGC
AGTCAGAAGGCAAAATCAACTGTTGCCATGAACACGGATCCTTGCTGAAGCCGAATTCCA
GCACACTGGCGGCCGTTACTAGTGGATCCGAGCTCGGTACCAAGCTTGGCGTAATCATGG
TCATAGCIGTTICCTGTGTG AAA1TGTTATCCGCTCACA ATTCCACAC AACATACG AGCC
GG AAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATr AATTGCG
ITGCGCrCACTGCCCGCTTTCCAGTCGGGAAAC'CTGTCGTGCCAGCTGCATTAATGAATC
GGC A ACGCGCGGGG AG AGGCGGTTT GCGTA1GGGCGCTCTTCGGCTTCT CGCT CACT G AC
TCGCTGCGCTCGGTCGTTCG
>pZK3_A91mT_forward read. MWG
CAAACAGCCAAGCTTAGTGATC.GTGATGGTGATGAGATCCGTGTTCATGGCAACAGTTGA
TTTTGCCTTCTGACTGCTCTAGGAGGTCCAGCATCTCCTCAATGATGGCCCGAAGTGCCC
GGCCCAGCTGGTCTGCATTGTACGGCTTGCCCACiAGGGGGCACGTGAACAAAGGCTGAGC
GGCCGTGACTCTGGTACAGAGAGGTATAGTAGCjTGAAGTCGCAGAGGTACCTGCCTGCAT
CITGTGAAATGGTCACTGACACATCTAAGCCCAGTGTAGTGACCCTCTTACACACAGCAT
CCATCiTCGATGATGGAGTCAATGCTTTCCGGCCCGTCCTCCACACAGCACTGGGAGCCGG
GGC'AGAATCGGCAGTTGTCCAGGCCCTTGTAACCCTTGITGTGTCCACACTTCTCCAGTG
TGACTGTGGriGCCA TGCCTG ACACGCCTACGTGC ACCACCAGCTGCGG ACTGTGCTTCT
CCCACAGGGCAGGGATC.AC1CCTCTC.C1ACCGTCTGATACTCCACTGC.AATCTCATACACAT
GTAGGTCCACGCTGTCCCCAAGCCCTAGTTTCTCCAGCTCCTGGACCGCAATCCAGCTGG
CATTCACAGTGTGTTCCCCAAAAGGGCCGAATCCCGTCACCACCACCGCCTTCCTGGGCT
GCTCCATGGTI AATTTCTCCrCTrrAATGAATTCTGTTTCCTGTGTGAAATI'GTTATCCG
CTCACAA rrCCAC ACATI ATACGAGCCGATGATTAATTGTCAACAGCTCAnTCAGAATA
TTTGCCAGAACCGTTATGATGTCGGCGCAAAAAACA H ATCCAGAACGGGAGTGCGCCTT
G AGCG ACACGAATTATGCAGTGATTTACGACCTGCAC AGCCAIACCACAGCTTCCGATGG
CTGCCTG ACGCCAG AAGCAH GG TGCACCGTGCAGTCGATA AGCCCGG ATCGCTCTAG AG
CGATCCTCTACGCCGGACGCATCGTGGCC
> pZK3 A91mT_revere read. MWG
GAAIT7UVCCATGGAGCAGCCCAGGAAÜGCGGT GGTGGTGACGGGATTCGGCCClTr IGGG
gaacacactgtgaatgccagctgc.attgcggtccaggagctggagaaactagggcttggg
GACAGCGTGGACCTACATGTGTATCiAGATTCCAGTGGAGTATCAGACGGTCCAGAGGCTC
ATCCCTGCCCTGTGGGAGAAGCACAGTCCGCAGCTGGTGGTGCACGTAGGCGTGTCAGGC
209
ATGGCAACCACAGTCACACTGGAGAAGTGTGGACACAACAAGGGTTACAAGGGCCTGGAC
AACTGCCGATTCTGCCCCGGCTCCCAGTGCTGTGTGGAGGACGGGCCGGAAAGCATTGAC
TCCATCATCGACATGGATGCTGTGTGTAAGAGGGTCACTACACTGGGCrTAGATGTGTCA
g t g a c c a t t t c a c a a g a t g c a g g c a g g t a c c t c t g c g a c t t c a c c t a c t a t a c c t c t c t g
TACCAGAGTCACGGCCGCTCAGCCTTTGTTCACGTGCCCCCTCTGGGCAAGCCGTACAAT
GCAGACCAGCTGGGCCGGGCACTTCGGGCCATCATTGAGGAGATGCTGGACCTCCTAGAG
CAGTCAGAAGGCAAAATCAACTGTTGCCATGAACACGGATCTCATCACCATCACCATCAC
TAAGCTTGGCIG rnTGGCGGATGAGAGAAGA rrrTCAGCCTGATACAGATTAAATCAGA
ACGCAGAAGCGGTCTGATAAAACAGAATT1GCCTGGCGGCAGTAGCGCGGTGGTCCCACC
TGACCCCATGCCGAACTCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCC
CCATGCGAGAG TAGGGAACTGCCAGGCATCAAA1AAAACGAAAGGCTCAGTCGAAAGACT
GGGCCTTTCGlTrTATCTGTTGTTTGTCGGTGAACGCTCTCCTGAGTAGGACAAATCCGC
CGGGAGCGGATTTGAACGTTGCGAAGCAACGGCCC
>pZK3_C205mY_ forward read, MWG
C AAAC AGCCAAGCTTAGTGATGGTGATGGTG ATG AGATCCGTCriTCA IGGCAATAGTTGA
TTTTGCCTTCTGACTGCTCTAGGAGGTCCAGCATCTCCTCAATGATGGCCCGAAGTGCCC
GGCCC AGCT GGTCT GC ATTGT ACGGCTTGCCC AG AGGGGGC ACGTG A AC AAAGGCTG AGC
GGCCGTGACTCTGGTACAGAGAGGTATAGTAGGTGAAGTCGCAGAGGTACCTGCCTGCAT
CTTGTGAAATGG TCACTGACACATCTAAGCCCAGTGTAGTGACCCTCTTACACACAGCAT
CCATG1CGA TGA TGGAGTCAATGCmCCGGCCCGTCCTCCACACAGCACTGGGAGCCGG
GGCAGAATCGGCAGTTGTCCAGGCCCTTGTAACCCTTGTTGTGTCCACACTTCTCCAGTG
TGACTGCGGTTGCCATGCCTGACACGCCTACGTGCACCACCAGCTGCGGACTGTGCTTCT
CCCACAGGGCAGGC.ATGAGCCTCTGGACCGTCTGATACTCCACTGGAATCTCATACACAT
GT AGGT CC ACGCT GTCCCC A AGCCCT AGTTI'CTCC AGCI'CCrGG ACCGC AATCC AGCT GG
CATTCACAGTGTGTTCCCCAAAAGGGCCGAATCCCGTCACCACCACCGCCTTCCTGGGCT
g c t c c a t g g t t a a t t t c t c c t c t t t a a t g a a t t c t g t t t c c t g t g t g a a a t t g t t a t c c g
c t c a c a a t t c c a c a c a t t a t a c g a g c c g a t g a t t a a t t g t c a a c a g c t c a t t t c a g a a t a
TTTGCCAGAACCGTrATGATGTCGGCGCAAAAAACATTATCCAGAACGGGAGTGCGCCTT
GAGCGAC'ACGAA TTATGCAGTGA ITI ACGACCTGCACAGCCATACCACAGCTTCCGATGG
CTGCCTGACGCCAGAAGCATTGGTGCACCGTGCAGTCGATAAGCCCGGATCGCTCTAGAG
CGATCCTCTACGCCGGACGCATCGTGGCCGGCATCACCGGCGCA
> pZK3_C205mY_reverse read, MWG
GGAGAAT1 AACCATGGAGCAGCCCAGGAAGGCGGTGGTGGTGACGGGATTCGGCCCmr
GGGGAACACAC IG TGAA IGCCAGCrGGATTGCGGTCCAGGAGCTGCiAGAAACTAGGGCTT
GGGGACAGCGI'GGACCI ACATGTGTATGAGATTCCAGTGGAGTATCAGACGGTCCAGAGG
CTCATCCCTGCCCTGTGGGAGAAGCACAGTCCGCAGCTGGTGGTGCACGTAGGCGTGTCA
GGCA1GGCAACCGCAGTCACACTGGAGAAGTGTGGACACAACAAGGGTTACAAGGGCCTG
GACAACTGCCGATTCTGCCCCGGCTCCCAGTGCTGTGTGGAGGACGGGCCGGAAAGCATT
GACTCCATCATCGACATGGATGCTGTGTGTAAGAGGGTCACTACACrGGGCTTAGATGTG
TCAGTGACCATTTCACAAGATGCAGGCAGGTACCTCTGCGACTTCACCTACTATACCTCT
CTGTACCAGAGTCACGGCCGCTCAGCCTTTGTTCACGTGCCCCCTCTGGGCAAGCCGTAC
AATGC'AGACCAGCTGGGCCGGGCACTTCGGGCCATCA ITGAGGAGATGCTGGACCTCCTA
GAGCAGTCAGAAGGCAAAATCAACTATTGCCATGAACACGGATCTCATCACCATCACCAT
CACTAAGCTrGGCTGITrrGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATC
AGAACGCAC.AAGCGCiTCTGATAAAACAGAA rrrGCCTGGCGGCAGTAGCGCGGTGGTCCC
ACCTGACCCCATGCCGAACTCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTC
TCCCCATGCGAGAGTAGGGAACTGCCAGGCATCAAATAAAACGAAAGGCTCAGTCGAAAG
ACTGGGGCC TTTCGTTTTATCTG TTGITTGICGGTGAACGCTCTCCTGAGTAGGACAAAT
CCGCCGGGAGCGGA1T1GAACG1TGCGAAGCAACGGCCCGGAAGGT
>pZK3_E208mK_forward read, MWG
CATCCGCCAAAACAGCCAAGCTTAGTGATGGTGATGGTGATGAGATCCGTGTTTATGGCA 
ACAGTTGATTTTGCCTTCIX3ACTGCTCTAGGA(30TCCAGCATCTCCTCAATGATGGCCCG 
A AGTGCCCGGCCCAGCTGGTCTGC ATTGT ACGGCTTGCCC AG AGGGGGC ACGTG AAC AAA 
GGCTGAGCGGCCGTGACICTGG TACAGAGAGGIAIAGTAGGT GÀAGTCGC AG AGGI ACCT 
GCCTGCATCTT G TGAA ATGGTCACTGACACATCTAAGCCCAGTGTAGTGACCCTCTTAC A 
CACAGCATCCAIGTCGATGATGG AGTCAATGCITTCCGGCCCGTCCTCC ACACAGCACTG 
GGAGCCGGGGCAGAATCGGCAGTI GTCCAGGC CCIT G IAACCCITGTI GTGTCCACACTT
210
CTCCAGl GTG ACrGCGGTTGCCA TGCCTG ACACGCCTACGTGCACC ACCAGCTGCGGACT
GTGCITCTCCCACAGGGCAGGGATGAGCCTCTGGACCGTCTGATACTCCACTGGAATCTC
ATACAC ATGTAGGTCCACGCTGTCCCCAAGCCCTAGTTICTCCAGCTCCTGGACCGCA AT
CCAGCTGGCATTCACAGTGTGTTCCCCAAAAGGGCCGAATCCCGTCACCACCACCGCCTT
CCTGGGCTGCTCCATGGTTAATTTCTCCTCTTTAATGAATTCTGTTTCCTGTGTGAAATT
GTTATCCGCTCACAATTCCACACATTATACGAGCCGATGATTAATTGTCAACAGCTCATT
TCAGAATATTTGCCAGAACCGTTATGATGTCGGCGCAAAAAACATTATCCAGAACGGGAG
TGCGCCTTGAGCGACACGAATTATGCAGTGATTTACGACCTGCACAGCCATACCACAGCT
TCCGATGGCTGCCrGACGCCAGAAGCATTGGTGCACCGTGCAGTCGATAAGCCCGGATCG
CTCTAGAGCGATCCrCIACGCCGGACGCATCGTGGCCGGCATCACCGGCGCCA
>pZK3_E208mK_reverse read. MWG
AGAGGAGAATTAACCATGGAGCAGCCCAGGAAGGCGGTGGTGGTGACGGGATTCGGCCCT 
TTT GGGG A AC AC ACT GTG A ATGCC AGCTGG ATF GCGGTCC AGG AGCTGG AG A AACT AGGG 
CTTGGGG AC AGCGTGGACCT AC AT GTGT ATG AGATTCCAGTGGAGT ATCAG ACGGTCCAG 
AGGCTCATCCCTGCCCTGTGGGAGAAGCACAGTCCGCAGCTGG1GGTGCACGTAGGCGTG 
TC AGGC ATGGC AACCGC AGT C AC ACTGG AG A AGT GTGG AC AC A AC A AGGGTTAC AAGGGC 
CTGGACAACTGCCGATTCTGCCCCGGCTCCCAGTGCTGTGTGGAGGACGGGCCGGAAAGC 
ATTGACTCCATCATCGACATGGATGCTGTGTGTAAGAGGGTCACTACACTGGGCTTAGAT 
GT GT C AGT G ACC A ITTC AC A AG ATGCAGGC AGGT ACCTCTGCG ACTTC ACCT ACT AT ACC 
TCTCTGTACCAGAGTCACGGCCGCTCAGCCTTTGTrCACGTGCCCCCTCTGGGCAAGCCG 
TACAATGCAGACCAGCTGGGCCGGGCACTTCGGGCCATCA H  GAGGAGATGCTGGACCTC 
CTAGAGCAGTCAGAAGGCAAAATCAACTGTTGCCATAAACACGGATCTCATCACCATCAC 
CATCACTAAGCTTGGCTGTTTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAA 
ATCAGAACGCAGAAGCGGTCrGATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGT 
CCCACCTGACCCCATGCCGAACTCAGAAGTG AAACGCCGTAGCGCCGATGGTAGTG1GGG 
GTCTCCCCATGCGAGAGTAGGGAACTGCCAGGCATCAAATAAAACGAAAGGCTCAGTCGA 
A AG ACT GGGGCCTTT1 CGTTT ATCT GTTGTn GTCGGTG AACGCTCTCCTG AGT AGG AC A A 
ATCCGCCGGGAGCGGATTTGAACGTTGCGAAGCAACGGCCCGG
>pZK_E85mD_forward read. MWG
C A A A C A G C C A A G C T T A C iT G A T G G T G A T G C .T G A T G A G A T C C G T G T T T G T G G C A A T A G T T G A
TTTTGCCCTCTGACTGCTCCAGGAGGTCCAACATCTCCTCAATGATGGCTCTCAGTGCCC
TGCCCAGCTGGICCGCG H  GTACGGCTTCCCCAGTGGGGGCACG1GGACGAAGGCTGATC
GACCGTGACTCrGGTACAAAGAGGTGTAGTAGGTAAAGTCGCAGAGATATCTGCCGGCAT
CCTGCGAGATGGTCACCGACACATCCAGGCCCAACGTGGTGACTCGCTTGCACACAGCAT
CCATGTCGATGATGGAGTCAATGCrTTCAGGCCCGTCCTCCACGCAGCACTGGGAGCCGG
GGC A A AAGCGGC AGTTGTCC AGCCCCTT GT AGCC CITGTTGT GTCC AC ATTT ATCC AGT G
TGACTGTGGTCGCCATGCCTGACACCCCCACATGCACCACCAGCTGTGGACTGTGCTTCT
CCCACAGC.GCGGGGATGAC.TCTCTGGACTGTTTGGTACTCAACCGGAATCTCGTACACAT
GCAGGTCCACGCTGTCGCCAAGGCCTAGCTTTTCTAGCTCCTGAACTGCAATCCAACTGG
CGTTCACGGTGTGTTCCCCAAAAGGGCCAAATCCCGTCACTACCACCGCCrrCCTCGGCT
G C T C C A T G G T I A A T T T C T C C T C n T A A T G A A T T C T G T T T C C T G T G T G A A A T T G T T A T C C G
CTCACAATTCCACACA IT AIACGAGCCGATGATTAATTGTCAACAGCTCA
> pZK E85niD reverse read. MWG
ATGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACC
G T G A A C G C C A G T T G G A T T G C A G T T C A G G A G C IA G A A A A G C T A G G C C T T G G C G A C A G C G T G
G ACCTGC AT GT GT ACG AG ATT CCGGTTG AGT ACC A AACAGTCC AG AG ACTC AT CCCCGCC
CTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACC
A C A G T C A C A C rG G A T A A A T G T G G A C A C A A C A A G G G C T A C A A G G G G C T G G A C A A C T G C C G C T
TTrGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATC
GACATGGATCÎCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATC
TCGCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGT
CACGGTCGATCAGCCrrCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAG
CTGGGCAGGGCACTGAGAGCCATCAITGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAG
GGCAAAATCAACI ATI GCCACAAACACGGA rCTC ATCACCATCACC A TC ACIAAGCTTGG
C I g tTTTGCiCGGATCiAGAG AAGATTTTCAGCCTGATACAGATTAAATCAGA a c g c a g a a g
CGGTCTGATAA A ACAG A ATTTGCCIGGC GG
211
>pZK E85niQ_forward read. MWG
GATGGTG Al GGTGATG AG ATCCGTGTTTGTGGC AATAGITGATTTTGCCCTCTG ACTGCTCCA
GGAGGTCCAACA rCTCCTCAATG ATGGCTC1C AGTGCCCTGCCCAGCTGGTCCGCGTTGTAC
GGCTT CCCC AGTGGGGGC ACGTGG ACG A AGGCTG ATCG ACCGT G ACT CT GGT AC A A AG AGG
TGTAGTAGGTAAAGTCGCAGAGATATCTGCCGGCATCCTGCGAGATGGTCACCGACACATCC
AGGCCCAACGTGGTGACTCGCTTGCACACAGCATCCATGTCGATGATGGAGTCAATGCTTTC
AGGCCCGTCCTCCACGCAGCACTGGGAGCCGGGGCAAAAGCGGCAGTTGTCCAGCCCCTTG
TAGCCCTTGrrG IGTCCACATTTCTGCAGTGTG ACTGTGGTCGCCATGCCTG ACACCŒCACA
TGCACCACCAGCrGTGGACTGTGCrrCTCCCACAGGGCGGGGATGAGTCTCTGGACTGTTTG
GTACTCAACCGGAATCTCG TACACATGCAGGTCCACGCTGTCGCCAAGGCCTAGCmTCTA
GCTCCIGA ACTGCAATCCAACTGGCG TI CACGGTGTGTTCCCCAAAAGGGCCAAATCCCGTC
ACTACCACCGCCTTCCTCGGCTGCTCCATGGTTAATTTCTCCTCTTTAATGAATTCTGTTTCCT
GTGTGAAATTGTTATCCGCTCACAATTCCACACATTATACGAGCCGATGATTAATTGTCAAC
AGCTCATTTCAGAATATTTGCCAGAACCGTTATGATGTCGGCGCAAAAAACATTATCCAGAA
CGGGAGTGCGCCTTGAGCGACACGAATTATGCAGTGAITTACGACCTGCACAGCCATACCAC
AGCTTTCGATGGCTGCCTGACGCCAGAAGCATTGGTGCA
> pZK E85raO_reverse read, MWG
AGCCGAGGAAGGCGGTGGT AGTGACGGGATTT GGCCCTTTTGGGG AAC AC ACCGTG AACGC
CAG H  GGATTGCAGTTC AGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCAT
GTGIACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAA
GCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTG
CAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCmTGCCCCGGCT
CCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTG
TGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAG
AT ATCTCTGCG ACTTTACCTACT ACACCTCTTTGTACCAG A G I C ACGGTCG ATC AGCCTTCGT
CCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGCC
ATCATrGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCACA
AACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGCGGATGAGAGAAGAT
ITTCAGCCTGATACAGATrAAATCAGAACGCAGAAGC'GGTCTGATAAAACAGAATTTGCCTG
GCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGAAGTGAAACGCCGTAG
CGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGGAACTGCCAGGCATCAAATAA
AACG AAAAGGCTC AGTCG AAAG ACTGGGGCCTTTCGTTTT ATCT GTT GTTTGTCGGT GA ACG
CTCTCCTGAGTAGGACAAAT
>pZK_E85mK forward read, MWG
G ATGGTGATGGIGATG AG ATCCGTGTTTGTGGC AATAGTTGATTTTGCCCrCTG ACTGCTCCA
GGAGGTCCAACATCTCCTCAATGATGGCTCTCAGTGCCCTGCCCAGCTGGTCCGCGTTGTAC
GGCrrCCCCAGTGGGGGCACGTGGACGAAGGCTGATCGACCGTGACTCTGGTACAAAGAGG
TGTAG1 AGG IAAAGTCGCAGAGAI ATCTGCCGGCATCCTGCGAGATGGTCACCGACACATCC
AGGCCCAACGTGGTGACTCGCTTGCACACAGCATCCATGTCGATGATGGAGTCAATGCnTC
AGGCCCGTCCTCCACGCAGCACTGGGAGCCGGGGCAAAAGCGGCAGTTGTCCAGCCCCTTG
TAGCCCTTGTTGTGTCCACATTTCTTCAGTGTGACTGTGGTCGCCATGCCTGACACCCCCACA
TGCACCACCAGCTGTGGACTGTGCrrCTCCCACAGGGCGGGGATGAGTCTCTGGACTGTTTG
GT ACTC A ACCGGA ATCTCGTAC ACATGC AGGTCC ACGCTG TCGCC AAGGCCTAGCTTTTCIA
GCTC CTG AACT GC A AT CC AACT GGCGTT C ACGGT GTGTTCCCC A A A AGGGCC AAAT CCCGT C
ACTACCACCGCCTTCCTCGGCTGCTCC'ATGGTTAATTTCTCCTCnTAATGAATTCTGTTTCCT
GTGTGAAATTGTrATCCGCTCACAATTCCACACATTATACGAGCCGATGATTAATTGTCAAC
AGCTCATTTCAGAATATTTGCCAGAACCGTTATGATGTCGGCGCAAAAAACATTATCCAGAA
CGGGAGTGCGCCTTGAGCGACACGAATTATGCAGTGATTTACGACCTGC’ACAGCCATACCAC
AGC1TCCGATGGCTGCCIG ACGCC AG AAG
> pZK_E85mK_reverse read, MWG
AGC AGCCG AGG AGGCGGT GGT AGTG ACGGG ATIT GGCCCTITT GGGG AAC AC ACCGT G A AC 
GCCAGTTGG ATT CiC AGTT C AGG AGCT AG A A A AGCT AGGC C IT  GGCG AC AGCGT GG ACCTGC 
ATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAG 
AAGCAC AG I CCACAGC'I GG 1 GG I GCATGTGGGGGIGTCAGGCATGGC GACCACAGTCACAC 
IGAAGAAAIGTGGACACA ACAAGGGCTACAAGGGGCTGG ACAACTGCCGCTTTTGCCCCGG 
CTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTG 
TGTGC AAGCGAG ICACCACGTIGCKiCCrGGAl GTGTCGGTGACCATCTCGCAGGATGCCGGC
212
AGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTC 
GTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAG 
CCATCATTGAGGAGATGTTGGACCTCCrGGAGCAGTCAGAGGGCAAAATCAACTATTGCCAC 
AAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGCGGATGAGAGAAGA 
TTITCAGCCTGATACAGAn AAA rCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGCCT 
GGCGGC AGT AGCGCGGT GGTCCC ACCT G ACCCC ATGCCG A
ACTCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGG 
G A ACTGCC AGGC ATC AAAT AAA AC G AAAGGCT C AGTCG A A AG ACT GGGCCmTCGTTTT AT 
CTGTTGTTTGTCGGTGAACGCTCTCCTGAGTAGGACAAATCCGCCGGGAGCGGGAT
>pZK G35mD_forward read. MWG
GTTG ATTITGCCCTCTGACTGCTCCAGGAGGTCC AACATCTCCTCAATGATGGCTCTCAG
TGCCCTGCCCAGCTGGTCCGCGTTGTACGGCTTCCCCAGTGGGGGCACGTGGACGAAGGC
TGATCGACCGTGACTCTGGTACAAAGAGGTGTAGTAGGTAAAGTCGCAGAGATATCTGCC
GGCATCCTGCGAGATGGTCACCGACACATCCAGGCCCAACGTGGTGACTCGCTTGCACAC
AGCATCCATGTCGATGATGGAGTCAATGCTTTCAGGCCCGTCCTCCACGCAGCACTGGGA
GCCGGGGCAAAAGCGGCAGTTGTCCAGCCCCTTGTAGCCCTTGTTGTGTCCACATTTCTC
CAGTGTGACTGTGGTCGCCATGCCTGACACCCCCACATGCACCACCAGCTGTGGACTGTG
CTTCTCCCACAGGGCGGGGATGAGTCrCTGGACTGTTTGGTACTCAACCGGAATCTCGTA
CACATGCAGGTCCACGCTGTCGCCAAGGTCTAGCTTTTCTAGCTCCTGAACTGCAATCCA
ACTGGCGTTCACG
> pZK_G35mD_reverse read, MWG
GGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCrrTTGGGGAACACACCGT
GAACGCCAGTrGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGA
CCTGCATGTGTACGAGATTCCGG1TGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCT
GTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCAC
AGTCAC ACTGGAGA AA IG IGG ACACAACAAGGGCTAC AAGGGGCTGGAC AACTGCCGCTT
TTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGA
CATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTC
GCAGGATGCCGGCAGA IATCTCTGCGACnTACCTACT ACACCrCTTrGTACCAGAGTCA
CGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCT
GGGCAGGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGG
CAAAATCAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCT
g t t t t t g g c g <;a t g a g a g a a g a t t t t c a g c c t g a t a c a g a t t a a a t c a g a a c g c a g a a g c
GGTCTGAT AAAAC AGAATTTGCC 
>pZK N90mD forward read. MWG
TTAGTG ATGGTG ATGGTG ATG AG ATCCGT’GTTTGTGGC AAT AGTT G ATTTT GCCCT CTG A 
CTGCTCCAGGAGGTCC AACATCTCCTCAA1GA TGGCICTCAGTGCCCTGCCCAGCTGGTC 
CGCGTTGTACGGCTTCCCCAGTGGGGGCACGTGGACGAAGGCTGATCGACCGTGACTCTG 
GTACAAAGAGGTGTAGTAGGTAAAGTCGCAGAGATATCTGCCGGCATCCTGCGAGATGGT 
CACCGACACATCCAGGCCCAACGTGGTGACTCGCTTGCACACAGCATCCATGTCGATGAT 
GGAGTCAATGCTTTCAGGCCCGTCCTCCACGCAGCACTGGGAGCCGGGGCAAAAGCGGCA 
GTI'GTCC AGCCCCTT GT AGCCCTTGTCGT GTCC ACATTTCTCC AGT GT G ACTGTGGTCGC 
CATGCCTGACACCCCCACATGCACCACCAGCTGTGGACTGTGCTTCTCCCACAGGGCGGG 
GATG AGTCTCIGGACIGTTTGGTACTCAACCGG AA1CTCGTACAC ATGCAGGTCCACGCT 
GTCGCCAAGGCCIAGCTTTTCrAGCTCCTGAACTGCAATCCAACTGGCGlTCACGGTGTG 
TTCCCCAAAAGGGCCAAATCCCGTCACTACCACCGCCTTCCTCGGCTGCTCCATGGTTAA 
TTTCTCCTCTTTAATGAATTCTG rrrCCTGTGTGAAATTGTTATCCGCTCACAATTCCAC 
ACA rrATACG AGCCGATG A TI AA1TGTCAACAGCTCATTTCAG AATATITGCCAG AACCG 
TT ATGATGTCGGCGCAAAAAACATTATCCAGAACGGGAGTGCGCCrrGAGCGACA
> pZK_ N90mD reverse read. MWG
GGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGT 
GAACGCCAGTTGGATTGCAGTTCAGCiAGCTAGAAAAGCTACìGCCTTGGCGACAGCGTGGA 
CCTGC AT GTGT ACG AG ATTCCGG TTGAGTACC AAACAGT CC AGAG ACTC AT CCCCGCCCT 
GT GGG AG AAGC AC AGTCC AC AGCTGGTGGTGC AT GT GGGGGT GTC AGGC AT GGCG ACC AC 
AGTCACACTGG AG AAATGTGGACACGACAAGCKìCTACAACKKKìCTGGACAACTGCCGCIT 
TTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGA
213
CATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTC
GCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCA
CGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCT
GGGCAGGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGG
CAAAATCAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCT
GTTTTGGCGGATGAGAGAAGA mTCAGCCTGATACAGA TrAAA TCAGAACGCAGAAGCG
GTCTGAIAA AACAG AAnTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTG ACCCC ATGC
CGAACTCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAG
TAGGGAACTGCCAGGCATCAAATAAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCG
nTTATCTGTTGTTTGTCGGTG AACGCT'CTCCTG AGTAGG ACAAATCCGCCGGGAG
>pZK_M192mT_forward read, MWG
GCCAAGCTTAGTGATGGTGATGGTGA rGAGATCCGTGTTTGTGGCAATAGTTGATTTTGC 
CCT CT G ACT GCTCC AGG AGGTCC A ACGTCTCCTC AATG ATGGCT CTC AGT GCCCTGCCC A 
GCTGGTCCGCGTTGTACGGCTTCCCCAGTGGGGGCACGTGGACGAAGGCTGATCGACCGT 
GACTCTGGTACAAAGAGGTGTAGTAGGTAAAGTCGCAGAGATATCTGCCGGCATCCTGCG 
AG ATGGTCACCG ACACA1CCAGGCCCAACGTGGTGACTCGCTTGC ACACAGCATCC ATGT 
CGA1GATGGAGTCAATGCTTTCAGGCCCGTCCTCCACGCAGCACTGGGAGCCGGGGCAAA 
AGCGGCAGTTGTCCAGCCCCTTGTAGCCCTTGTTGTGTCCACATTTCTCCAGTGTGACTG 
TGGTCGCCATGCCTGACACCCCCACATGCACCACCAGCTGTGGACTGTGCTTCTCCCACA 
GGGCGGGG ATG AGT CT CTGG ACTGTTTGGT ACTC AACCGG AAT CTCGT AC AC AT GC AGGT 
CC ACGCTGTCGCC A AGGCCTAGC ITrrCTAGCTCCTG AAC1GC AATCC AACTGGCGTTC A 
CGGTGTGTTCCCCAAAAGGGCCAAATCCCGTCACTACCACCGCCITCCTCGGCTGCTCCA 
TGGTTAATTTCTCCTCTTTAATGAATTCTGTTTCCTG1GTGAAATTGTTATCCGCTCACA 
ATTCCACACATTATACGAGCCGATGATTAATTGTCAACAGCTCAlTTCAGAATArrTGCC 
AG AACCGTT ATG AT GTCGGCGC A A A A A AC ATr ATCC AG A ACGGG AGTGCGC CTTGAGCGA 
CACGAATTATGCAGTC.ATTTACGACCTGCA
>pZK M 192m I reverse read, MWG
TGGAGCAGCCGACiGAAGGCGGTGGTAGl G ACGGGA TTTGGCCCTTTTGGGG AAC ACACCG
TGAACGCCAGTTGGATTGCAGTrCAGGAGCTAGAAAAGCTAGGCCn GGCG ACAGCGTGG
ACCTGCATGTGTACGAGATTCCGGTrGAGTACCAAACAGTCCAGAGACTCATCCCCGCCC
TGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCA1GGCGACCA
CAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCT
TTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCG
ACATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCT
CGCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTC
ACGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGC
TGGGCAGGGCACTGAGAGCCATCATTGAGGAGACGTTGGACCTCCTGGAGCAGTCAGAGG
GCAAAATCAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGC
TGrnTGGCGGATGAGAGAAGATTTrCAGCCTGATACAGAlTAAATCAGAACGCAGAAGC
GGTCTG AT AAA AC AG A ATTTGCCT GGCGGC AGT AGCGCGGTGGT CCCACCTG ACCCC AT G
CCGAACTCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGA
GTAGGGAAC'TGCCAGGCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCG
TTTTATCT1 GTT GTTT GTCGGT G AACGCTCTCCTG
>pZK_K.94mR_forward read, MWG
CAAACAGCCAAGCTTAGTGATGGTGATGGTGATGAGATCCGTGTTTGTGGCAATAGTTGA 
TTTTGCCCTCTGACTGCTCCAGGAGGTCCAACATCTCCrCAATGATGGCTCTCAGTGCCC 
TGCCCAGCTGGTCCGCGTTGTACGGCTTCCCCAGTGGGGGCACGTGGACGAAGGCTGATC 
G ACCGTGACTC1GGTACA AAG AGGTGTAGTAGGTAAAGTCGCAG AGATATCTGCCGGCAT 
CCTGCGAGA1GGTCACCGACACATCCAGGCCCAACGTGGTGACTCGCTTGCACACAGCAT 
CCATGTCGATGATGGAGTCAATGCTTTCAGGCCCGTCCTCCACGCAGCACTGGGAGCCGG 
GGCA A AAGCGGCAGTTGTCCAGCCCCCIGTAGCCCTTGTTGTGTCCACATTICTCC AGTG 
TGACTGTGGTCGCCATGCCTGACACCCCCACATGCACCACCAGCTGTGGACTGTGCTTCT 
CCCACAGGGCGGGGATGAGTCTCTGGACTGTTTGGTACTCAACCGGAATCTCGTACACAT 
GCAGCiTCCACGCTGTCGCCAAGGCCI AGC1TTTC1AGCICCIGAACI GC A A TCCA ACTGG 
CGTTCACGG1G1GITCCCCAAAAGGGCCAA ATCCCGTCACTACCACCGCCTTCCTCGGCT 
GCTCCATGGlTAATTTCTCCrCTTTAATGAATTCTGTTTCCTGTGTGAAATTGTTATCCG 
CTCACAATTCCACACATTATACGAGCCGATGATTAATTGTCAACAGCTCATTTCAGAATA
214
TTTGCCAGAACCGTTATGATGTCGGCGCAAAAAACATTATCCAGAACGGGAGTGCGCCIT
GAGCGACACGAATTATGCA
>pZK K94mR reverse read. MWG
ATGG AGC AGCCG AGG AAGGCGGTGGT AGTG ACGGG ATTT GGCCCTnTGGGG AAC AC ACC
GTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTG
GACCTGCATGTGTACGAGATTCCGGTrGAGTACCAAACAGTCCAGAGACTCATCCCCGCC
CTGIGGGAGA AGCACAGTCCACAGCrGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACC
ACAGTC AC ACTGG AG A AA TGTGG AC AC AAC AAGGGCTAC AGGGGGCTGGAC A ACTGCCGC
TTIT GCCCCGGCT CCC AGT GCT GCGTGG AGG ACGGGCCTG AAAGC ATTG ACTCC ATC ATC
GACATGGATC.CTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATC
TCGCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCrCTTTGTACCAGAGT
CACGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAG
CTGGGCAGGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAG
GGCAAAATCAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCITGG
CTGTTTTGGCGG ATG AG AG AAGATTTTC AGCCTG AT AC AG ATT AAATC AGAACGCAG AAG
CGGTCTGAIA AAACAG AA ITTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCAT
GCCGAACTCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAG
AGTAGGGA ACTGCC AGGC ATCA A AT A A A A ACG A A A AG
>pZK_A 165mV forward read. MWG
CCAAGCTTAGTGATGGTGATGGTGATGAGATCCGTGTTrGTGGCAATAGTrGATTITGCC
CTCTGACTGCTCCAGGAGGTCCAACATCTCCTCAATGATGGCTCTCAGTGCCCTGCCCAG
CTGGTCCGCGTTGTACGGCTTCCCCAGTGGGGGCACGTGGACGAAGACTGATCGACCGTG
ACTCTGGTACAAAGAGGTGTAGTAGGTAAAGTCGCAGAGATATCTGCCGGCATCCTGCGA
GATGGTCACCGACACATCCAGGCCCAACGTGGTGACTCGCTTGCACACAGCATCCATGTC
G ATGATGG AGTCA ATGCITTCAGGCCCGTCCTCCACGCAGCACTGGGAGCCGGGGCAA AA
GCGGC AGTTGTCC AGCCCCTT GT AGCCCTTGTr GT GT CC AC ATTTCTCC AGTGT G ACT GT
GGTCGCCATGCCTGACACCCCCACATGCACCACCAGCTGTGGACTGTGCTTCTCCCACAG
GGCGGGGATGAGTCTCTGC.ACTGTTTGGTACTCAACCGG AATCTCG1ACACATGCAGGTC
CACGCTGTCGCCAAGGCCTAGCTTTTCTAGCTCCTGAACTGCAATCCAACTGGCGTTCAC
GGTGTGTTCCCCAAAAGGGCCAAATCCCGTCACTACCACCGCCTTCCTCGGCTGCTCCAT
GGTT AATTTCT CCT CTTT A AIG AATT CT GTTTCCTGTGTG AAATT GTT ATCCGCTC AC A A
TTCCACACA TIATACGAGCCGATGATTAATTGTCAACAGCTCATTTCAGAATATTTGCCA
GAACCG1TATGATGTCGGCGCAAAAAACA1TATCCAGAACGGGAGTGCGCCTTGAGCGAC
ACGAATTATGCAGTGATTTACGACCTGCACAGCCATACCACAGCTTCC
>pZK_ A165m V reverse read. MWG
GAGCAGCCGAGG AAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTG
A ACGCC AGTT GG ATT GC AGTT C AGG AGCT AG AAAAGCT AGGCCTT GGCG AC AGCGTGG AC
CTGCATGTG1ACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTG
TGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGG<jTGTCAGGCATGGCGACCACA
GTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTT
rGCCCCGGCTCCCAGTGCIGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGAC
ATGGATGCTGTGTGC'AAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCG
C AGG AIGCCGGCAGA TATCTCTGCGACITIACCIACTACACCTCTTTGTACCAGAGTCAC
GGTCG AT C AGTCTTCGTCC ACGT GCCCCC ACT GGGG A AGCCGT AC A ACGCGG ACC AGCT G
GGCAGGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGC
AAAATCAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTG
TrTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGG
TCTGATAAAACAGAATTTGCCTGGCGGCAGT
>pZK_A27mT_forward read, MWG
GATGGTGATGOTGATGAGATCCGTGTTTGTGGCAATAGTTGATTTTGCCCTCTGACTGCT 
CCAGGAGGTCCAACATCTCCTCAATGATGGCTCTCAGTGCCCTGCCCAGCTGGTCCGCGT 
TGTACGGCTTCCCCAGTGGGGGCACGTGGACGAAGGCTGATCGACCGTGACTCTGGTACA 
AACiACiGTGTAGTAGGTAAAGTCGCAGAGATATCTGCCGGCATCCTGCGAGATGGTCACCG 
ACACAICCAGGCCCAACGTGGTGACICGC n  GC ACACAOCA rCCAl GTCGATOATGOAOT 
CAATGCTTTCAGGCCCGTCCTCCACGCAGCACTGGGAGCCGGGGCAAAAGCGGCAGTTGT 
CCAGCCCCTTGTAGCCCTTGTTGTGTCCACATTrCTCCAGTGTGACTGTGGTCGCCATGC 
CTGAC ACCCXX.’ AC ATGC ACC ACXTAGCIGTGG ACTGTGCTTCTCCC AC AGGGCGGGG ATG A
215
GTCTCTGGACTGTTTGGTACTCAACCGGAATCTCGTACACATGCAGGTCCACGCTGTCGC 
CA AGGCCTAGCTTTTCT AGCTCCTG AACTGT AATCCA ACTGGCGTTC ACGGTGTGTTCCC 
C A A A AGGGCCA A ATCCCGTCACT ACC ACCGCCTTCCTCGGCTGCTCC ATGGTT A ATTTCT 
CCTCTTTA ATG A ATTCTGTTTCCTGTGTGA A ATTGTT ATCCGCTC AC A ATTCCAC AC ATT
AT ACCì AGCCG ATGATTAATTGTCAAC AGCTC ATTTC AG A A T ATTT GCC AG A ACCGTT ATG 
ATGTCGGCGCAAAAAACATTATCCAGAACGGGAGTGCGCCTTGAGCGACACGAATTATGC 
AGTGATTTACGACCTGCACAGCCATACCACAGCTTCCGATGGCTGCCTGACGCCAGAAGC 
ATTGGTGCACCGTGC AGTCGATAACCCGGATCGCT
>pZK_A27mT_reverse read. MWG
AGCCG AGG AAGGCGGTGGT AGTGACGGG ATTTGGCCCTTTTGGGG A ACACACCG ATG AAC
GCCAGTTGGATTACAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTG
CATGTGT ACG AG ATTCCGGTTG AGT ACCA AACAGTCC AG AG ACTCATCCCCGCCCTGTGG
GAGAAGC AC AGTCC ACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTC
ACACTGG AG A A ATGTGG AC AC AAC A AGGGCT AC AAGGGGCTGGAC AACTGCCGCTTTTGC
CCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATG
C.ATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAG
G ATGCCGGC AG AT ATCTCTGCG ACTTT ACCT ACT AC ACCTCTTTGT ACCAG AGTCACGGT
CG ATC AGCCTTCGTCC ACGTGCCCCC ACTGGGGAAGCCGT AC A ACGCGG ACCAGCrGGGC
AGGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGACiCAGTCAGAGGGCAAA
ATCAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTT
TGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCT
GATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAA
CTCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGG
GAACTGCCAGGCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCCTTTCGTTTT
ATCTGTTGTTTGT
>pZK_G77mD_forward read. MWG
T CCCC AGT GGGGGC ACGT GG ACG AAGGCTG AT CG ACCGTG ACTCT GGT AC A AAG AGGT GT
AGTAGGTAAAGTCGCAGAGATATCTGCCGGCATCCTGCGAGATGGTCACCGACACATCCA
GGCCCAACGTGGTGACTCGCrTGCACACAGCATCCATGTCGATGATGGAGTCAATGCTTT
CAGGCCCGTCCTCCACGCAGCACTGGGAGCCGGGGCAAAAGCGGCAGTTGTCCAGCCCCT
TGTAGCCCTTGTTGTGTCCACATTTCTCCAGTGTGACTGTGGTCGCCATGTCTGACACCC
CCACATGCACCACCAGCTGTGGACTGTGCTTCTCCCACAGGGCGGGGATGAGTCTCTGGA
CTGTTTGGTACTCAACCGGAATCTCGTACACATGCAGGTCCACGCT
>pZK_G77mD_rcvcrsc read. MWG
TGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCACAGTCCACAGCT 
GGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGGAGAAATGTGGACA 
CAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCTCCCAGTGCTGCGT 
GGAGG ACGGGCCTGAAAGCATTGACTCCATCATCGACA IGGATGCrGTGTGCAAGCGAGT 
CACCACG rrGGGCCTGGA rGTGTCGGTGACCATCTCGCAGGATGCCGGCAGATATCTCTG
>pZK_P67mR_forward read, MWG
GCCAAGCTTAGTGATCK i I ( iA I (X2TGA1 GAGA IC C CÌIGC ITrGTGGCAATAGTTGATTTTG
CCCTCTGACTGCTCCAGGAGGTCCAACATCTCCTCAATGATGGCTCTCAGTGCCCTGCCC
AGCTGGTCCGCGTTGTACGGGTTCCCCAGTGGGGGCACGTGGACGAAGGCTGATCGACCG
TGACTCTGGTACAAAGAGGTGIAGTAGGTAAAGTCGCAGAGATATCTGCCGGCATCCTGC
GAGATGGTCACCGACACATCCAGGCCCAACGTGGTGACTCGCTTGCACACAGCATCCATG
TCGATGATGGAGTCAATGCTTTCAGGCCCGTCCTCCACGCAGCACTGGGAGCCGGGGCAA
AAGCGGCAGTTGTCCAGCCCCTTGTAGCCCTTGTTGTG 1C CACATTTCTCCAGTGTGACT
GTGGTCGCCATGCCTGACACCCCCACATGCACCACCAGCTGCGGACTGTGCTTCTCCCAC
AGGGCGGGGATGAGTCTCTGGACTGTTTGGTACTCAACCGGAATCTCGTACACATGCAGG
TCC ACGCTGTCGCCA AGGCCTAGCTTTTCTAGCTCCTG A ACTGC A ATCC A ACTGGCG TTC
ACGGTGTGTTCCCCAAAAGGGCCAAATCCCGTCACTACCACCGCCTTCCTCGGCTGCTCC
ATGGTTAATTTCTCCTCTÍTAATGAATTCTGTTTCCTGTGTGAAATTGTTATCCGCTC
>pZK P67mR_forward read, MWG
ACiCCCiAOOAAGCiCGGTGGTAGTGACGGGATnGGCCCmTGGGGAACACACCGTGAACG 
CCAG n  GGA1IGCAGIT CAGGAGC I ACiAAAACiC TAGCiC CTTGGCGACAGCGTGGACCTGC 
ATGTGIACGAGATTCCGGTIGAGTACCAAACAGTCCAGAGACTCA TCCCCGCCCTGTGGG 
AC.AAGC'ACAGTCCGCAGCTGCrrGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCA
216
C ACTGG AG AAATGT GG AC AC AAC A AGGGCT AC A AGGGGCT GG AC A ACT GCCGCTTTT GCC
CCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGG
ATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGG
AT GCCGGC AG AT ATCTCTGCG ACTTTACCTACT,AC ACCT CTTTGT ACC AG AGT CACGGTC
GATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCA
GGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAA
TCAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTT
GGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTG
ATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAAC
TC AG AAGT GAAACGCCGT AGCGCCG ATGGT AGTG
>pZK N22mH [forward read, MWG
CATGGTGATGAGATCCGTGTTTGTGGCAATAGTTGATTTTGCCCTCTGACTGCTCCAGGA 
GGTCC A AC ATCT CCTC A ATG AT GGCTCTC AGTGCCCTGCCC AGCTGGTCCGCGTTGT ACG 
GCTT CCCC AGTGGGGGC ACGTGG ACG A AGGCT G ATCG ACCGTG ACT CT GGT AC A A AG AGG 
TGTAGTAGGTAAAGTCGCAGAGATATCTGCCGGCATCCTGCGAGATGGTCACCGACACAT 
CCAGGCCCAACGTGGTGACTCGCTTGCACACAGCATCCATGTCGATGATGGAGTCAATGC 
TTT C AGGCCCGT CCTCC ACGC AGC ACT GGG AGCCGGGGC AA AAGCGGC AGTTGTCC AGCC 
CCTTGTAGCCCTTGTTGTGTCCACATTTCTCCAGTGTGACTGTGGTCGCCATGCCTGACA 
CCCCCACATGCACCACCAGCTGTGGACTGTGCTTCTCCCACAGGGCGGGGATGAGTCTCT 
GGACTGITTGGTACTCAACCGGAATCTCGTACACATGCAGGTCCACGCTGTCGCCAAGGC 
CTAGCrrnCTAGCTCCTGAACTGCAATCC.\ACTGGCGTTCACGGTC»TGTTCCCCAAAAG 
GGCCAAATCCCGTCACTACCACCGCCTTCCTCGGCTGCTCCATGGTTAATTTCTCCTCTT 
TAATG A ATTCTGTTrCCrGTGTG A A ATTGTT ATCCGCTCAC AA1TCC AC ACATTATAC G A
g c c g a t g a t t a a t t g t c a a c a g c t c a t t t c a g a a t a t t t g c c a g a a c c g t t a t g a t
>pZK_N22mH_rcversc read. MWG
CGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTGCACGCCA
GTTGGATTGCAGlTCAGGAGCrAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCATG
TGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGA
AGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACAC
TGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCG
GCTCCCAGTGCTGCGTGGAGGACGGGCCrGAAAGCATTGACTCCATCATCGACATGGATG
CTGTG1 GC'AAGCGAGTCACCACG TIGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATG
CCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGAT
CAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGG
CACTGAGAGCCATCA H  GAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAA ATCA
ACIA IT GCCAC A A ACACGG ATCrCATCACC ATC ACCAT CACT AAGCTTGGCTGTTTT GGC
GGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATA
AAACAGAATriGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCA
GAAGTGAAACGC
>pZK_P48mR_forward read. MWG
TGGGGTCAGGTGGGACCACCGCGCTACTGCCGCCAGGCAAATTCTGTTTTATCAGACCGC
TT CT GCGTT CT G ATTT AAT CT GT ATC AGiiCTG AAA AT CTT CT CT C ATCCGCC AA A AC AGC
CAAGCTTAGTGATGGTGATGGTGATGAGATCCGTGlTrGTGGCAATAGTTGATTTTGCCC
TClGACTGCTCCAGGAGGTCCAACATCrCCTCAATGATGGCTCTCAGTGCCCTGCCCAGC
TGGTCCGCGTTGTACGGCTTCCCCAGTGGGGGCACGTGGACGAAGGCTGATCGACCGTGA
CTCTGGTACAAAGAGGTGTAGTAGGTAAAGTCGCAGAGATATCTGCCGGC'ATCCTGCGAG
ATGGTCACCGACACATCCAGGCCCAACGTGGTGACTCGCTTGCACACAGCATCCATGTCG
ATGA1GGAGTCAAIGCTTTCAGGCCCGTCCICCACGCAGCACTGGGAGCCGGGGCAAAAG
CGGC AGTT GT CC AGCCCCTTGT AGCCCTT GTTGT GTCC AC ATITCT CC AGT GTG ACTGT G
GTCGCCATGCCTGACACCCCCACATGCACCACCAGCTGTGGACTGTGCTTCTCCCACAGG
GCGGGGATGAGTCTCTGGACTGTTTGGTACTCAACCCGAATCTCGTACACATGCAGGTCC
ACGCTGTCGCCAAGGCCTAGCTTTTCTAGCTCCTGAACTGCAATCCAACTGGCGTTCACG
G IG IG IICCX C A A A AGGGT AC A AATCCCCiTC ACTACC ACCCirCTTCCTCriC.rTC.CTCr
217
>pZK P48mR reverse read MWG
GGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGTACCCTTTTGGC.GAACACACCG
TGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGG
ACCTGCATGTGTACGAGATTCGGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCC
TGIGGGAGAAGCAC AGTCCACAGCTGG TGG1GCAIG1GGGGGTG TCAGGCATGGCG ACCA
CAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCT
TTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCG
ACATGGATCKTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCT
CCjCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTC
ACGGTCGATCAGCCriCGTCCACGTGC'CCCCACTGGGGAAGCCGTACAACGCGGACCAGC
TGGGCAGGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGG
GCAAAATCAACTArrGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGC
TG TnTGGCGGA IGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGC
GGTCTG AT AA AAC AG A ATTTGCCT GGCGGC AGTAGCGCGGTGGT CCC ACCT G ACCCC A
>pZK_P48mQ,D 143mH_forward read, MWG
TACGGCTTCCCCAGTGGGGGCACGTGGACGAAGGCTGATCGACCGTGACTCTGGTACAAA 
GAGGTGTAGTAGGTAAAGTCGCAGAGATATCTGCCGGCATGCTGCGAGATGGTCACCGAC 
ACATCCAGGCCCAACGIGGTG ACTCGCTTGCACACAGCATCCATGTCG ATGATGGAGTCA 
ATGC ITrCAGGCCCG ICCTCCACGCAGCACTGGGAGCCGGGGCAAAAGCGGCAGTTGTCC 
AGCCCCTTGI'AGCCCTTGTTGT GT CC AC ATTTCTCC AGT GTG ACT GT GGTCGCC ATGCCT 
GACACCCCCACATGCACCACCAGCTGTGGACTGTGCTTCTCCCACAGGGCGGGGATGAGT 
CTCIGGACTGTTTGGTACTCAACCTGAATCTCGTACACATGCAGGTCCACGCTGTCGCCA 
AGGCCT AGCTTT
>pZK P48mQ.D143mU_reverse read MWG
AAAGCTAGGCCTTGGCGACAGCGTGGACCTGCATGTGTACGAGATTCAGGTTGAGTACCA 
AACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCA 
TGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGGAGAAATGTGGACACAACAAGGG 
CT AC A AGGGGCT GG AC AACT GCCGCTTTT GCCCCGGCr CCC AGTGCT GCGTGG AGG ACGG 
GC CT G AA AGC ATTG ACTCC AT C ATCG AC AT GG AT GCT GTGTGC A AGCG AGTC ACC ACGTT 
GGGCCTGGATGTGTCGGTGACCATCTCGCAGCATGCCGGCAGATATCTCTGCGACTTTAC 
CTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGTCCACGTGCCCCCACT 
GGGGAAGCCGTA
>pZK P4mS. SI64mP_forward read. MWG
ATGGTG ATGGTGATGAG ATCCGTG1TIGTGGC AA IAGTTG ATTTTGCCCTCTG ACTGCTC
CAGGAGGTCCAACATCTCCTCAATGATGGCTCTCAGTGCCCTGCCCAGCTGGTCCGCGTT
GTACGGCTTCCCCAGTGGGGGCACGTGGACGAAGGCTGGTCGACCGTGACTCTGGTACAA
AGAGGTGTAGTAGGTAAAGTCGCAGAGATATCTGCCGGCATCCTGCGAGATGGTCACCGA
CACATCCAGGCCCAACGTGGTGACTCGCTTGCACACGGCATCCATGTCGATGATGGAGTC
AATGCTTTCAGGCCCGTCCTCCACGCAGCACTGGGAGCCGGGGCAAAAGCGGCAGTTGTC
CAGCCCCrrGTAGCCCTTGTTGTGTCCACATTTCTCCAGTGTGACTGTGGTCGCCATGCC
TG AC ACCCCC AC ATGC ACC ACC AGCT GTGG ACTGTGCTTCT CCC AC AGGGCGCiGG ATG AG
TCTCTGGACTGTTTGGTACTCAACCGGAATCTCGTACACATGCAGGTCCACGCTGTCGCC
AAGGCCT AGCTTTT CT AGCTCCT G AACT GC'AATCC AACT GGCGTTC ACGGTGTGTTCCCC
AAAAGGGCCAAATCCCGTCACTACCACCGCCTTCCTCGACTGCTCCATAGTTAATTTCTC
CrCTTTAATGAATTCTGTTTCCrGTGTGAAATTGTTATCCGCTCACAATTCCACACATTA
TACGAGCCGATGATTAATTGTCAACAGCTCATTTCAGAA1A riTGCCAGAACCGTTATG A
TGTCGGCGCAAAAAACA n  ATCCAGAACGGGAGTGCGCCTTGAGCGACACGAATTATGCA
GrGATTTACGACCTGCACAGCCATACCACAGCTTCCGATGGCTGCCTGACG
>pZK_P4mS, S164mP reverse read. MWG
GAGCAGTCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGCr
GAACGCCAGrTGGATTGCAGTTCAGGAGCIAGAAAAGCTAGGCCTTGGCGACAGCGTGGA
CCTCiCATGTGTACGAGATTCCGGrrGAGTACCAAACAGTCCAGAGACTCATCCCCOCCCT
GIGGG AG A AGC ACAGTCCAC AGClCiG 1 GG IGC A1GIGGGGGTGIC AGGC ATGGCG ACC AC
AGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTT
TTGCCCCGGCTCCC AGT GCTGCGTGG AGG ACGGGCCT G AAAGC ATTG ACTCCATC ATCGA
CATGGATGCCGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTC
218
GCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCA
CGGTCGACCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCT
GGGCAGGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGG
CAAAATCAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCT
GTTTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCG
GTCTGATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGC
CGAACTCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAG
TAGGGAACTGCCAGGCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGT
TTTATCTGTTGTTTGTC
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Appendix C 
Activity & Kinetics
Quantification of PAP1 activity
One unit of activity is defined as the amount o f enzyme, which releases 1 nanomole of 
AMC per minute at 37°C (unit = nmoles mm l)
Derivation
AMC released (X) is defined as fluorescent intensity (Fi) divided by the slope of the 
appropnate AMC standard curve (Appendix A)
Fi
m
= Xf i M 
= ¿¿moles L
The reaction volume is 125x1 O'6 L and duration is 15 min
AMC released
Reaction uses 25x106 L enzyme
AMC released by enzyme
X(125 x 106)
--------------- — umoli
15(25 xlO )
X(125 x 106 )(1000) 
15(25 x l0 “6)(1000)
I moles mm 1 L 1
nmoles min 1 ml
— units m l1
3
—  units m l1
3m
From AMC standard curve, m = 42 042
Enzyme activity
Fi
units ml
126 12
2 2 1
Determination of Km and V max
The Michaehs constant (Km) of an enzyme, for a particular substrate, is defined as the 
substrate concentration which gives rise to half the maximal enzyme velocity (Vmax) 
This constant can be determined by measuring reaction velocity at various 
concentrations of substrate, giving rise to the Michaehs-Menten hyperbola curve In the 
case o f PAP 1, activity is determined by measuring fluorescent intensity (Fi) resulting at 
various concentrations of the substrate pGlu- AMC, as described in Section 2 18 6 1 A 
plot of Fi versus [pGlu-AMC] yields the Michaelis-Menten curve Once an enzyme- 
catalysed reaction follows normal Michaelis-Menten kinetics, data can be applied to a 
choice o f kinetic models
Lmeweaver-Burk Plot of 1/Fi versus l/[pGlu-AMC] The intercept of the line on the x- 
axis gives -1/Km and the intercept of the line on the y-axis gives 1/Vmax
Eadie-Hofstee Plot of Fi versus Fi/[pGlu-AMC] The slope is -Km and the intercept on 
the y-axis represents Vmax
Hanes-Woolf Plot of [pGlu-AMC]/Fi versus [pGlu-AMC] The intercept on the x-axis 
gives -Km, and the slope is 1/Vmax
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Determination of kcat
The turnover constant (kcat) of an enzyme can be determined if the Vmax and total 
enzyme (Et) are known
V
k c a t= - f
E t
nmoles min 1 ml 1 i , K
= mm (s )
nmoles ml 1
In the case of PAP1, Vmax (nmoles m in1 m l1 or units m ll) is determined experimentally 
as described above Et (nmoles m l l) can be calculated from the molecular weight 
(g mole ]) and amount of enzyme used (g ml"1) The molecular weight of His-tagged 
recombinant human PAP1 (xHsaVAPUh) is 24,105 g mole"1, as deduced from the amino 
acid sequence
Determination of Kt
The inhibition constant (K,), or dissociation constant for the enzyme-inhibitor complex, 
can be determined by measuring the apparent Km (Kmapp) observed in the presence of an 
inhibitor at a specific concentration ([I]), as described in Section 2 18 6 2 and applied to 
the following equation
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Appendix D 
Anuno Acids
Tiny
Ammo acid properties
Venn diagram presenting properties of the 20 amino acids
Charged
Alanine Ala A
Arginine Arg R
Asparagine Asn N
Aspartic acid Asp D
Cysteine Cys C
Glutamic acid Glu E
Glutamine Gin Q
c h 3
n h 2
nh2
A*NH ^NH
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Glycine
Histidine
Iso leucine
Leucine
Lysine
Methionine
Phenylalanine
Pro line
Serine
Threonine
Tryptophan
Tyrosine
Valine
Gly G
NH,
His H
Ile I
Leu L
Lys K
Met M
Phe F
Pro
Ser S
Thr T
Trp W
Tyr Y
Val
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SecondPositon
First
Position
U C A G
u
UÜUPhe 
UUC Phe 
UUA Leu 
UUG Leu
UCU Ser 
UCC Ser 
UCA Ser 
UCG Ser
UAUTyr
UACTyr
UAA Stop 
UAG Stop
UGUCys 
UGC Cys
UGA Stop 
UGGTrp
U
c
CUU Leu 
CUC Leu 
CUA Leu 
CUG Leu
CCU Pro 
CCC Pro 
CCA Pro 
CCG Pro
CAU His 
CAC His 
CAA Gin 
CAGGIn
CGU Arg 
CGC Arg 
CGA Arg 
CGG Arg
c
A
AUU Ile 
AUC Ile 
AUA Ile 
AUG Met
ACUThr 
ACC T t v  
ACAThr 
ACGThr
AAU Asn 
AAC Asn 
AAA Lys
AAG Lys
AGU Ser 
AGC Ser 
AGA Arg 
AGG Arg
A
G
GUU Val 
GUC Val 
GUA Val 
GUG Val
GCU Ala 
GCC Ala 
GCA Ala 
GCG Ala
GAU Asp 
GAC Asp 
GAA Glu 
GAG Glu
GGUGIy 
GGCGIy 
GGA Gty 
GGGGIy
G
Third
Position
G cn ctic  code
Amino acid codons applicable to both //. sapiens and E. coli.
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Appendix E 
Crystallisation Data Sheets
D ata  Collection F o r  H u m a n  PAP1 C rys ta l l isa t ion  S tu d y .
Crystal Screen 1 was utilised (see Table 2.8) and a PAP1 protein concentration of 12 mg/ml was used.
(Stage 1 - Hun 2b
fee: lp ci u * .’lit o' v . f .  _• l* d -i
tanta PAP 1 -1 Pmrjrni 10**00* e r.««4i«j io 
¿Mtotgrt 7 Plain 20
3 light Pt»optat« 8 SU’i
4 viiwi Hovy Pr*c^ «jr;t 9 Sal -0 2 nm
5 Spt»wes 10 to Char««
Sutter Screen 1
ieservor Voiwne: tnl
>op TuImrrpte . ?ul b.rtw
femoefature. 24 C
Dale (18 hr j) 
j 1.04/2004
De*e(48*s) bale (144lv*) 
0 ¿04/2004 ¡07)04/2004
I 301MPO. 0 IMNa Acaaw pH 4 8,0 02 M C<e*jm CNortd*
1« 201 PEO 8000. 0.1 MNa Caco<*lal« pH8 5.02 M ¿ c a t «« J
¡4 201 «»-Propanol. 0.1 M Ha AcaUU pH 4 0. 0.2 M C jkium Chfcoi«
«6 181 PECUOO.O 1 MM* C»co<V*»«pH8 5.02 Mar* Aulat* [ ; ]
« 21 PEO 8000 1 0 M Ufrwjrr. Sort««
50 HI PEO 8000.0 5 M lithium SJtu*
char-8« vaf ob*«tv««J afar 1«  hr*. all cantroJ» remained <*•#
to c/or-0c oil obstr.«<3 Jt«r 1442 hrs (12 Miy-04)tic«pt pr»c*«tak><i h»S nereas*c r  18 * ccrtrWf ofejr
Data Collection For Human PAP1 Crystallisation Study.
Crystal Screen 1 was utilised (see Table 2.8) and a PAP1 protein concentration o f 1.5 mg/ml was used. 
Stage 1 Run 3a
Set up on ft# 7tn of Apni 2004
i*n p l© PAP 1 - l.imgml 1 CW«r Drop tMwfclD 
2tejoigni ?PHl«s20 
3 Lgt* Pw««*:« 8 St»r,
Mn»u(Ti H«av> Pr*CV-til* S »«1 »0 J fTKTl 
5 $pn«rjt*«» 10 to Chano*
duller Semen 1
VokJW LM
>oo ?ul Mmpie * ?i* btAar
r«npefalijre ?4C
b*e (5 hrs) 
P7A4/2004
D*e (172*8)
14A4C004
Date , 360hrs)
22.04/2004¡hanging drop method used
|T 301 MPO. 0 1M Na Ae«tat* pH 4 8.0 02 M C jtei*n  CNoriA* I m m m 10
he 201 PEO 8000. 0.1 M Na Cacodyl«« pH8 5. 0-2 Mfcbgn*»«*« * « c a « J »•
B4 201 iso-ProfansJ. 0.1 M Ma AxUte pH 4«. 0.2 M C*wn CWonde 10
MS 181 PEG 8000.0 1 MNj Caco<M*« pH ».S.OJM&k Acca* 1 M
[se: ‘-3 cn ; .e to of April 2Q'H
kampte PAP1 ■ l.9molnl 1 Ctear Drop ( 10
2 tei <* grt 7 Put«* 20 
'i bgH 8 Swrj
£ Udkjrr hta>* Pi»uO*jU 9 >1*1 -0 2 n»ri 
5 ^iw ktf 10 to Ch**«
Buna ’Screen 1
Re e^rvor Vo*l»w *nl
Sul san^ itr. ♦ 5*il t*ifn
24 C
bate (5 hrs) b*e(17»»8) 
l»M>4«04 *4*4*004
Dale (360hrs) 
22/W20Q4HANGING DROP METHOD USED
I »1H»0 0 IMMa Ac4'aMpH 4 6.0 02MCatou'nChiotM« ) 10
18. 201 PEO 8000 0 1 M Hi Cac«<iy»at. pH 0 «. 0.2 M M A mUU 3 10
24. 201 so-Prepanol. O.t M Ha pH 4 0. 02 M Cakwr. CNood»
a t c i  per. ft/Wt a | u Mi rwAM« nu a a a>u tv- .v « 1 i
I Oi*T*«l shapes
25 10
VO. Ifl * r tv 9 U. 1#. 1 MNJ lit pnoo II i M UTK /<CUt
.«himUs BoOi »«r* ch*cw«d jt«r &40fn (12-A%y-04) B<s «nmai tamed «1 tMi«r4J of boUi
A ___i 4 Sure | 10
------------------
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Data Collection For Human PAP1 Crystallisation Study.
Crystal Screen I was utilised (see Table 2.8) and a PAP1 protein concentration of 3 and 8 mg/ml were
used.
¡Set up on the 15m or Apnl 2004
Sample: PAP 1 - 3mgmi 1 Ch» Drop 6 N»*J»** ID
Sutter: Screen 1 2 tot i of on 7 PI**» 20
?eservcHr Volume 15ml 3 Lgrt PrtcipitJ!« 3 Siars
Xop 2ul »ample * 2ul birter 4M*4ut. - Hun Prvciptjt«
3 ** »0.2
TKD
Temperature 24 C 5 Sph*"Atw 10 Wo Char-3#
[•ate (72 tvs) Date(170Hrj)
Date
410hrs)
18(04*004 2ZAMJ20Q4 12X15*004
t 30% MPO. 0 1 M Ha Ac**** pH 4 6.0 02 M QMn CNoAJ* 1
«8 20% PEG 8000 0.1 M Ha Cacrtytal* pH 0 5.03 M*bgr»»KjfT> «c<U< i
>4 20% I*©-Propanol, 0.1 M Na Ac*»** pH4 6. 0 2 M C*ckjm CNoM* 25 red erysais to nnj«ufw
K 19% PEG 8000, 0.1 M Ha C*co<Ms« pHO 0.02 MZoc Acaat* ' 1 ;t*r cry aj'
[Stage 1 Run 4 b
I H I i l l
PAP 1 - «mornl
Screen 1
1 CJ*ar Drop
2 ftts Ofgr*
6 Naadtes ID
7 PkM 2D
Reservo* Volume p.5ml 3 light Pr«CTpot« 8 Stars
Drop. 2ul s*nple * 2ul biifa 4 NV*jm • H«j»y Pr*cip«j:« 9 &a: >0 2 mm
[Temper due: 24 C 5 SpheruH*! 10 Ho »Jiyj*
Xe (72 hrs)
>ate
[170hrs) Dale (41 cur j)
HANGING PRO 1&04/2004 22XM/2C04 fl 2X35*004
1, WO. D 1M HI «c«Ut [il 4.V.BS1 M tUCUn CNtmO«
18 20% PEG 8000.0.1 M Na Caccrtrlat* pH 0.5. 0 2 M htogn**«jn Ac««* 4
.
10 ■ 1
9am* a* abov*
*4.20%.»-Pn*.an«-I.0 1 M Na *«ac* pH 4.0. 0.2 MCMM CMoM* 7 .0 • px* quaKycry «tail
*5 18% PEG 8000.0 1 M Na Cae«*tR* pHO 5. 02 MOve Acoat* 2 star crywata ,0 2wy«Hf.
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Data Collection For Human PAP1 Crystallisation Study.
Crystal Screen 2 was utilised (sec Tabic 2.9) and a PAP1 protein concentration of 5 mg/ml was used.
Stage 1 • Run 5
Bat up on the 1 5tn Gf Apnl 2004
imWe PAP 1 5iiiu-«ii Cltir Orop
2«i<*9m 7 Plx«s 20
3 Ughf Pr*c*>4*t« 8 «a1 <0 2 mrr
4 Mtdium*Hw»y Pro*.«« 5 Mai >03 iwn
5 Stars 10 Mo Chang*
Scrorn ?
ieservxvcfcjr* 1.4ml
>op ?ul si»n»lr . ?ul bt/fc*
24C
Date (72 hrs)
Dote
;i7orw)
22X34/2004
Data (650)
12/35/2004IANGING DROP METHOD
1 101 PEO 0000 20 M So<*um CNond« 1 10
2 0i M So4vm Chtond*. 0 01 M CTA0. Oil MM*jn«wum Chtond« 1 10
3. 261 Bhyltn« S IS to
» 361 Gtoxar»« « 10
1 61 «>Propano!. 20 M AmmoMum Sutlile 3 t
1 1 0 W *t*1»oU£H_7 0 •
r 101 PEG IOOO. 101 PEO 8000 1 10 Ortjdup
! 101 BhjrMl. 1 5 M $<xSwn Chlon* 3 10
) 2.0 M Sodnan Ctoride. 0 I M Na A:etJ>« i>H 4.6 3 10
10 JOINTS.« 1 MMa At«Ut«(lH4».0aMSotfMm Own«* I 2 10
II 1 £ M 1.6 HauMdni. 0 1 MMj A.«ui* pH 4 0.3 01 M Cow* Ctfonda 10 On* Up
12 301 PEO 400.0 I MNi At«tat« pH 4 0.0 1 M Cadmun OkuvM J 10 1
13 301 PEC MME 2000. 0.1 M Na fiettM* pH 4 0. 02 M Ammomm SuCxt 4
14. 2.0 M AwiKrtum SOfai«. 0.1 M Nj Ctoat« pH 60.0.2M K/Ka Tartrat« J 3
15 I.OMUhfcim SUfaw.O 1 MMa ClraMpHOO.O-OMAmYx***». S*tf»« 3 J
10. 21 Poiydtiyltr^ mnc. 0 1 M ft. CM« pH 6.0. 0 6M S«dKim CNoride 3 * «
17. 361 t«I Buund. 0.1 M Na Ctrx* pH 5 0 Uo 10
18. 101 MOOO. 0.1 M Na Ctral. pH 5.0. OKI M F«nfc CNxxfc ) _* Omd Up
10. 2.5 M 1.0 Ht.vwdM. 0 1 M Na Ckra« pH5.0 1 10
20. (.OMUigrMiMT! StffM.O.t MMESpHO.5 -3 *
Ftorrwrtout
21.2 0 M SodMTi CNmM*. 0 1 MME$ pH 6 5. 02 M Na/K Phojphat« 3 • 1
22. 121 PEO 20.000. 0 1 MMES pH 0 5 1 4 10
23. 101 Dtoxar*.0 1 MkCSpHOS. 1 8MAmmonwm Sutfs« 3 On*d Up
24. 301 J*ffarr*»« N40C0. 0.1 M»*S pH 0.5. 0 OS M C*fium CNcnd* 1 * 0<*p«a«d
26 1 8MArwof*jm So»*«.01 MlyCSpH0 5 0 01 M Co*^ i CNoAJ* 3 3 10
26 301 PEC MME 6000. 0 1 M bC$ pH 0.6. 0.2 M Ammoraurv Suttx« fl «
Rameftou«On**
27. 251 PEO MMt 650. 0 1 MMtS pH 0.5. 001 M2nc $<*au 2 H««« tfy*Mi 10 Wf4am«to<ji sro«th
28 I.OMSoWn CknKtpH0.5 » 1 10
29 MlkTO.O 1 M H*p*« pH 7.5.05 M Amiwior Sutat« 1 10
30 101 PEG 6000. 0 1 M Hep*» pH 7 5.51 MPO 1 10 a. ii m in
it 2fll J*fan*»u«00.0 1 MH«f»«pH76 1 10
32 1.0 M Anmortim SUffatc. 0 1 M H«pcs pH 75. 0 1M So4um CMmW« * to
33. 2D MAnmoniun FomoM.0.1 M H«p«s pH7 5 3 * 10
>4 ID M $o<fcjm Ao«iai«. 0 1 M H«p«i pH 7,5. 0 05 M Ca<kr«jm UJiZi 3 4 10
35 701 liTO. 0.1 M H<tp«t pH 7.5 EKarJi 10 10
30 4.3 M Sodnaii CMonfe. 0.1 M H«p«s pH 7.6 4 1
)7 101 PEG8CC0.0 1MH«p«tpH7 5.81 ah*1«n« G^col 3 1 10
» 201 PEO 10.000, 0 1 MH*p*spH7« DrM Up
* 3.4M 1.0 HtaarwdM. 0 1 M Trt* pH 05. 0.2MMagrMtkKn ChfcyW* > 10 1C
«0 2511««t-E>JUr>ol. 0.1 MTrtj pH 8 5 1 on«] up
»1. IJMUMjm SJTate.O 1 M Trlj pH 8 5.0.01 M fte*d(ll)Cl*yVJ« 1 3 «
tt 121 0tyc«fe!.0.1 M Tris pH 8.5.1.5 M Anmonwrn $*0M* 1 3 10
tt. 501 M>D. 0.1 MTrt* pH 8.5. 0.2 M Anmorautn Phojphat«
1
10
W. 201 Shane!. 0.1 M Trt* pH 8.5 10 Dn*d Up
16 201 PEO MME 2000. 0.1 M Tns pH 8.6. 0.01 M Mck«i(ll)QWond« 1 » 10
» 201 PEO MME 650. 0 1 M »on« pH 90. 0 1 M So4um CNond« 1 10
riarrxotouj
0r»»th
V 2.0 M CNond«. 0 1 M Ow<n« pH 9.0 1 3 6
•C. 101 PEO 20000. 0 1 M (fcer* pH 9.0. 21 Utoxan* 1 10 BubOi* «fp«rt«4
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Data Collection For Human PAPI Crystallisation Study.
Crystal Screen 2 was utilised (see Table 2.9) and a PAPI protein concentration of 12 mg/ml was used.
ieser vo r VoUne:
>ate(18hrs) (48hrs) (144hrs)
15. 1U M Ulhfcim Sutst*.0.1 M Nj Clrau pH 50. 0.5M Avmormjn- UilM*
10.21 Poty«hr1W>«>TWit.O»MHjClPatpHa.O.OOMSo^T>CfttoVk
¡8 1.8 M Awrwfium SdtJtt. 0.1 MME$ pH 0.8.0 01 M Cobafc CWortd« 
» 301 PE0KW6 50CI0 0.1 MfcCSpHOS.OZMAmKWum Mix*
13 2 0 M Anmoniuni Fqiwmm.O 1 MHtp««pH7 6
II S-jlfrtt.CUMTrtipH8 6.0 0l MNkUQQCMortd«
W 201 PEQMME2000 0 I MTrtt pH 8 S. 001 M McfcriQOChtortd«
No ctijng« Mm I W hr* 04C hr* ►» coctmlt mman«) tlur
Noclanp« a i  ofcfnred *T.- 14lBMt (l2-*>yO*)»«i»ii»«vfMf> n pno^tabefi
232
Data Collection For Human PAP1 Crystallisation Study.
Crystal Screen 2 was utilised (sec Table 2.9) and a PAP1 protein concentration of 1.5 mg/ml was used.
|Sl«iqK 1 Hun 3b
|88’ ufi (in Ihfi 7th of April 2004
PAP 1 1.4mo*rt 1 Chr Drop e ip
>Jrt«r Screen 2 2 Bni etgrt 7 Pljftt 20
teservar
/dime «.«ml 3 l»gh* toot**« 8 «ji <0 2 mm
>op 2ulm«mp* . 2ulb4rtM 4 Mt4um-HtSVy PmclpCM« 9** -0 2 mm
Tenperature. 24C 5 Sl*> 10 No Chjn-i*
>ato (5 hrs) Date (172hr») Data (MOhr*)
HANGING DF S1C4/20C4 08)04/2004 1208/2004
18 ID1 jenmn« v. i m m un gs, v vi m rcm, uwrai
Î0 1 B MN*gr*tium Si/t**. 0 1 MMES pH 8 5 <
*
«
»
to
DO 101 PEG 8000.0 1 M H«*s pH 7 8.61 MPD « 1
O »1 MPD.O 1 UTn*pH8A.0?M*iVTvartMT> B*o»pMU • - i 1
*4 201 Bhjoo4. 0.1 MTn* pH 8 8 1
Data Collection For Human PAP1 Cry stallisation Study.
Crystal Screen 2 was utilised (see Table 2.9) and a PAP1 protein concentration o f 3 and 8 mg/ml were 
used.
[Staqe 1 Run 4c
eel up on the I6in of April 200*
iair»D*o PAP 1 JmQiri 1 0«»r Oroç 6N««4*«IC
2 Ms ot gn 7 Plr.«; 20
3 Ugnc Pr*c***i« 8 4* <03 nvn
FV»-(<r* 3 4» >0 2 mm 
Î StJn 10 No Chjng«
ÎUTT« Screen 2
teservor VofcJffie Lfiml
>oo 2ul sample ♦ ?ul buffer
Temper ature 24C
>at9 C72hrs) 
18/M/2004
M l (170hrs)
.224)4/2004
DMe (410hrs) 
12*5/2004(HANGING orop  mfthod
18 101 WBCO. 0 1 MNi Ctr*« pH 58. 0 01 U Feme ChfcxvS* 1
». liMMv^un. SJIjte. 0 1 MMES pH 0.5 . • . * 0ro*lh
10 101 PEC 8000.0 1 MH4f»s pH 7 5.81 MPD 1 > 0n*d Up
Ü 501 MPD. 0.1 M Tn* pH 8 5. 02 M «mwwn Ptv»iptuu 1 On* up On* Up
14.201 Bhjnot. 0.1 MTnt pH 8 5 1 ■
Istaqe 1 Run 4d
(Set up on U>‘ 1 fitr, of April 2004
Sttnpte 9AP1 amo»rt 1 Cl«x Drop 8 10
îulfflr Scrrmn2 î c< on 7®t*«j20
<ese*vw Yowmo ).8ml 3 UyK P'r-fnui« 8 *x <01 iran
>00 2ul*«nple . 2ulbUfer 4 3 *» >0 2 mm
renoerature 24C 3 Stars 10 No Cnar*«
X» (5 hrs) Date (172t»s) L>«te (410hrs)
HANGING DROP METHOD ----------------------------------- —01 AM/2004 08*4/2004 12AJV2004
is iui jtnann« wow. u i mpu Lmtpnis.wui urtm umnet 
» 1 8 M kfegn*<ium UtlM*. 0 1 M MES pH 8 5
>
1
r - -  .1 - ÿ -  
«
F ÉBTMfAOUf
» 101 PEC- 8000.0 IMHfti pH 7 5.51 MPD 1 • 1
»3 801 MPD.O 1 MTn* pH 8 5, 02 M Awrwwm Pho»pMt* Buff* CM* Up to On* Up
«4 201 BhwwJ.O 1 MTm pH 8 5 - « _ On* Up
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